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ANOVA Analysis of variance 
BMI  Body mass index (kg/𝑚2) 
BP  Blood pressure 
DBP  Diastolic blood pressure (mmHg) 
F  Female 
HbA  Haemoglobin (g/dl) 
HbA2  Haemoglobin alpha type-2 (%) 
HbF  Foetal haemoglobin (%) 
HbS  Sickle haemoglobin (%) 
HWE  Hardy-Weinberg Equilibrium 
IMF  Intraerythrocytic multiplication factor 
M  Male 
Max.  Maximum 
MCHC  Mean corpuscular haemoglobin concentration (g/dl) 
MCV  Mean corpuscular volume (fL) 
Mean  Average 
Min.  Minimum 
N  Number of cases 
P.falciparum Plasmodium falciparum 
RBC  Red blood cell count (million cells/µl) 
SBP  Systolic blood pressure (mmHg) 
SCA  Sickle cell anaemia 
SD  Standard deviation 
SE  Standard error 
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VOC  Vaso-occlusive pain crises 
WBC  White blood cell count 𝑋(10)9/𝐿 
SUMMARY 
Background: Although sickle cell anaemia (SCA) is genetically characterised by a single point 
mutation, patients can manifest varying degrees of clinical severity due to various genetic 
modulators that affect the phenotype of this disease. The co-inheritance of alpha-thalassemia 
(α-thalassemia) has been associated with a milder phenotype in SCA patients (e.g. lower stoke 
rate), but could also result in the increase of vaso-occlusive (VOC) pain episodes. There is a 
scarcity of data on the co-inheritance of α-thalassemia and SCA in Cameroon. The present 
study explored the correlation between α-thalassemia, haematological indices, and clinical 
events in Cameroonian SCA patients. 
Materials and Methods: For this cross-sectional study, a full blood count and clinical 
phenotype profile was collected for 262 Cameroonian individuals. Restriction fragment length 
polymorphism - polymerase chain reaction (RFLP-PCR) was performed for the molecular 
diagnosis of SCA and for the study of the β-globin (HBB) gene cluster haplotypes. Multiplex 
Gap-PCR was performed to investigate the 3.7kb and 4.2kb α-thalassemia gene deletions. 
Results: There were 178 SCA patients (HbSS), 32 carriers (HbAS) and 52 unaffected individuals 
(HbAA), with median ages of 18, 23 and 26 years, respectively. Among patients, 57% (101) 
had less than three vaso-occlusive pain crises (VOCs) per year. The median haemoglobin (HbA) 
level was 7.8g/dl for patients, 12.7g/dl for carriers and 13g/dl for unaffected individuals. HBB 
gene-haplotype analysis revealed the following: 42.2% (71) Benin, 14% (22) Benin/atypical, 
26.8% (42) Benin/Cameroon and 5.1% (8) Cameroon haplotypes among patients and carriers. 
Up to 37.1% (66) of SCA patients (HbSS) co-inherited α-globin gene deletions, compared to 
the 20% (10) prevalence of these gene deletions in the unaffected (HbAA) and carrier (HbAS) 
cohorts. Among patients, the genotype distribution was 30.3% (54) αα/α-3.7 (one 3.7kb α-
globin gene deletion), 6.8% (12) α-3.7/α-3.7 (two 3.7kb α-globin gene deletions), and none 
had the 4.2kb deletion. 
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Among patients, the median red blood cell count (RBC) increased with the number of 3.7kb 
deletions [2.6, 3.0 and 3.4 million cells/dl, with no, one and two deletions, respectively 
(p=0.01)]. The median mean corpuscular volume (MCV) [86, 80 and 68fL, with no, one and 
two deletions, respectively (p<0.0001)] and the median white blood cell count (WBC) [13.2, 
10.5 and 9.8 X 109/L with no, one and two deletions, respectively (p<0.0001)] decreased with 
an increase in the number of 3.7kb deletions. An analysis of the affect of the co-inheritance 
of α-thalassemia and SCA on the haematological parameters revealed a significantly lower 
lymphocyte and monocyte count, which is known to be associated with a better clinical 
phenotype. In addition, the co-inheritance of α-thalassemia was significantly associated with 
a delayed age of disease onset among Cameroonian SCA patients. Furthermore, after 
performing linear logistic regression analysis, the co-inheritance of α-thalassemia was 
associated with a lower consultation rate (p=0.038). 
Conclusion: The co-inheritance of α-thalassemia with SCA was associated with an improved 
haematological profile, with an increase in the number of α-globin gene deletions. The 
possible positive effect of the co-inheritance of α-thalassemia on SCA patients’ survival could 
explain the high proportion of α-thalassemia among SCA patients when compared to the 
unaffected controls. These results have implications for disease management in Cameroon in 




CHAPTER 1: INTRODUCTION 
Sickle cell anaemia (SCA) is the most common form of sickle cell disease and is a life-long 
genetic disease that begins during childhood (Weatherall and Clegg 2001a). A mutation in the 
HBB gene leads to the formation of aberrant haemoglobin (HbS), which causes the 
erythrocyte to ‘sickle’ (Weatherall and Clegg 2001b). These 'sickle cells' are rigid, which 
hinders their movement through blood vessels (Weatherall and Clegg 2001b). This increases 
the possibility of infection and leads to the blockage of blood vessels, thereby resulting in 
organ damage, which in turn may lead to death (Weatherall and Clegg 2001b). 
On the global scale, SCA affects the tropical regions of the world, with 305,800 neonates 
affected annually (Modell and Darlison 2008; Weatherall 2010). The majority of cases occur 
in Africa, making this disease one of the biggest public health problems on the continent 
(Modell and Darlison 2008; Weatherall 2010; Piel et al. 2013). The dearth of early detection 
and treatment initiatives has resulted in an extremely high (92%) mortality rate (Piel et al. 
2013). The distribution of SCA is growing due to the migration of individuals from sub-Saharan 
Africa to other parts of the world, like Europe and South Africa, placing a greater burden on 
the healthcare systems of these countries (De la Iglesia Iñigoet al. 2012; Piel et al. 2013). 
Treatment and management initiatives aimed at the most severely affected nations of the 
world could drastically reduce the SCA-induced mortality rate, thereby improving the lives of 
millions of children (Piel et al. 2013). 
SCA is genetically characterised by a single point mutation (Pauling et al. 1949; Ingram 1957; 
Shelton and Schroeder 1960). However, various genetic modulators affect the phenotype, 
resulting in varying degrees of clinical severity manifesting in patients with the SCA 
(Weatherall and Clegg 2001b; Belisário et al. 2010). Increased levels of fetal haemoglobin 
(HbF) and the genetic loci associated with this trait influence the clinical severity of SCA (Lettre 
et al. 2008). 
Alpha-thalassemia (α-thalassemia) is a heritable haemoglobinopathy that decreases the 
amount of HbA via α-globin gene deletions or a reduction in α-globin, thereby affecting the 
processes of oxygen transportation, resulting in anaemia, fatigue and serious, life-threatening 
complications (Weatherall and Clegg 1981). The co-inheritance of α-thalassemia and SCA has 
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been associated with a milder phenotype in SCA patients, thereby affording a protective 
effect against the more severe complications associated with SCA (Steinberg and Nagel 2009). 
The present study aimed at exploring the prevalence of α-thalassemia and its correlation with 
the haematological indices and clinical manifestations in a cohort of Cameroonian SCA 




CHAPTER 2: LITERATURE REVIEW 
2.1 SICKLE CELL ANAEMIA (SCA) 
2.1.1 EPIDEMIOLOGY 
2.1.1.1 SCA WITHIN THE GLOBAL CONTEXT 
SCA is thought to have occured in humans for thousands of years (Weatherall and Clegg 
2001b), with the first sickle cells found in a patient from the West Indies in the early 1900s 
(Herrick 1910). It is the most frequently occurring genetic disease in Africa, the Caribbean, 
India, the Middle East, North America, and South America (Lorey et al. 1996; Solovieff et al. 
2011). 
SCA is also the most frequent haemoglobinopathy present in the Middle East and Asia, 
specifically in the Eastern and South Western regions of Saudi Arabia (Akinsheye et al. 2011). 
In Bahrain, the incidence is 40.3% (Mohammad et al. 1995) and 49.4% in Jordan (Al-Rimawi 
et al. 2006). In the Chhattisgarh and Madhya Pradesh regions of India, the prevalence of SCA 
ranges from 15% to 20% (Gupta 2006). In Western Nepal, SCA has a prevalence of 5% 
(Modiano et al. 1991). 
In Europe, SCA occurs at low frequencies (Howard and Davies 2007). In Turkey, a frequency 
of 3.2% was reported (Koçak et al. 1995). Most occurrences in Europe are as the result of 
immigrant populations from tropical regions, particularly Africa. Kéclard et al. (1996) reported 
a high incidence of SCA in the African immigrant French population (72.7%), which Neonato 
et al. (2000) confirmed. In Italy, the frequency is reported as 21.4% (Russo-Mancuso et al. 
1998) and in Norway, the frequency is 16.8% (Graesdal et al. 2001). 
2.1.1.2 SCA WITHIN THE AFRICAN CONTEXT 
The frequency of SCA in Africa differs depending on the region under investigation 
(Angastiniotis and Modell 1998). In equatorial Africa, the carrier frequency is 20% of the 
population, whereas in North Africa, it is less than 1% of the population (Angastiniotis and 
Modell 1998). In sub-Saharan Africa, 240,000 neonates are affected by SCA each year (Modell 
and Darlison 2008; Weatherall 2010), with the occurrence of the sickle cell trait in 5% - 40% 
of the population (Weatherall 2008). Sudan has a prevalence of SCA that varies from region 
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to region (4% - 24%), with a carrier frequency of 54% (Bayoumi et al. 1985; Elderdery et al. 
2008; Osman and Alfadni 2010; Munsoor and Alabid 2011). In Tanzania, 8,000 neonates are 
born with the sickle trait annually (Modell and Darlison 2008; Weatherall 2010). Nigeria has 
a carrier frequency of 2% of the population (Smith 1943; Afolayan and Jolayemi 2011; Piel et 
al. 2013). SCA also occurs in Senegal (Pagnier et al. 1984), Burkina Faso (Labie et al. 1984), 
Mauritius (Kotea et al. 1995), the Democratic Republic of Congo (DRC) (Tshilolo et al. 1996; 
Agasa et al. 2010; Aloni and Nkee 2014), Zambia (Beet 1947), Kenya (Foy et al. 1951; Suchdev 
et al. 2014), Ghana (Edington 1953), Algeria (Pagnier et al. 1984), Benin (Pagnier et al. 1984), 
Togo (Segbena et al. 2002) and Malawi (Brabin et al. 2004). 
There is a low occurrence of SCA in South Africa (Bird et al. 1982, Ramsay et al. 1984; Bird et 
al. 1987). However, a new trend in the disease prevalence pattern in South Africa, specifically 
in Cape Town, as a result of immigrants from sub-Saharan Africa using the local healthcare 
facilities (Wonkam et al. 2012). There has been an increase in the number of SCA patients 
accessing clinical services, with three patients being seen in 2001 and 12 patients in 2009, 
which were seen at Red Cross Children’s War Memorial Hospital (Wonkam et al. 2012). In 
Johannesburg, SCA occurs at a low frequency among South Africans of Indian descent (Krause 
et al. 2013). 
2.1.2 MOLECULAR AND CLINICAL MANIFESTATIONS OF SCA 
2.1.2.1 SIGNS AND SYMPTOMS 
SCA manifests in several ways. A common manifestation is vaso-occlusive pain crises (VOCs), 
which are episodic bouts of intense pain (Darbari et al. 2012) caused by the inability of the 
sickled erythrocytes to navigate through the body’s smaller blood vessels effectively due to 
their altered shape (Smith et al. 2008). Another common manisfestation is anaemia. The 
sickled erythrocytes have a decreased lifespan (10 to 20 days) which results in an insufficient 
amount of erythrocytes to transport oxygen throughout the body (Platt et al. 1994; Smith et 
al. 2008). This leads to lethargy, a very pale complexion, and shortness of breath (Smith et al. 
2008). Anaemia can in turn hinder growth. The growth rate decreases as the body does not 
receive the optimal amount of oxygen for regular growth and development (Clarke and 
Higgins 2000). SCA patients have a lower BMI as opposed to healthy individuals of the same 
age and gender (Smith et al. 2008). 
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SCA can also cause eye irregularities, susceptibility to infection, strokes and acute chest 
syndrome. Eye irregularities occur because low cellular oxygen concentrations can result in 
damage to the eye and blindness (Elagouz et al. 2010). Infections occur because SCA patients 
are immune-compromised due to the damage of certain immune protecting cells.  This 
increases their susceptibility to a host of different infections (Platt et al. 1994). Strokes are 
due to the sickled erythrocytes compromising the blood flow to the brain (Gladwin et al. 
2004). Finally, SCA can cause acute chest syndrome, manifesting in severe chest pains and 
high fevers, which may lead to death (Platt et al. 1994). 
2.1.2.2 MOLECULAR PATHOLOGY 
2.1.2.2.1 Normal haemoglobin (HbA) (α2β2) 
HbA is found in the erythrocytes of healthy adults (Engelhard 1825; Adair 1925), and is of the 
metalloprotein/globulin protein type (Perutz et al. 1960). The HbA tetramer (Figure 1) consists 
of two α-globin proteins (141 amino acids in length) and two β-globin proteins (146 amino 
acids in length) (Perutz et al. 1960). Attached to each chain, is an iron component called 
“haem’’ (Engelhard 1825; Adair 1925). HbA is responsible for the transport of oxygen in the 
blood (Hünefeld 1840). The Hbα1 protein is the product of the HBA1 gene, which is located 
on chromosome 16p13.3 (Perutz et al. 1960). The Hbα2 protein is the product of the HBA2 
gene, which is located on chromosome 16p13.3 (Perutz et al. 1960). The Hbβ protein is the 




Figure 1: Structure of HbA 
The healthy red blood cell contains HbA, which is a three dimentional, quaternary protein with a prosthetic 
group. It is composed of four polypeptide chains, two α and two β polypeptides. Each polypeptide is 
associated with an iron-containing haem group. The whole molecule consists of 574 amino acids. In terms of 
function, HbA aids the transfer of oxygen from the lungs to the rest of the body (Mader 1997). 
2.1.2.2.2 Sickle Haemoglobin (HbS) (α2𝜷𝑺2) 
SCA is one of the first heritable, Mendelian diseases for which the fundamental genetic 
foundation has long been understood (Herrick 1910; Pauling et al. 1949). SCA is an autosomal 
recessive, monogenic condition due to a single point mutation (Figure 2; Clark and Higgins 
2000; Rees et al. 2010; Alpert and Chen 2011; Rees and Gibson 2012). The transition mutation 
(rs334; c.20A>T) substitutes an Adenine with a Thymine at position 20 of the consensus 
coding sequence for the HBB gene (NM_000518.4) (NCBI 2014). This nucleotide substitution 
leads to an altered amino acid sequence at the sixth codon (Protein: NP_000509.1:p.Glu6Val) 
(NCBI 2014) of the β chain of the HbA molecule, thereby forming sickle haemoglobin (HbS; 
Figure 2; Clark and Higgins 2000; Rees et al. 2010; Alpert and Chen 2011; Rees and Gibson 
2012; Steinberg and Sebastiani 2012). In SCA, the RBC has an elevated response to oxidative 
stress, which results in an abnormal haemorheological profile (Hierso et al. 2014). 
Heterozygotes (HbAS) are asymptomatic and homozygotes (HbSS) are symptomatic, because 
the manifestation of symptoms depends on the amount of HbS. Carriers (HbAS) have half the 




Figure 2: Structure of HbS 
HbS is a mutational form of HbA, which occurs due to a point mutation, where Adenine replaces Thymine at 
position 20 of the nucleotide sequence (Nucleotide: NM_000518.4: c.20A>T) (NCBI 2014). This nucleotide 
substitution leads to an altered amino acid sequence in the sixth codon (Protein: NP_000509.1:p.Glu6Val) 
(NCBI 2014) of the β chain of the HbA molecule, thereby forming sickle haemoglobin (HbS). Two 𝜷𝑺 molecµles 
are formed, hence the structural nomenclature of α2𝜷𝑺2 (Adapted from Odièvre et al. 2011; Steinberg and 
Sebastiani 2012). 
2.1.2.2.3 Foetal Haemoglobin (HbF) (α2ƴ2) 
Due to its high affinity to bind oxygen molecules, HbF is mainly expressed in the erythrocytes 
during foetal life, to meet the huge metabolic demand of the developing foetus (Huisman et 
al. 1977; Steinberg and Sebastiani 2012). The HbF molecule contains a tetramer that is 
composed of two α-globin and two ƴ-globin protein units (Huisman et al. 1977). There are 
two genes located on chromosome 11p15.5, HBG1 and HBG2, and on chromosome 16p13.3, 




Figure 3: The production of HbF 
The short arm of chromosome 11 is contains the following genes: HBE (epsilon), HBG2 and HBG1 (gamma 
globin cluster), HBD (delta) and HBB (beta) producing HbE, HbF, HbA2 and HbA. Chromosome 16 carries the 
following genes: HBζ1 and HBζ2 (zeta globin cluster), and HBA2 and HBA1 (α globin cluster), producing HbE 
and, HbA2 and HbA. The arrows indicate protein products from their relevant genes. 
2.1.3.3 PATHOPHYSIOLOGY OF SCA 
SCA occurs due to a sickle mutation (NM_000518.4: c.20A>T; NP_000509.1:p.Glu6Val) (NCBI 
2014) which leads to the HbA molecule becoming HbS and losing a negative charge, thereby 
becoming more hydrophobic as a result of the Valine substitution (Bunn et al. 1977; Samuel 
et al. 1990). There is no alteration in the oxygen affinity, as the mutation exposes a 
hydrophobic patch in deoxy-HbA, which leads to the build-up and formation of fibres running 
through the entire length of the erythrocyte, leading to sickling (Figure 4; Bunn et al. 1977; 
Wilson et al. 1979; Samuel et al. 1990). At the outset, this process is reversible. However, with 
continued sickling, the erythrocytes ultimately lose their membrane plasticity, and the sickled 
structure remains (Bunn et al. 1977; Wilson et al. 1979; Samuel et al. 1990). Sickling results in 
a shortened erythrocyte lifespan (one to two days) and hinders the flow of erythrocytes 
throughblood vessels and tissues (Bunn et al. 1977; Wilson et al. 1979; Samuel et al. 1990). 
SCA leads to various clinical complications illustrated in Figure 5. 
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A healthy red blood cell is 
biconcave. As the result of SCA, the erythrocyte forms a c-shape (sickle cell) (Gabriel and Pryzbylski 2010). 




Figure 4: Complications caused by SCA 
This figure depicts the multifaceted nature of SCA as a pathway of many varying complications. The 
polymerisation of sickle haemoglobin (HbS) leads to erythrocytic dehydration and an elevation in the 
manifestation of the adhesion molecules which results in an elevation in erythrocytic inflexibility. This leads 
to vaso-occlusion. Vaso-occlusion may lead to infarction, inflammation, haemolysis, and anaemia. Infarction 
may lead to reperfusion injury, organ destruction and thereby cause cognitive abnormalities and fatigue. 
Inflammation may lead to hypercoagulability and infection, which may also lead to cognitive abnormalities. 
Haemolysis leads to vasculopathy, resulting in latrogenic complications. Anaemia leads to a deficiency in nitric 
oxide, which leads to an abnormally low concentration of oxygen in the blood, leading to psychological 
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problems. Each eventuality may lead to death. The intricate network displays the complexity of the 
pathophysiology of SCA (Rees and Gibson 2012). 
 
2.1.3.4 INHERITANCE PATTERN 
SCA inheritance takes on an autosomal recessive pattern (Neel 1949). The disease (HbSS) will 
manifest in the offspring if both parents carry the “sickle trait” or are heterozygous (HbAS; 
Neel 1949). If each parent is a carrier, there is a 25% chance of conceiving a healthy child, a 
25% chance of producing a child with SCA (HbSS), and 50% chance of having a child with the 
sickle cell trait (HbAS), who would be asymptomatic (Neel 1949). 
2.1.4 HAPLOTYPES OF THE HBB GENE 
The five haplotypes of clinical relevance to SCA (which were identified across the β-globin 
gene cluster) are the (1) Arab-/Saudi-Indian, (2) Bantu/Central African, (3) Benin, (4) 
Cameroon, and (5) Senegal haplotypes (Figure 6; Pagnier et al. 1984; Kulozik et al. 1986; 
Lapoumeroulie et al. 1992). The Bantu/Central African, Benin, Cameroon and Senegal 
haplotypes originated in Africa, while the Arab-/Saudi-Indian haplotype originated in Asia 
(Figure 6; Lie-Injo et al. 1987; Labie et al. 1989). Each haplotype confers a varying degree of 
clinical severity in SCA patients (Labie et al. 1985; Nagel et al. 1985; Nagel et al. 1987; Labie 
et al. 1989; Green et al. 1993; Nagel 1994). 
2.1.4.1 The global distribution of the HBB gene haplotypes 
How severely the phenotype manifests can be predicted by determining which haplotype is 
present, since genetic variants have an impact on the production of HbF (Steinberg and 
Sebastiani 2012). The Arab-/Saudi-Indian haplotype has the highest associated levels of HbF 
(Labie et al. 1989), followed by the Senegal and Benin haplotypes (Green et al. 1993; Nagel 
1994), while the Bantu haplotype has the lowest concentration of HbF (Labie et al. 1985; 
Nagel et al. 1985; Nagel et al. 1987). 
A study by Hattori et al. (1986), investigating a population from Georgia (USA), reported that 
15% of the patients studied, carried the Senegal haplotype, 27% carried the Bantu haplotype 
and 54% carried the Benin haplotype. Magaña et al. (2005) reported that the Bantu (78.8%) 
and the Benin (18.2%) haplotypes were most prevalent in Mexico. In a later study, the 
occurrence of the Senegal (2.5%) and Cameroon (1.2%) haplotypes were reported in the same 
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population (Guzmán et al. 2010). Jones-Lecointe et al. (2008) reported that the Benin (61.8%), 
Bantu (17.3%), Senegal (8.5%), Cameroon (3.5%), and Arab-Indian (3.2%) haplotypes occurred 
in the Trinidad population. In Jamaica, the Benin haplotype is most prevalent (Ndugwa et al. 
2012).  
The Uruguayan population is made up of individuals of African, European, and Native 
American origin (Da Luz et al. 2006). Over 30% of the Uruguayan population is of African 
descent, more specifically from Angola, Benin, Congo, Mozambique, and Gambia (Da Luz et 
al. 2006). The most common haplotypes found in the Uruguayan population are the Bantu 
and Benin haplotypes (Da Luz et al. 2006). A study by Pante-de-Sousa et al. (1999) reported 
that 67% of the Brazilian cohort carried the Bantu haplotype, 30% of the cohort carried the 
Benin haplotype and the remaining 3% carried the Senegal haplotype. A later study by 
Cardoso and Guerreiro (2006), confirmed that the Bantu and the Benin haplotypes were most 
prevalent, and the Senegal and Cameroon haplotypes were the least frequently occurring 
types in the Brazilian population. Arends et al. (2000) reported that the Benin (51%), Bantu 
(29.5%), Senegal (12.5%), and Cameroon (2.5%) haplotypes occur in Venezuela. In Colombia, 
the Bantu, Benin, Senegal, and Cameroon haplotypes were found at the following respective 
frequencies: 55.5%, 34.8%, 4.3%, and 5.4 % (Cuéllar-Ambrosi et al. 2000). 
In Southern India, the Arab-Indian haplotype is most common (91%; Labie et al. 1989). 
Mukherjee et al. (2004) reported that the Arab-Indian haplotype (91.5%) was most common, 
with the rare occurrence of the Cameroon haplotype (0.7%) in West India. 
In Congo, the Bantu and Senegal haplotypes are most common (Mouélé et al. 2000). In Sudan, 
the Cameroon, Benin, Bantu, and Senegal haplotypes were most prevalent (Mohammed et 
al. 2006; Elderdery et al. 2012). Veten et al. (2012), reported that the Senegal (77.8%), Benin 
(8.8%), Arab-Indian (5.5%) and Bantu (4.4%) haplotypes occurred in the Mauritanian 
population. In Uganda, the Bantu haplotype is most prevalent (Ndugwa et al. 2012). 
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Figure 5: The global distribution of the HBB gene haplotypes 
Five distinctive HBB gene haplotypes are linked to SCA (designated by specific colours). Each colour depicts a 
particular haplotype, named after its geographic region of origin. These five haplotypes are the Benin (yellow), 
Cameroon (red), Bantu/Central African (blue), Saudi-/Arab-Indian (purple) and Senegal (green) types. The 
haplotype distribution is not restricted to their countries of origin, with a broad distribution across the globe, 
as the result of migration (Gabriel and Pryzbylski 2010). 
2.1.4.2 Genetic modifiers of SCA: HbF, haplotypes and clinical severity 
HbF is a genetic modifier for SCA (Steinberg and Sebastiani 2012). The difference in HbF levels 
for each haplotype can be attributed to the variance in the regulation of the HBG1 and the 
HBG2 genes (Ngo et al. 2013; Lettre et al. 2008; Steinberg and Nagel 2009; Steinberg and 
Sebastiani 2012). High levels of HbF have a pain-preventing effect as it decreases the 
polymerisation of HbS, which leads to a decrease in erythrocytic sickling and vaso-occlusion 
in SCA patients (Darbari et al. 2012). 
2.1.4.2.1 ARAB-/SAUDI-INDIAN HAPLOTYPE 
The Arab-/Saudi-Indian haplotype occurs most frequently in people of Indian and Arab 
descent (Pagnier et al. 1984; Kulozik et al. 1986; Labie et al. 1989; Lapoumeroulie et al. 1992; 
Pandey et al. 2012; Alsultan 2014). The nomenclature for this SNP is NM_000184.2:c.-211C>T, 
(rs7482144), (NCBI 2014) digested by the Xmn1 restriction endonuclease, which recognises 
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the T-allele (Gilman and Huisman 1985; Nagel 1994). This causes the elevated expression of 
HBG2, thereby increasing the production of HbF (Ngo et al. 2013). The rs7482144 SNP 
significantly influences the phenotypic representation of SCA, where patients have high levels 
of HbF and present with a milder phenotype (Labie et al. 1989). A recent study by Colah et al. 
(2014) found that Indian SCA patients with the Arab-/Saudi-Indian haplotype do not manifest 
a mild form of the disease, despite their high HbF levels. 
2.1.4.2.2 BANTU/CENTRAL AFRICAN HAPLOTYPE 
The Bantu haplotype occurs mainly in individuals originating from Angola, the Congo, and 
Mozambique (Pagnier et al. 1984; Lavinha et al. 1992; Öner et al. 1992; Da Luz et al. 2006; 
Carvalho dos Santos et al. 2012). This haplotype is most frequent in Brazil and Tanzania (Labie 
et al. 1985; Nagel et al. 1985). The SNP associated with this haplotype is NM_000559.2:c.-
264C>T (rs63750033), (NCBI 2014) recognised by the T-allele by HincII restriction 
endonuclease digest (Bouhassiera et al. 1989; Month et al. 1990). Individuals with this 
haplotype have low levels of HbF, which results in a severe form of SCA (Labie et al. 1985; 
Nagel et al. 1985; Nagel et al. 1987; Steinberg et al. 2001; Leite et al. 2011). 
2.1.4.2.3 BENIN HAPLOTYPE 
The Benin haplotype originated in West Africa and occurs most frequently in the Caribbean, 
North America, South America, Algeria, Brazil, and in the Bamileke, Bassa, Boulou, Ewondo, 
and Yambassa African population groups (Pagnier et al. 1984; Lapoumeroulie et al. 1992; Öner 
et al. 1992; Da Luz et al. 2006). NM_000184.2:c.327T>A (rs281860625) (NCBI 2014) is the SNP 
associated with the Benin haplotype, recognised by the A-allele, and digested by HindIII 
(Pagnier et al. 1984). The Benin haplotype is associated with intermediary levels of HbF where 
the clinical features common to this haplotype include leg ulcers and priapism (Green et al. 
1993; Alsultan et al. 2012). 
2.1.4.2.4 CAMEROON HAPLOTYPE 
The first discovery of the Cameroon haplotype was in the Eton population located in the East 
of Cameroon (Lapoumeroulie et al. 1992). NM_000559.2:c.316-73G>A (rs112599588) (NCBI 
2014) is the SNP associated with the Cameroon haplotype, recognised by the A-allele and 
digested by HindIII (Lapoumeroulie et al. 1992). Patients with the Cameroon haplotype have 
low HbF levels (Green et al. 1993). Infants with SCA and the Cameroon haplotype are at an 
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elevated risk for the development of cerebrovascular disease (Sarnaik and Ballas 2001; Lyra 
et al. 2005). 
2.1.4.2.5 SENEGAL HAPLOTYPE 
The Senegal haplotype occurs most frequently in West Africa (Lavinha et al. 1992; Öner et al. 
1992). NM_000184.2:c.-211C>T, (rs7482144) (NCBI 2014) is the SNP associated with the 
Senegal Haplotype, which is recognised by the HinfI restriction endonuclease at the T allele 
(Month et al. 1990; Nagel 1994; Steinberg and Sebastiani 2012). Patients with this haplotype 
have elevated HbF levels (Green et al. 1993; Nagel 1994). High HbF levels lengthen the survival 
of SCA patients who have been left untreated (not on Hydroxyurea; Steinberg and Sebastiani 
2012). High concentrations of HbF are linked to: (1) a decrease in the frequency of severe 
painful incidences, (2) fewer leg ulcers, (3) a reduction in the occurrence of severe chest 
disorders, (4) a protective effect against osteonecrosis, splenic sequestration and 
cholelithiasis, (5) a prolonged life expectancy for erythrocytes, (6) an elevation in the amount 
of haemoglobin, (7) increased longevity and (8) a lower risk of peri-natal death during 
pregnancy (Steinberg and Sebastiani 2012). A low level of HbF elevates the patient’s risk of 
splenic sequestration, which can lead to a loss in splenic function and an increase in capillary 
occlusion, thereby pre-disposing the patient to retinopathy (Steinberg and Sebastiani 2012). 
2.2 ALPHA-THALASSEMIA (α-thalassemia) 
2.2.1 EPIDEMIOLOGY 
Alpha-thalassemia affects 5% of the global population (Chui 2005; Vichinsky 2010). The global 
distribution of α-thalassemia corresponds to the tropical and sub-tropical regions of the 
world: sub-Saharan Africa, the Mediterranean (Italy and Greece), the Middle East, and parts 
of Asia, such as East India, South East Asia and China (Weatherall and Clegg 2001a). 
2.2.1.1 Alpha-thalassemia within a global context 
Alpha-thalassemia was introduced to America because of the slave trade and mainly affects 
African Americans (Weatherall and Clegg 2001a). Europe has a low incidence of α-thalassemia 
(Affronti et al. 2011; Calleri et al. 2011). High frequencies have been reported in Central and 
Western Nepal (83% and 73%; Modiano et al. 1991), Melanesia (68%; Flint et al. 1985), Saudi-
Arabia (55%; El-Hazmi and Warsy 2000), India (50.84%; Purohit et al. 2014), France (44%; 
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Kéclard et al. 1996) and Venezuela (proportion not available; Arends et al. 2000). Relatively 
lower frequencies have been reported in Spain (1.24%; Pellicer 1969), Norway (4.7%; 
Graesdal et al. 2001), Portugal (5%; Peres et al. 1995), Egypt (8%; Novelletto et al. 1989) and 
Trinidad (17%; Jones-Lecointe et al. 2008). 
2.2.1.2 Alpha-thalassemia within the African context 
Alpha-thalassemia is highly prevalent in Nigeria (21%; Kotila 2012), the Congo (29%; Mouélé 
et al. 2000), Togo (47%; Segbena et al. 2002), Kenya (48.1%; Foote et al. 2013; Suchdev et al. 
2014), Malawi (49.8%; Brabin et al. 2004), Senegal (proportion not available; Tine et al. 2012) 
and Burkina Faso (proportion not available Labie et al. 1984). Alpha-thalassemia occurs at low 
frequencies in Tunisia (2%; Zorai et al. 2002), Zimbabwe (3.3%; Chidoori et al. 1989), Gambia 
(12%; Allen et al. 1993), Rwanda (15.1%; Gahutu et al. 2012) and South Africa (Matthew et al. 
1983; Rousseau et al. 1985). In South Africa, the 3.7kb α-globin gene deletion is most 
commonly reported (Krause et al. 2013). For Cameroon, there is no data available for the 
incidence of α-thalassemia (as per a PubMed search using the key words: “Alpha-thalassemia 
Cameroon”). 
2.2.2 MOLECULAR AND CLINICAL MANIFESTATIONS OF α-THALASSEMIA 
2.2.2.1 SIGNS AND SYMPTOMS 
Patients with α-thalassemia may manifest symptoms such as a pale facial appearance, mild 
anaemia, constant weakness, fatigue, slowed growth, delayed puberty, poor appetite, dark 
urine, jaundice and osteoporosis (Higgs and Weatherall 2009). 
2.2.2.2  MOLECULAR PATHOLOGY 
The α-globin gene cluster is composed of genes HBA1 and HBA2, and pseudo-genes HBZP, 
HBAP1 and HBM located on chromosome 16p13.3 (Figure 3; Weatherall et al. 1981; Galanello 
and Cao 1993). Genes HBA1 and HBA2 are responsible for the production of α-globin, forming 
HbA (Weatherall et al. 1981). In a healthy human (diploid), there are four α-globin chains 
(Weatherall et al. 1981). 
Alpha-thalassemia is categorised by a reduced production of the α-globin chain due to 
mutations in the HBA1 or HBA2 genes, which in turn leads to a decrease in the production of 
HbA (Weatherall and Clegg 2001; Cao and Galanello 2010). In child patients, there is an 
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increase in the β-globin subunits, forming haemoglobin H (HbH), and in affected infants there 
is an increase in the ƴ-globin subunits, resulting in the inability of oxygen to bind to the HbA 
molecule, which leads to inefficient oxygen transport throughout the body (Weatherall and 
Clegg 2001; Cao and Galanello 2010). Alpha-thalassemia also occurs due to a mutation where 
one (αα/α-, silent carrier), two (αα/- -), three (α-/- -) or four (- -/ - -) copies/alleles of the α-
globin chains are deleted (Weatherall et al. 1981). There are two forms of the single-gene 
mutation types: α-thalassemia type-1, which is the result of a cis deletion of both α-globin 
genes on the same chromosome (- -/αα), and α-thalassemia type-2, a trans deletion of α-
globin genes on opposite chromosomes (-α/-α; Bowden et al. 1987). 
The two α-thalassemia mutations that occur most commonly are the 3.7kb and the 4.2kb α-
globin gene deletions (Tan et al. 2001). These deletions are located in the HBAP1 pseudogene 
(Genbank ID: 3041), affecting the HBA2 gene (Galanello and Cao 1993). 
2.2.2.3 PATHOPHYSIOLOGY 
The noteworthy variety in phenotypes manifested by patients with SCA is linked to the co-
inheritance of α-thalassemia, where the patient inherits two HbS mutations on both HBB 
genes, HbSS, along with one or more deletions of the α-globin chain (Cao et al. 1994; Ashraf 
2008; Akinsheye et al. 2011). 
Alpha-thalassemia is due to the quantitative haemoglobinopathies, as a result of the 
reduction in the α-chain production. In most cases, this is as the result of a deletion of one or 
more of the four α-globin genes (Culligan and Watson 2009). The consequence of these 
mutations and reduction in α-globin proteins, is an unbalanced excess of the β-globin chains 
that form tetramers which crystallise in the red blood cell, and damage them; enhancing a 
massive haemolysis of the developing and mature erythrocytes (Culligan and Watson 2009). 
Haematologically, α-thalassemia manifests as microcytic or hypochromic anaemia (Culligan 
and Watson 2009). Clinically, α-thalassemia may range from being asymptomatic to resulting 
in intra-uterine death due to severe anaemia or heart failure (Culligan and Watson 2009). The 
heart problems associated with α-thalassemia are myocardial infarction, ischaemia and 
arrhythmias (Higgs and Weatherall 2009). If these complications are not sufficiently treated, 
it may lead to death (Higgs and Weatherall 2009). 
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One or two α-globin gene deletions are classified as “α-thalassemia trait”. Individuals with 
one deletion have a normal haematological profile and slightly lower mean corpuscular 
volume (MCV; Murphy 1999; Culligan and Watson 2009). Individuals with two deletions 
have low MCV, low mean corpuscular haemoglobin concentration (MCHC), microcytosis 
and, in some cases, anaemia (Murphy 1999; Culligan and Watson 2009). Individuals with 
three deletions may present with moderate anaemia (HbA = 7-10g/dl), splenomegaly and 
varying HbA2 levels (Murphy 1999). Individuals with four deleted genes do not produce α-
globin and are unable to transport oxygen (Murphy 1999). In this case, infants are stillborn 
between 28-40 weeks or die shortly after birth (Murphy 1999). These infants are pale, 
oedematous and have an enlarged spleen and liver (Murphy 1999). 
2.2.2.4 INHERITANCE PATTERN 
Alpha-thalassemia is heritable. If both parents are heterozygous (α-thalassemia trait, having 
one or two α-globin gene deletions) for this condition, there will be a 25% chance of 
conceiving a healthy or diseased child, or a 50% chance to conceive a child that may be an 
asymptomatic carrier of the disease (Weatherall et al. 1981). If only one parent carries a single 
gene deletion and the other has no alpha-globin gene deletion, all the offspring will be 
asymptomatic. Here there is a 50% chance to conceive a child carrying the single gene copy 
deletion, while there is a 50% chance to conceive a child with no α-globin gene deletions 
(Weatherall et al. 1981). Varying genotypes give rise to varying phenotypes based on the 
amount of α-globin genes inherited (Bianchi et al. 1986; Higgs et al. 1989). The inheritance of 
none of the four α-globin genes (- -/- -) results in HbA Barts syndrome which leads to severe 
intra-uterine anaemia (Bianchi et al. 1986; Higgs et al. 1989). When one α-globin gene is 
inherited (- -/- α), HbH disease develops, resulting in moderately severe haemolytic anaemia 
(Bianchi et al. 1986; Higgs et al. 1989). 
2.2.4 ALPHA-THALASSEMIA: A GENETIC MODIFIER OF SCA 
Alpha-thalassemia is a genetic modifier of SCA that diminishes the severity of the disease by 
reducing the amount of sickled erythrocytes, increasing the HbF level, and decreasing the 
intracellular HbS level (Embury et al. 1982a; Embury et al. 1982b; Steinberg and Embury 1986; 
Galanello and Cao 1998; Belisário et al. 2010). This results in a reduction in HbS-prompted 
cellular destruction, thereby reducing haemolysis (Embury et al. 1982a; Embury et al. 1982b; 
Steinberg and Embury 1986; Galanello and Cao 1998; Belisário et al. 2010). When the mean 
MCV and MCHC are low, there is a reduction in intravascular sickling (Condon et al. 1983). 
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These patients manifest an improved clinical phenotype in the form of milder acute chest 
syndrome, and leg ulceration (Condon et al. 1983). Patients display a decrease in the bilirubin 
concentration, a lower lactate dehydrogenase (LDH) concentration, less sickled erythrocytes, 
a prolonged lifespan of the erythrocytes, and an increase in HbA and packed cell volume (PCV) 
(Steinberg and Embury 1986; Belisário et al. 2010). The extent of the protective effect 
depends on the amount of α-globin genes that are deleted (Steinberg and Embury 1986; 
Belisário et al. 2010). The presence of α-thalassemia in a SCA patient reduces the risk of 
stroke, silent infarction, priapism, leg ulcers, splenic sequestration, cholelithiasis, 
cardiovascular disease; it also plays a role in the protection of splenic and renal functioning 
(Belisário et al. 2010; Steinberg and Sebastiani 2012). In children, the presence of α-
thalassemia lessens the risk of acute chest syndrome (Steinberg and Sebastiani 2012). The co-
inheritance of α-thalassemia has also been associated with decreasing the risk of abnormal 
cerebral blood flow in Tanzanian SCA patients (Cox et al. 2014). 
However, the findings that α-thalassemia improves the SCA phenotype remain controversial 
(Condon et al. 1983; Steinberg 2005; Joly et al. 2011). It has been reported that the presence 
of α-thalassemia in SCA patients can also have adverse effects (Steinberg and Sebastiani 
2012). Alpha-thalassemia has been linked to a heightened the risk of VOCs and an elevated 
the risk of osteonecrosis due to higher PCV levels and red blood cell adhesion (Steinberg and 
Sebastiani 2012). Condon et al. (1983) reported that α-thalassemia had no effect on the more 
severe phenotypic characteristics such as the VOCs. In addition, Steinberg (2005) reported 
that α-thalassemia has little or no effect on survival and the number of VOCs. Furthermore, 
Joly et al. (2011) reported no positive relationship between the occurrence of α-thalassemia 
and a decrease in the clinical severity of the phenotypes associated with SCA in HbSS patients, 
which could be attributed to the length of data compilation, availability of neonatal screening, 
use of transcranial Doppler ultrasound to prevent vasculopathies, and the kind of HBB gene 
haplotype. These studies show that the coinheritance of α-thalassemia does not improve the 
SCA phenotype in all cases.  
2.3 ROLE OF MALARIA 
Malaria occurs in 90% of Cameroon (WHO, 2014). SCA and α-thalassemia is prevalent in areas 
where malaria occurs, and widely distributed throughout sub-Saharan Africa, the Middle East 
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and parts of India (Alison 1964; Bayouni 1987; Marsh 1992; Saraf et al. 2014). The significant 
overlapping in the geographical distribution of malaria, SCA and α-thalassemia, results in 
frequent co-inheritance (Flint et al. 1998). A survival advantage against severe malaria 
explains the occurrence of HbAS and α-thalassemia at high frequencies in malaria-endemic 
populations (Purohit et al. 2014). These disorders in the heterozygous state act as malaria 
resistance genes and influence the susceptibility to the malaria parasite (Purohit et al. 2014). 
More recently, migration patterns have led to the distribution of SCA into non-endemic 
malaria regions (Saraf et al. 2014). Malaria protective polymorphisms have reached high 
frequencies in tropical areas despite the spectrum of deleterious consequences linked to their 
homozygous state (Beaudry et al. 2014). Furthermore, little is known about the 
epidemiological and clinical consequences of the co-inheritance of SCA and α-thalassemia, 
which are common occurences in many parts of the malaria-endemic world. More specifically, 
it is the SCA trait (HbAS) that is protective against malaria (Alison 1964; Ringelhann et al. 1976, 
Bayouni 1987; Ojwang et al. 1987; Marsh 1992; Aluoch 1997; Albiti and Nsiah 2014; Suchdev 
et al. 2014). HbAS offers more protection when compared to other traits (Amoake et al. 2014). 
Sickle haemogobin offers a selective advantage against malaria (Amoake et al. 2014). This 
protective effect by the heterozygote is due to a ‘balanced polymorphism’, where a 
heterozygote has a selective advantage over a homozygote genotype (Arif 2012). The risk of 
contracting malaria decreases by 90% for individuals with the sickle cell trait (HbAS) (Taylor 
et al. 2012). This beneficial effect can be attributed to the malaria parasite exerting selection 
pressure on human populations to increase the presence of the HbAS gene (Liddell et al. 
2014). More specifically, higher malaria mortality rates can exert selective pressure to 
increase the prevalence of the SCA trait (Liddell et al. 2014). Parasite density decreases in 
HbAS with malaria co-infection, when compared to patients with Malaria only (no SCA) (Albiti 
and Nsiah 2014). The mean levels of HbA, PCV, reticulocytes, platelet count, lymphocytes, 
eosinophils and serum iron were significantly decreased in malaria only patients when 
compared to HbAS indiviudals co-infected with Malaria (Albiti and Nsiah 2014). Total 
leukocytes, immature granulocytes, monocytes, erythrocyte sedimentation rate, transferrin 
saturation and serum ferritin were significantly increased in patients with Malaria only, when 
compared to HbAS indivuduals who were co-infected with Malaria (Albiti and Nsiah 2014).  
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The mechanism of protective action is not fully understood. Upon infection, the malaria 
parasite, Plasmodium falciparum (P.falciparum), is prematurely deprived of its growth 
medium due to the red blood cell membrane becoming instantaneously impermeable to the 
sporozite and/or merozite (Luzzatto et al. 1970; Aluoch 1997; Ayi et al. 2004). An increase in 
phagocytosis (by the monocytes) results in a breach of the red blood cell membrane with 
erythrocyte sickling and fragmentation; therefore, trophozoiteosis is rarely accomplished 
(Luzzatto et al. 1970; Roth et al. 1978; Aluoch 1997; Ayi et al. 2004). The sickled erythrocytes 
are detached from circulation and destroyed in the reticuloendothelial system, thereby 
decreasing the effect of malaria in SCA carriers (Luzzatto et al. 1970; Roth et al. 1978; Aluoch 
1997; Ayi et al. 2004). P.falciparum may also be killed in the sickled erythrocytes due to low 
oxygen tensions and resultant metabolic destruction (Friedman 1978; Friedman 1979). 
Oxygen radical development in the erythrocytes of carriers also inhibits the growth of 
P.falciparum (Anastasi 1984).  
The host immune system plays a role in the pathogenicity of the malaria parasite (Cornille-
Brogger et al. 1979; Fleming et al. 1979; Fleming 1989). For a foetus, maternal antibodies 
provide the protection against malaria, which ceases during infancy, where the infant’s 
immune system begins to provide the protection (Cornille-Brogger et al. 1979; Fleming et al. 
1979; Fleming 1989). 
Alpha-thalassemia also confers a resistance to malaria, in patients with SCA (HbSS; Flint et al. 
1985), specifically protecting against severe and fatal malaria in both the heterozygous and 
homozygous forms (Williams et al. 2005a; Taylor et al. 2012). However, the co-inheritance of 
α-thalassemia in SCA carriers (HbAS) results in a 10% protection against malaria (Williams et 
al. 2005; May et al. 2007). Opoku-Okrah et al. (2013), reported that α-thalassemia, specifically 
the 3.7kb deletion, had no protective effect against malaria. The protective mechanism in this 
instance was due to the impaired ability of infected erythrocytes to adhere to the 
microvascular endothelial cells and the monocytes (Krause et al. 2012). In a more recent 
study, Glushakova et al (2014), showed that haemoglobin erythrocytes reduce the 
intraerythrocytic multiplication of P.falciparum thereby delaying the development of the 
parasite. These authors used a mathematical model to assess the effect of intraerythrocytic 
multiplication factor (IMF) (an in vitro assay that quantifies the number of merozites released 
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from an individual schizont) on malaria progression (Glushakova et al 2014). This lower IMF 
limits parasite density and offers a lesser clinical severity against anaemia over the first two 
weeks of P.falciparum replication (Glushakova et al 2014). However, for future research and 
perspective, IMF has yet to be examined in other low-index erythrocytes (Glushakova et al 
2014). The mechanism by which α-thalassemia on its own protects against severe malaria 
remains unresolved (Opi et al. 2014). 
Opi et al. (2014), reports that the negative epistasis between HbAS and α-thalassemia can be 
explained by host genotype-specific changes in the parasitized RBC’s adhesion properties that 
contribute to parasite sequestration and disease pathogenesis in vivo. However, rather than 
conferring an additive protective advantage, the co-inheritance of both HbAS and α-
thalassemia is associated with the loss of the malaria shield that is ordinarily afforded by each 
when co-inherited individually, through an unknown mechanism (Williams et al. 2005b; May 
et al. 2007; Crompton et al. 2008). 
Despite the extraordinary protection that HbAS affords against malaria, there are few 
geographic regions places where the carrier frequency exceeds 25%. This is seemingly due to 
the rise of the mutation in populations, above 25%, being kept in check by the 
morbidity/mortality-disadvantage as a result of homozygosity (Grosse et al. 2011). 
2.4 STUDY RATIONALE: 
Despite the fact that more than 70% of SCA sufferers live in Africa (which amounts to about 
13 million people; Piel et al. 2013), the understanding and management of SCA has been 
based on investigations in the north of Africa and in other parts of the world (Smith 1943; 
Embury et al. 1982a; Pagnier et al. 1984; Bayoumi et al. 1985; Steinberg and Embury 1986; 
Guasch et al. 1999; Da Luz et al. 2006; Belisário et al. 2010; Pandey et al. 2011). Thus, there is 
a dearth in data on the incidence of SCA in places like Cameroon. 
The co-inheritance of α-thalassemia in Africa is also poorly understood. Alpha-thalassemia-2 
is the most commonly occurring type in Africa, where it is present in 30% of individuals, with 
the 3.7kb α-globin gene deletion as the most frequently observed disease-causing mutation 
(Baysal and Huisman 1994; Da Luz et al. 2006). It has been suspected that co-inheritance of 
α-thalassemia and SCA correlates to a reduced morbidity and mortality rate of SCA patients 
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(Embury et al. 1982; Embury et al. 1982b; Steinberg and Embury 1986; Galanello and Cao 
1998; Belisário et al. 2010; Steinberg and Sebastiani 2012). However, little is known about the 
prevalence of α-thalassemia and its effect on the clinical phenotypes in Cameroonian SCA 
patients. 
This study will provide new data for understanding the genotype to phenotype correlation of 
SCA in Africa, specifically contributing towards a better understanding of the occurrence of 
this disease within the Cameroonian population. It will further positively contribute towards 
the anticipatory guidance in the healthcare of patients such as establishing and following early 
diagnosis, neonatal screening, protocols for optimal disease management, faster treatment 
initiation, and appropriate comprehensive medical care before the onset of symptoms. In 
addition, this study will serve as an initial attempt to gauge the influence of α-thalassemia on 
the clinical severity of SCA in Cameroonian patients. 
2.5 AIM AND OBJECTIVES: 
The aim of this project is to study the prevalence of α-thalassemia in a sample of Cameroonian 
SCA patients and to study the correlation between the α-thalassemia genotypes and 
phenotypes in SCA patients in order to: 
1. Confirm the molecular diagnosis of SCA (HbSS type). 
2. Describe the HBB gene haplotypes in the patient cohort. 
3. Study the deletions of the α-thalassemia genes in SCA patients and unaffected 
individuals. 
4. Study the correlation between the α-thalassemia genotypes, the haematological 




CHAPTER 3: MATERIALS AND METHODS 
3.1 ETHICAL CONSIDERATION 
The study was performed in accordance with the guidelines of the Helsinki Declaration (WMA, 
2008). Ethical approval was given by the National Ethical Committee Ministry of Public Health, 
Republic of Cameroon N°033/CNE/DNM/07 on 23 April 2007, and by the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee (HREC; RE: 132/2010) 
on 19 January 2010. Written and signed informed consent was obtained from participants 
who were 18 years or older, while assent was obtained from the parents/guardians of the 
children under the age of 18 years. 
3.2 STUDY DESIGN 
This study was a cross-sectional, descriptive, and analytical based-study. 
3.3 RESEARCHER’S ROLE 
The project’s journey began with the formulation of a research question. The project was 
designed by Professor Ambroise Wonkam, the principle supervisor. Under his supervision, 
individuals were recruited in Cameroon by the staff at Yaoundé Central and Laquitine Douala 
Hospitals, and controls from the areas surrounding these hospitals. DNA was extracted at the 
molecular diagnosis laboratory of the Gyneco-Obstetric and Paediatric units at Yaoundé 
Central Hospital. The DNA was stored and brought to Cape Town, South Africa, by Miss 
Valentina Josiane Ngo Bitoungui, a PhD candidate at The University of Yaoundé. All of the 
experimental analysis, trouble-shooting, data analysis, interpretation of the data, presented 
in this dissertation, and the writing up of this dissertation, was performed by Miss Maryam 
Bibi Rumaney, the MSc candidate working on this project towards a MSc degree in Human 
Genetics from the University of Cape Town. The project was co-supervised by Miss Anna 
Alvera Vorster, a Scientific Officer at the Division of Human Genetics at the University of Cape 
Town, who provided assistance on the experimental and data analysis, and Professor Raj 
Ramesar, the Head of the Division of Human Genetics at the University of Cape Town, who 
provided input on the writing of this dissertation. 
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3.4 RESEARCH SETTING AND CLINICAL DATA COLLECTION 
The study was conducted at the Yaoundé Central Hospital, and Laquitine Douala Hospital, in 
Cameroon. An introductory explanation (Appendix A1) informed patients, parents, and 
guardians of the purpose of the study. Signed, informed consent (Appendix A2) was obtained 
at this stage. Socio-demographic and clinical data was collected by means of a structured 
questionnaire (Appendix A3). The socio-demographic questionnaire enquired about the age, 
gender, level of formal education, employment, household income, marital status, and 
residence of each participating individual. Patients’ medical records were reviewed to 
delineate their clinical features, specifically for the confirmation of the number of hospital 
attendances, admissions, blood transfusions and any administration of hydroxyurea. 
Haemoglobin electrophoresis and the complete routine blood count of participants were 
performed upon arrival at the hospital. Patients were previously diagnosed as having the 
HbSS form of SCA, which was determined based on their medical records. 
3.5 SAMPLE/PATIENT INFORMATION 
The sample size was mathematically determined. The estimated prevalence of the variable of 
interest, the desired level of confidence and the acceptable margin of error was considered. 




𝑡2 × 𝑝(1 − 𝑝)
𝑚2
 
Where ‘n’ refers to the required sample size, ‘t’the confidence level at 95% (standard value 
of 1.96), ‘p’the estimated prevalence in the project area and ‘m’ the margin of error at 5% 
(standard value of 0.05). 
Approximately 20% of the Cameroonian population are heterozygous carriers of the α-






1.962 × 0.2(1 − 0.2)
0.052
 
= 245 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 (𝑎𝑝𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑡𝑒𝑙𝑦) 
The study was composed of 262 individuals, with 52 (20%) HbAA, 32 (12%) HbAS and 178 
(68%) HbSS individuals. 
The control cohort (HbAA and HbAS) consisted of randomly selected individuals who were 
apparently healthy blood donors, and who volunteered their participation in the study. A 
complete haematological profile (full haematological indices and haemoglobin 
electrophoresis results) and socio-demographic data (age, gender, and ethnic background) 
was collected for these individuals. 
The inclusion criteria for SCA patients consisted of (1) the confirmed molecular diagnosis of 
SCA by the HbSS (homozygous) variant only, (2) a complete haematological profile (full blood 
count and haemoglobin electrophoresis results) and (3) the availablility of clinical data 
(frequency of VOCs, stroke, hospital consultations and hospitalisations). 
The exclusion criteria consisted of: (1) patients that have had a blood transfusion in the past 
six months, (2) patients who have had a clinical event requiring hospitalisation and (3) 
patients who have been subjected to hydroxyurea treatment (Hydroxyurea is the treatment 
offered to SCA patients to help prevent the formation of sickled erythrocytes. For the purpose 
of this study, it is important to consider patients without factors that could modify the 
disease.). 
Individuals who were found to have any haemoglobinopathies other than the HbSS form of 
SCA (upon High Performance Liquid Chromatography (HPLC) screening at Haematology 
Laboratory of the Centre Pasteur in Yaoundé, Cameroon) were excluded from the study. One 
haemoglobin C (HbSC) individual and 3.5% of the individuals screened had β-thalassemia. The 
remaining individuals were HbAA, HbAS, or HbSS. 
Education-related data was only available for 98 of the patients in the study cohort. The 
education levels of patients was documented, which revealed that the majority had been 
educated at secondary school level (N=37), followed by primary school education (N=37), 
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university education (N=18), and a few patients with no formal education (N=6). The Appendix 
contains all the information and data on the subjects that participated in the study (Appendix 
A4; Table 24). 
3.6 LEVEL OF PATIENT CARE 
The management of SCA is multidisciplinary, affecting the patient and their family members 
(Asnani 2010). Comprehensive care requires patient and parent data, genetic counselling, 
social services, infection prevention, dietary evaluation and suggestions, psychotherapy, 
specialist medical care, and maternal and child health care (Okpala et al. 2002). 
Care is provided mainly by the public health care system in rural areas, which is composed of 
primary level medical facilities, district hospitals and community clinics (Echouffo-Tcheugui 
and Kengne 2011). Private medical care is slowly growing in the urban areas (Echouffo-
Tcheugui and Kengne 2011). However, medical insurance is not widely used due to its high 
cost (Echouffo-Tcheugui and Kengne 2011; Wonkam et al. 2014a). The healthcare system is 
composed of two physicians and 16 nurses and/or midwives for every 100 000 people 
(Echouffo- Tcheugui and Kengne 2011). In addition, the general resource shortages result in 
major care being the resposibility of caregivers and family members of patients (Echouffo-
Tcheugui and Kengne 2011). Late diagnosis is common due to high laboratory costs. Transport 
costs are a factor in determining whether consultations were upheld and hospitalisation 
depends on the severity of the disease (Echouffo-Tcheuguiand and Kengne 2011). 
Patients were selected because of their presence at the SCA clinics from which recruitment 
was performed. Adults have two consultations per year and children have them more 
frequently.  
3.7 HbF DETECTION 
Two methods for HbF detection were employed in this study: (i) an Alkali denaturation test 
(ADT) (Betke et al. 1959; Perutz 1974), and (ii) high performance liquid chromatography 
(HPLC) (Shelton et al. 1979; Tietz 1990; Fucharoen et al. 1998; Guideline 1998). Both 
procedures were performed at the Haematology Laboratory of the Centre Pasteur in 
Yaoundé, Cameroon. 
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3.7.1. ALKALI DENATURATION TEST (ADT) 
3.7.1.1 Sample preparation 
The blood sample in the EDTA tube (Greiner Bio-One, Chonburi, Thailand ) was rinsed 
thoroughly with 0.9% saline and lysed by adding 2 volumes of distilled water with 1 volume 
of toluene or carbon tetrachloride (CCl4) (Sigma Aldrich, Munich, Germany). The erythrocytes 
were mixed using a vortex (Vortex Genie 2, New York, USA) and centrifuged for 30 minutes at 
1200xg. The remaining clear haemoglobin solution (haemolysate) was pipetted off and 
retained. 
3.7.1.2 Components 
The following reagents and solutions were required: (1) Drabkin’s solution [200mg of 
K3Fe(CN)6 (Sigma Aldrich, Munich, Germany) and 200mg of KCN (Sigma Aldrich, Munich, 
Germany) in 1L of distilled water], (2) 1.2M NaOH (4.8g in 100ml distilled water) (Sigma 
Aldrich, Munich, Germany), and (3) (NH4)2SO4 saturated solution (706g in 1L distilled water, 
which was heated to dissolve, and then slowly cooled to room temperature - 22°C). 
3.7.1.3 Method 
The haemolysate (0.6ml) was added to the Drabkin’s solution (10ml), which produced a 
cyanmet solution. Then, 2.8ml of this solution was added to 0.2ml of the alkali solution 
(NaOH) and mixed using a vortex (Vortex Genie 2, New York, USA). After 2 minutes, 2ml of 
the (NH4)2SO4 solution was added. The solution was mixed using a vortex (Vortex Genie 2, 
New York, USA) and left to precipitate for 10 minutes. The precipitate was removed by 
filtration, by using a double layer of filter paper (Whatman no. 6 or 42, GE, Connecticut, USA) 
and the optical density of the filtrate at 415nm was determined using a Nanodrop (ND-1000 
Spectrophotometer, Thermo-fischer Scientific, Delaware, USA). 
A control solution was prepared by mixing 1.4ml of the cyanmet solution, 1.6ml of distilled 
water and 2ml of saturated (NH4)2SO4. This solution was diluted, in a 1:10 ratio, with distilled 
water to obtain a suitable optical density. 




OD TEST SAMPLE AT 415MM X 100
OD CONTROL SAMPLE AT 415MM X 20
 
 
3.7.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
HPLC is an automated process. The CLHP Bio-Rad D-10 analyser (Bio-Rad, California, USA) was 
used to establish the types of haemoglobin present in the study cohort. A blood sample from 
the EDTA collection tube (Greiner Bio-One, Chonburi, Thailand) was loaded onto the cartridge 
and results were produced within 6 minutes. The CLHP Bio-Rad D-10 analyser functions on 
the principle that samples are automatically diluted and injected into the analytical cartridge. 
A gradient is established, where haemoglobin types are separated according to their ionic 
correlation, to the material of the cartridge. The separated haemoglobins are measured for 
changes in absorbance at 415nm. The built-in software generates a report. 
Table 1: Methods of HbF detection for the study cohort 
 
 




































The two methods of HbF detection that were employed in this study were the Alkali 
denaturation test (ADT) and high performance liquid chromatography (HPLC). The number 
of cases (N) as a percentage and the mean HbF level (%) is shown for controls (HbAA and 
HbAS) and patients (HbSS). HbF data was available for 237 individuals. The ADT method of 
detection (haemoglobin electrophoresis acid or basic media) was most frequently used. 
3.8 DNA EXTRACTION 
3.8.1 Rationale 
DNA was extracted from peripheral blood lymphocytes. High yield and good quality allows for 




DNA extraction was performed using two methods – the Gentra Purgene Blood Kit Plus 
(Qiagen, California, USA) and the salting out method (Miller et al. 1988) used by the laboratory 
where the experimental analysis was performed (University of Cape Town, Division of Human 
Genetics, Cape Town, RSA). 
3.8.3 Principle 
The general principle for DNA extraction is through the separation of white blood cells from 
whole blood by way of partial erythrocytic destruction. In an anionic environment, the white 
blood cells are broken down and the proteins are removed by precipitation. The purified DNA 
is recovered by ethanol precipitation. The resultant DNA falls within A260/A280 ratio 
between 1.7 and 1.9. The DNA can be safely stored at 2°C, -8°C, -20°C or -80°C. 
3.8.3.1 GENTRA PURGENE BLOOD KIT PLUS (QIAGEN, CALIFORNIA, USA) 
Blood samples were collected in 10ml Vacuette EDTA tubes (Greiner Bio-One, Chonburi, 
Thailand). The DNA was isolated according to the manufacturer’s protocol (Qiagen 2011). 
Briefly, 30ml of the RBC Lysis Solution (Qiagen, California, USA) was dispensed into a 50ml 
centrifuge tube (Corning, New York, USA). Then 10ml of whole blood was added and mixed 
via inversion (10 times). The mixture was incubated for 5 minutes at room temperature 
(22°C), with one mixing by inversion during the incubation period. The mixture was 
centrifuged (Eppendorf, Hamburg, Germany) for 2 minutes at 2000xg to obtain a white blood 
cell pellet. The liquid was discarded, keeping 200µl with the suspended pellet. The pellet was 
vigorously mixed, using a vortex (Vortex Genie 2, New York, USA), to completely re-suspend 
the pellet. After that, 10ml of Cell Lysis Solution was added (Qiagen, California, USA) and 
mixed using a vortex (Vortex Genie 2, New York, USA) for 10 seconds. Then 3.3ml of Protein 
Precipitation Solution (Qiagen, California, USA) was added and mixed vigorously, using a 
vortex (Vortex Genie 2, New York, USA), for 20 seconds. The mixture was centrifuged 
(Eppendorf, Hamburg, Germany) for 5 minutes at 2000xg. Isopropanol (Sigma-Aldrich, 
Munich, Germany) was added (10ml) to a new 50ml centrifuge tube (Corning, New York, USA) 
and the supernatant from the former step was added. The mixture was mixed by inversion 
(50 times). Thereafter, the mixture was centrifuged (Eppendorf, Hamburg, Germany) for 3 
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minutes at 2000 x g. After the supernatant was removed and the pellet left to dry, 10ml of 
70% ethanol (Sigma-Aldrich, Munich, Germany) was added to the pellet and mixed by 
inversion (20 times), and thereafter centrifuged (Eppendorf, Hamburg, Germany) for 1 minute 
at 2000 x g. The supernatant was drained and the pellet left to dry for 10min, after which 1ml 
of DNA Hydration Solution (Qiagen, California, USA) was added to the pellet and mixed using 
a vortex (Vortex Genie 2, New York, USA) for 5 seconds. Thereafter, the mixture was 
incubated at 65°C for 1 hour. Samples were stored at -20°C. 
3.8.3.2 Salting out method (Miller et al. 1988)  
Blood samples were collected in 10ml Vacuette EDTA tubes (Greiner Bio-One, Chonburi, 
Thailand). From the sample, 3ml were transferred to a 15ml centrifuge tube (Corning, New 
York, USA). Then 9ml of RBC lysis buffer (Appendix A10) was added, mixed and incubated at 
room temperature (22°C) for 30 minutes. The lysate was mixed every five minutes for the 
duration of the incubation period. This was followed by centrifugation (Eppendorf, Hamburg, 
Germany) for 10 minutes at 2000rpm. The supernatant was discarded and 1ml of RBC lysis 
solution (Appendix A10) was added to the pellet to remove excess red blood cell debries 
(Vortex Genie 2, New York, USA). For the lysis of the WBCs, 3ml of cell lysis solution (Appendix 
A10) was added to the WBC pellet and mixed using a vortex (Vortex Genie 2, New York, USA). 
Then 12.5µl of 20mg/ml Proteinase K (Sigma-Aldrich, Munich, Germany) and 100µl of 20% 
SDS (Sigma-Aldrich, Munich, Germany) was added and mixed, using a vortex (Vortex Genie 2, 
New York, USA). The mixture was incubated at 37°C for 3 days. For the precipitation of 
proteins from the lysate, 1ml of saturated 6M NaCl (Sigma-Aldrich, Munich, Germany) was 
added and mixed, using a vortex (Vortex Genie 2, New York, USA). This was followed by 
centrifugation (Eppendorf, Hamburg, Germany) for 20 minutes at 2000rpm. After that, 5ml of 
the supernatant was transferred to a 15ml centrifuge tube (Corning, New York, USA) 
containing two volumes of absolute ethanol (Sigma-Aldrich, Munich, Germany) was added, 
mixed by inversion (50 times) and centrifuged (Eppendorf, Hamburg, Germany) for 10 
minutes at 2000rpm to precipitate the DNA from solution. The supernatant was discarded 
and 2ml of ice-cold 70% ethanol (Sigma-Aldrich, Munich, Germany) was added to remove 
excess NaCl from the DNA pellet. It was then centrifuged (Eppendorf, Hamburg, Germany) for 
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10 minutes at 2000rpm. The DNA pellet was air dried overnight and re-suspended in 50µl of 
1 x TE buffer (Appendix A6). 
3.9 PHASE I: MOLECULAR DIAGNOSTIC TESTING FOR SCA (HbSS) 
3.9.1 Rationale 
The HbSS genotype relating to SCA is of relevance to this study because the homozygous state 
results in the most common and most severe form of the disease (Kan and Dozy, 1987). 
3.9.2 Method  
For the molecular diagnostic testing for SCA, Restriction Fragment Length Polymorphism 
(RFLP) – PCR method as used by Saiki et al. (1985) was implemented with a few modifications. 
3.9.3 Principle  
RFLP is a method of experimental inquiry that is performed to detect an alteration in the 
genetic sequence arrangement that is found at a position where a restriction endonuclease 
DdeI (Promega, Madison, USA) nicks at the C▼TNA  G/G  ANT▲Crecognition site (Saiki et al. 
1985). These restriction endonucleases are proteins that are found in bacteria (Saiki et al. 
1985). These proteins are able to identify particular short DNA sequences and then cut at the 
selected site or sites (Saiki et al. 1985). Varying lengths of fragments are produced thereby 
allowing for differential analysis (Saiki et al. 1985). 
3.9.3.1 PCR  
Each DNA sample (re-suspended in 1XTE Buffer; Appendix A5) was measured 
spectrophotometrically using a Nanodrop (ND-1000 Spectrophotometer, Thermo-fischer 
Scientific, Delaware, USA) to obtain the concentration and purity readings of each sample. A 
100ng/µl dilution of each DNA sample was generated. 
A total PCR reaction volume of 25µl was prepared from sterile distilled water, 5X Colourless 
GoTaq Buffer (1.5mM Mg𝐶𝑙2; Promega, Madison, USA), dNTPs (0.2mM each; Thermo 
Scientific, California, USA), Forward primer (5`-ATAGACCAATAGGCAGAGAGAG-3`; 0.4µM; 
IDT, California, USA; Saiki et al. 1985), Reverse primer (5`-TGTCATCACTTAGACCTCACC-3`; 
0.4µM; IDT, California, USA; Saiki et al. 1985), GoTaq DNA Polymerase (0.5U; Promega, 
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Madison, USA), and 1µl of DNA (100ng/µl). The PCR was performed using a thermal cycler 
(BIO-RAD T100, California, USA), under the following cycling conditions: an initial DNA 
denaturation step at 95°C for 5min, followed by 35 cycles, composed of a DNA denaturation 
step for 30sec at 95°C, a primer annealing step at 59°C for 30sec and an extension step for 
2min at 72°C. This was followed by a final extension step of 7min at 72°C. 
Gel electrophoresis was performed to confirm that the correct fragment sizes have been 
amplified (380bp). A 1.5% (w/v) agarose gel (Seakem Lonza, Basel, Switzerland; Appendix A6), 
with Ethidium Bromide (EtBr; 0.5ug/ml; Sigma-Aldrich, Munich, Germany; Appendix A7) as 
the nucleic acid stain, was prepared. The process of loading was performed as follows: 5µl of 
5X loading dye (Appendix A9) was utilised for each component - 10µl of GeneRuler 100bp plus 
DNA ladder (0.5ug/µl; Thermo Scientific, California, USA), 25µl of the no-template control 
(NTC; a PCR sample that has no DNA, to detect contamination), 25µl of the positive control (a 
PCR sample that has a known HbSS status) and 25µl of the sample, mixed and loaded into 
separate wells. The electrophoretic run was performed in 1XTBE buffer (Appendix A8) for 
45min at 160V. Thereafter, the gel was viewed under UV light using a protected imaging 
capture system (UVITech; Bath, UK) and a gel image was captured (Uvipro Gold 
transilluminator, Bath, UK). 
3.9.3.2 RESTRICTION ENDONUCLEASE DIGEST 
The purpose of the restriction endonuclease digest was to confirm the presence of the HbSS 
variant in the study cohort. 
A restriction endonuclease digest was performed using the restriction endonuclease DdeI 
(10U/µl; Promega, Madison, USA). A total reaction mixture of 20µl was prepared using sterile 
distilled water, 10X Buffer D (Promega, Madison, USA), acetylated BSA (0.1ug/µl; Promega, 
Madison, USA), DdeI enzyme (0.25U; Promega, Madison, USA) and 1µl of DNA (PCR product). 
The mixture was incubated overnight, at 37°C, using a heating block (BIO TBD-100 BOECO, 
Hamburg, Germany). 
Gel electrophoresis was performed by preparing a 1.5% (w/v) agarose gel (Seakem Lonza, 
Basel, Switzerland; Appendix A6), with EtBr (0.5ug/ml; Sigma-Aldrich, Munich, Germany; 
Appendix A7) as the nucleic acid stain. The process of loading was performed as follows: 5µl 
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of 5X loading dye (Appendix A9) was utilised for each component - 10µlof GeneRuler 100bp 
plus DNA ladder (0.5ug/µl; Thermo Scientific, California, USA), 20µl of the no-template control 
(NTC; a digested sample that has no DNA, to detect contamination), 20µl of each positive 
control (confirmed HbAA, HbAS and HbSS samples) and 20µl of the digested PCR sample, 
mixed and loaded into separate wells. The electrophoretic run was performed in 1XTBE buffer 
(Appendix A8) for 45min at 160V. Thereafter, the gel was viewed under UV light using a 
protected imaging capture system (UVITech, Bath, UK) and a gel image generated (Uvipro 
Gold transilluminator, Bath, UK). 
3.9.4 Expected fragment sizes 
Expected fragment sizes for HbAA was one band of 192bp, for HbAS two bands of 192bp and 
380bp, and for HbSS one band of 380bp. Three fragments are produced which are 10bp, 
188bp and 192bp. The 10bp fragment is too small to detect via agarose gel electrophoresis. 
The 188bp and 192bp fragments are close in size and were therefore seen as one band on the 
gel. 
3.10 PHASE II: HAPLOTYPING OF THE HBB GENE 
3.10.1 Rationale 
The HBB gene haplotypes may be used as genetic markers to infer phenotypic variations in 
SCA patients by correlating the genotypic data with the phenotypic data (Clarke and Higgins 
2000). Since there is little data available on the frequency of these variable haplotypes in 
African SCA patients, more specifically, from Cameroon (Clarke and Higgins 2000), this aspect 
of the study will help to exclude the specific confounding genetic modifiers related to the HBB 
gene when comparing the α-thalassemia genotypes to the clinical phenotypes associated 
with SCA. 
3.10.2 Method 




RFLP-defined detection of the HBB gene haplotypes is a proven method that operates 
effectively in determining and analysing genetic variations that occur in the region under 
study. Additionally, it provides the platform for the investigation of genotype/phenotype 
correlations in the Cameroonian study cohort (Sutton et al. 1989). 
 
Figure 6: The HBB gene region 
Chromosome 11 is composed of the following gene regions: Gy (HBG2), Ay (HBG1), ψβ, δ and β (HBB). The 
restriction enzyme utilised on each section of the gene to determine a specific cutting pattern for haplotype 
characterisation is depicted where arrows indicate the cutting site. XmnI cuts the 5’Gy region, HindIII cuts the 





Table 2: HBB haplotyping primers 
GENE 
REGION 
PRIMER SEQUENCE (5` to 3`) PCR THERMAL CYCLING CONDITIONS FRAGMENT SIZE 
(bp) 
  FORWARD REVERSE     
5’Gy AACTGTTGCTTTATAGGATTTT AGGAGCTTATTGATAACTCAGAC 1 cycle of 95 °C for 5min 657 
35 cycles of 94°C for 30sec, 55°C for 30sec, 72°C for 
40sec 
1 cycle of 72°C for 7min 
Gy/Ay1 TGCTGCTAATGCTTCATTACAA AAGTGTGGAGTGTGCACATGA 1 cycle of 95 °C for 5min 780 
35 cycles of 94°C for 30sec, 53°C for 30sec, 72°C for 
40sec 
1 cycle of 72°C for 7min 
Gy/Ay2 TGCTGCTAATGCTTCATTACAA TAAATGAGGAGCATGCACACAC 1 cycle of 95 °C for 5min 780 
35 cycles of 94°C for 30sec, 53°C for 30sec, 72°C for 
40sec 
1 cycle of 72°C for 7min 
3’ψβ TCTGCATTTGACTCTGTTAGC GGACCCTAACTGATATAACTA 1 cycle of 95 °C for 5min 614 
35 cycles of 94°C for 30sec, 55°C for 30sec, 72°C for 
40sec 
1 cycle of 72°C for 7min 
5’β CTACGCTGACCTCATAAATG CTAATCTGCAAGAGTGTCT 1 cycle of 95 °C for 5min 386 
35 cycles of 94°C for 30sec, 55°C for 30sec, 72°C for 
40sec 




3.10.3.1 5’Gy, Gy/Ay1, Gy/Ay2, 3’ψβ, 5’β Amplification  
A total PCR reaction volume of 25µl was prepared, using sterile distilled water, 5X GoTaq 
green buffer (1.5Mm Mg𝐶𝑙2; Promega, Madison, USA), dNTPs (0.2mM each; Thermo 
Scientific, California, USA), Forward primer (Table 2; 0.4µM; University of Cape Town’s 
Department of Molecular and Cell Biology, Cape Town, RSA), Reverse primer (Table 2; 0.4µM; 
University of Cape Town’s Department of Molecular and Cell Biology, Cape Town, RSA), GoTaq 
DNA polymerase (0.5U; Promega, Madison, USA) and 1µl of DNA (100ng/µl). Thermal cycling 
was performed on a Bio-Rad T100 thermal cycler (Table 2; Bio-Rad, California, USA). 
Gel electrophoresis was performed by preparing a 2% (w/v) agarose gel (Seakem Lonza, Basel, 
Switzerland; Appendix A6), with EtBr (0.5µg/ml; Sigma-Aldrich, Munich, Germany; Appendix 
A7) as the nucleic acid stain. The process of loading was performed as follows: 5µl of 5X 
loading dye (Appendix A9) was utilised for each component - 10µl of GeneRuler 100bp plus 
DNA ladder (0.5ug/µl; Thermo Scientific, California, USA), 25µl of the no-template control 
(NTC; a PCR sample that has no DNA, to detect contamination), 25µl of the positive control (a 
PCR sample that has a known status) and 25µl of the PCR sample, mixed and loaded into 
separate wells. The electrophoretic run was performed in 1XTBE buffer (Appendix A8) for 
45min at 160V. Thereafter, the gel was viewed under UV light using a protected imaging 
capture system (UVITech; Bath, UK) and a gel image was generated (Uvipro Gold 
transilluminator, Bath, UK). 
3.10.3.2 Restriction enzyme digestion 
Each PCR fragment was digested using a specific restriction endonuclease: (1) 5’Gy using 


















5'...G A A N N↓N N T T C...3' 






5'...A↓A G C T T...3' 
3'...T T C G A↑A...5’ 
37°C 20min 340; 430 
Gy/Ay2 HindIII 
5'...A↓A G C T T...3' 
3'...T T C G A↑A...5’ 
37°C 20min 340; 430 
3’ψβ HincII 
5'...G T Y↓R A C...3' 
3'...C A R↑Y T G...5' 
37°C 20min 470; 590 
5’β HinfI 
5'...G↓A N T C...3' 
3'...C T N A↑G...5' 
37°C 20min 240 
3.10.3.3.1 5’Gy  
A total reaction mixture with of 16µl was prepared consisting of sterile distilled water, 10X 
Buffer Tango (Thermo Scientific, California, USA), XmnI enzyme (Thermo Scientific, California, 
USA; 0.625U) and 1µl of PCR product. The mixture was incubated according to the conditions 
shown in Table 3, using a thermal cycler (Bio-Rad T100, California, USA). 
3.10.3.3.2 Gy/Ay1, Gy/Ay2, 3’ψβ and 5’β 
A total reaction mixture of 15µl (Gy/Ay1, Gy/Ay2, 3’ψβ and 5’β ) was prepared using sterile 
distilled water, 10X Fast Digest Green Buffer (Thermo Scientific, California, USA), a restriction 
endonuclease (XmnI,HindIII, HincII and HinfI enzyme, respectively; Figure 7; Thermo Scientific, 
California, USA; 0.333U) and 1µl of the PCR product. The mixture was incubated according to 
the conditions shown in Table 3, using a thermal cycler (Bio-Rad T100, California, USA). 
Gel electrophoresis was performed by preparing a 2% (w/v) agarose gel (Seakem Lonza, Basel, 
Switzerland; Appendix A6), with EtBr (0.5µg/ml; Sigma-Aldrich, Munich, Germany; Appendix 
A7) as the nucleic acid stain. The process of loading was performed as follows: 5µl of 5X 
loading dye (Appendix A9) was utilised for each component - 10µl of GeneRuler 100bp plus 
DNA ladder (0.5µg/µl; Thermo Scientific, California, USA), 25µl of the no-template control 
(NTC; a digested sample that has no DNA, to detect contamination), 25µl of the positive 
control (an uncut PCR sample) and 25µl of the digested sample, mixed and loaded into 
separate wells. The electrophoretic run was performed in 1XTBE buffer (Appendix A8) for 
45min at 160V. Thereafter, the gel was viewed under UV light using a protected imaging 
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capture system (UVITech, Bath, UK) and a gel image was generated (Uvipro Gold 
transilluminator, Bath, UK). 
3.10.4: Expected fragment sizes 
The amplification of the 5’Gy region produced a 657bp fragment, Gy/Ay a 780bp fragment, 
3’ψβ a 614bp fragment, and 5’β a 386bp fragment. The endonuclease digestion of Gy/Ay by 
HindIII (Thermo Scientific, California, USA) resulted in fragments of 340bp and 430bp in size, 
3’ψβ by HincII (Thermo Scientific, California, USA) resulted in fragments of 470bp and 590bp, 
and 5’β by HinfI (Thermo Scientific, California, USA) resulted in a 240bp fragment. 
3.10.5: Haplotype determination 
Haplotypes were determined based on the cutting pattern specified by Sutton et al. 1989. A 
profile of pluses (+) and minuses (-) were recorded based on the cutting pattern and 
compared to the haplotype profile table. The (+) signifies that the site was cut by the specific 
restriction enzyme, and the (-) signifies that it was not cut. Haplotypes were thus determined 









XmnI (5'Gγ) HindIII (Gγ) HindIII (Aγ) HincII (3'̕Ψβ) HinfI (5'β) 
Senegal + + - + + 
Bantu/Central 
African 
- + - - - 
Cameroon - + + + - 
Benin - - - + - 
Arab-Indian + + - + - 
(+) = Cut by a specific restriction endonuclease; (-) = Not cut by that specific restriction endonuclease  
3.11 PHASE III: α-THALASSEMIA DELETION SCREENING 
3.11.1 Rationale 
This aspect of the study dealt with the α-globin chain deletions, their association with the 
haematological indices and the clinical phenotypeof SCA patients. This is known as the co-
inheritance of α-thalassemia by SCA patients. 
3.11.2 Method 
The method used was Multiplex Gap-PCR by Chong et al. (2000), with a few modifications. 
3.11.3 Principle 
The identification of the deletions found in the α-globin gene cluster on chromosome 16 by 
multiplex PCR is the principle upon which this section of the study was based. Primers were 
designed to flank the deletion breakpoints (Chong et al. 2000). The deletions were 3.7kb and 
4.2kb in size (Tan et al. 2001). These are large deletions and therefore the distance between 
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the flanking primers were too big to amplify the "normal" allele. The product obtained was 
therefore much smaller than the “normal” allele, thereby indicating the presence of a 
deletion. The 3.7kb and 4.2kb deletions can be detected in one assay, using five different 
primers. 
 
Figure 7: The chromosomal arrangement of the α-globin gene cluster located on 
chromosome 16 
The α-globin gene cluster is located on chromosome 16 and composed of the following regions ζ2, ζ1, ψα1, 
α2 and α1. The primers for the detection of the 3.7kb and 4.2kb deletions are indicated by arrows. The 
following combinations may occur: (1) Normal/unaffected (αα/αα) produced by α2/3.7F and α2R, (2) 3.7kb 
homozygous deletion (α3.7/α3.7) produced by α2/3.7F and 3.7/20.5R, (3) 4.2Kb homozygous deletion 
(α4.2/α4.2) produced by 4.2F and 4.2R, (4) 3.7kb heterozygous deletion (αα/α3.7) produced by the (1) and (2) 
primer combination, and (5) 4.2kb heterozygous deletion (αα/α4.2) produced by the (1) and (3) primer 
combination. 
3.11.3.1 Multiplex gap-PCR 
Multiplex gap PCR was used to detect the α-globin gene deletion mutations present in the study 
population. This technique is based upon amplification using five oligo-primers flanking known 
deletion breakpoints, thereby generating a unique amplicon that will be smaller in the mutant 
sequence compared with the wild type. The presence or absence of a PCR product is detected by 
electrophoresis. 
Table 5: Primers for the detection of the α-globin gene deletions by multiplex gap PCR 
NUMBER PRIMER SEQUENCE (5` to 3`) 
1 α2/3.7-F CCCCTCGCCAAGTCCACCC 
2 3.7/20.5-R AAAGCACTCTAGGGTCCAGCG 
3 α2-R AGACCAGGAAGGGCCGGTG 
4 4.2-R CCCGTTGGATCTTCTCATTTCCC 
5 4.2-F GGTTTACCCATGTGGTGCCTC 
A total reaction mixture of 25µl was prepared using 10X Roche Expand Long Template Buffer 








Figure 1: The chromosomal arrangement of the α-globin gene cluster, located on 
chromosome 16. The distances between each gene differs (measurement taken between 
two centres in kb). (1) 4.2kb pair deletion classified as the leftward-deletion, (2) 3.7kb pair 
deletion classifi d as the rightward deletion – one α-globin gene is deleted and the other 
is 3.7kb shorter than normal, and (3) a triplicated α-globin loci- three α-globin genes which 
are 3.7kb longer than normal classified as the triplicate deletion. 
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Betaine (1M; Sigma-Aldrich, Munich Germany), Expand Long Template Taq (1.875U; Roche, 
Mannheim, Germany), primers (0.8µM each) – (1) α2/3.7-F, (2) 3.7/20.5-R, (3) α2-R, (4) 4.2-
F, and (5) 4.2-R (Table 5; University of Cape Town’s Department of Molecular and Cell 
Biology,Cape Town, RSA), 1µl of DNA, DMSO (1.5%; Thermo Scientific, California, USA), and 
sterile distilled water. The PCR was performed using a thermal cycler (Bio-Rad T100, 
California, USA) under these cycling conditions: 1 cycle of 95°C for 5min, 35 cycles of 94°C for 
45sec, 62.8°C for 1min and 15sec, 72°C for 2min and 30sec, and 1 cycle of 72°C for 5min. 
Gel electrophoresis was performed by preparing a 1% (w/v) agarose gel (Seakem Lonza, Basel, 
Switzerland; Appendix A6), with EtBr (0.5µg/ml; Sigma-Aldrich, Munich, Germany; Appendix 
A7) as the nucleic acid stain. The process of loading was performed as follows: 5µl of 5X 
loading dye (Appendix A9) was utilised for each component: 10µl of GeneRuler 100bp plus 
DNA ladder (0.5µg/µl; Thermo Scientific, California, USA), 25µl of the no-template control 
(NTC; a PCR sample that has no DNA, to detect contamination), 25µl of the positive control (a 
PCR sample of known deletion status) and 25µl of the PCR sample, mixed and loaded into 
separate wells. The electrophoretic run was performed in 1XTBE BUFFER (Appendix A8) for 
1hr to 2hrs at 160V. Thereafter, the gel was viewed under UV light using a protected imaging 
capture system (UVITech; Bath, UK) and a gel image generated (Uvipro Gold transilluminator, 
Bath, UK). 
3.11.4: Expected fragment sizes 
A homozygous 3.7kb deletion presents with one 2020bp band, a homozygous 4.2kb deletion 
presents with one 1628bp band and no deletion presents a with one 1800bp band. 
Heterozygous combinations may occur; 2020bp and 1800bp represents a 3.7kb heterozygote 
and 1628bp and 1800bp represents a 4.2kb heterozygote. 
3.12 STATISTICAL ANALYSIS USING SPSS (V21, IBM, USA) 
Descriptive statistics were performed for all quantitative data. Numerical data was expressed 
in the form of the mean, median, minimum, maximum and standard deviation (SD). 
Quantitative data was expressed in the form of frequencies and percentages. Distribution 
plots were constructed for all the qualitative variables, to assess the normality of the data 
(parametric vs. non-parametric). The mean was expressed for parametric data and the 
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median for non-parametric data. Normality was confirmed by the Shapiro-Wilk Test. The 
following parametric tests were used to determine the p-value: Chi-squared test for 
categorical variables and the t-test for scale variables. The following non-parametric tests 
were used to determine the p-value: Mann-Whitney U test for two samples or the Kruskal-
Wallis one-way analysis of variance (ANOVA) for more than two samples. Significance was set 
at the 5% level, p<0.05, for an association to be deemed significant. A one-way ANOVA 
Tukey’s Post-hoc Test was performed to assess the level of significance between and within 
groups. In addition, an Additive model per copy of the α-globin gene deletions was performed, 
as well as multinomial or linear logistic regression analysis, incorporating the SCA and α-
thalassemia genotypes, age, gender, and clinical events. To correct for the skewness of the 
HbF distribution, a log10-transformation was applied, which normalised the data to obtain 
the quantitative trait used in the association analysis (after correcting for age, gender, and 
the electrophoresis technique). The effects of α-thalassemia on key clinical and 
haematological indices were investigated in generalised linear regression models, adjusted 
for age, sex and six SNP genotypes (always assuming log-additive genetic effects) using the R 
statistical package version 3.0.3 (The R Foundation for statistical computing, Vienna, Austria). 
A Hardy-Weinberg Equilibrium (HWE) test was performed for the genotype results of the 
3.7kb α-globin gene deletions and the ten selected SNPs. The observed 3.7kb α-globin gene 
deletion allele frequencies in the control group was consistent with HWE (𝑋2=2.37; p=0.12), 
equal to the SCA patients (𝑋2=1.69; p=0.19). 
In a separate study, Wonkam et al. (2014b) reported that sequence variants at the BCL11A 
and HBS1L-MYB loci influence HbF levels. In addition to BCL11A, the rs4671393 SNP was 
associated with a wider range of haematological indices, independently of the HbF levels. In 
addition, two SNPs in the HBS1L-MYB locus were associated with the number of 
hospitalisations (Wonkam et al., 2014b). Statistical analysis was performed to investigate the 
effects of α-thalassemia on the clinical and haematological indices, in relation to these above-
mentioned variants. Two SNPs were excluded because of a significant violation of the HWE 
(rs1188686 in BCL11A, HWE p-value = 0.00030; and rs9389269 in the HBS1L-MYB locus, HWE 
p-value: 0.002876). In addition, two other SNPs were monomorphic (at rs9376090 in the 
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HBS1L-MYB locus, all the patients were T/T homozygous; and at rs7482144 in the HBG loci, 
where all the patients were G/G homozygous).  
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CHAPTER 4: RESULTS 
4.1 MOLECULAR CHARACTERISATION OF SCA (HbSS) 
HbSS is the most severe form of SCA. Genotyping was essential for this study to denote individuals as 
HbAA (unaffected), HbAS (carriers) and HbSS (patients). The molecular detection of SCA allowed for 
the foundation of the study to be set and a “working” cohort to be created. 
(a) Gel image for the molecular characterisation of SCA by electrophoresis
(b) An illustrataion of the HBB gene, digested by the Dde1 restriction endonuclease and the fragments
produced
Figure 8: Gel image of a diagnostic test for the detection of HbSS 
(a) M= 1Kb molecular weight marker (Bioline, USA); NTC= No-template control: clear, thereby indicating that
no contamination had occurred; U= uncut DNA amplified with the diagnostic primer set (White Head
Scientific, RSA): 380bp; 1-4= DNA amplified using the diagnostic primer set, then cut using DdeI (Promega,
Madison, USA): lane 1 – HbSS at 380bp, lane 2 – HbAS at 192bp and 380bp, lane 3 – HbAA at 192bp. (b) The
section of the HBB gene, digested by DdeI and the fragments produced. The gene region under study is
380bp in length, spanning the end of exon 3 of the δ region, exon 1 and the beginning of exon 2 of the β
region. DdeI cuts twice at the 10bp and 190bp marks. Three fragments are produced which are 10bp, 188bp
and 192bp. The 10bp fragment is too small to detect via agarose gel electrophoresis. The 188bp and 192bp






A single band represented a homozygote and two bands represented a heterozygote. The 
molecular detection of the banding pattern allowed for the diagnosis of individuals as 
unaffected (HbAA), carriers (HbAS) or patients (HbSS). Individuals were genotyped by HPLC 
prior to the RFLP assay, thereby acting as a validation assay. Results from the RFLP-PCR 
assay were compared to the results generated by HPLC haemoglobin electrophoresis, to 
eventually confirm the Hb SS status. 
4.2 SOCIO-DEMOGRAPHIC CHARACTERISATION OF THE STUDY COHORT 
The socio-demographic characterisation of the study cohort illustrated the age, gender and 
ethnicity of the individuals of the study cohort. 
4.2.1: Age and gender 
Table 6: Socio-demographics; a comparison of age and gender between unaffected 
individuals (HbAA), carriers (HbAS) & patients (HbSS).  
 HbAA HbAS HbSS 
N Mean ± SD Median N Mean ± SD Median N Mean ± 
SD 
Median 
AGE (years) 47 26.0 ± 7.5 26.5 29 21.5 ± 9.8 24.0 160 19.8 ± 
10.7  
17.5 
GENDER MALE 14 - - 11 - - 75 - - 
  FEMALE 33 - - 18 - - 86 - - 
N = Number of cases; SD = Standard deviation 
The socio-demographic characterisation for unaffected individuals (HbAA), carriers (HbAS) 
and patients (HbSS) in terms of age and gender was compared. The mean age for the 
unaffected individuals was 26.5 years (25th percentile = 23.2 years; 75th percentile = 30 years), 
carriers 24 years (25th percentile = 17.5 years; 75th percentile = 26 years) and 17.5 years for 
patients (25th percentile = 11 years; 75th percentile = 24 years). Females formed the bulk of 
the study cohort (70%). Post-Hoc analysis revealed the following p-values between groups for 
the age variable: (1) HbAA vs. HbAS p= 0.057, (2) HbAA vs. HbSS p<0.0001 and (3) HbAS vs. 
HbSS p= 0.437. For the gender variable, the following p-values were revealed: (1) HbAA vs. 
HbAS = 0.487, 2) HbAA vs. HbSS = 0.043 and (3) HbAS vs. HbSS = 0.835. There is thus a 





Figure 9: Distribution curve for the age variable for the unaffected individuals (HbAA) in 
the study cohort 
The age variable for the unaffected cohort (HbAA), quantified in years, was normally distributed (parametric 
data), the Shapiro-Wilk Test p-value is 0.021, and was therefore expressed in the form of the mean. N = 
number of cases and Std. Dev. = Standard deviation (SD). The mean age was 26.02 years, with a SD of 7.525 
and a median of 26.5. 
 
Figure 10: Distribution curve for the age variable for carriers (HbAS) in the study cohort 
The age variable for the carrier cohort (HbAS), quantified in years, was normally distributed (parametric data), 
the Shapiro-Wilk Test p-value is 0.168, and was therefore expressed in the form of the mean. N = number of 





Figure 11: Distribution curve for the age variable for the patient cohort 
The age variable for the patient cohort, quantified in years, was mildly skewed to the left illustrating a lower 
number of patients above the third decade. The Shapiro-Wilk Test, p-value was <0.0001, indicating that the 
data was abnormally distributed (p<0.05). N = number of cases and Std. Dev. =Standard deviation (SD). The 
mean age was 19.72 years, with a SD of 10.511, and a median of 17.5 years. 
The patient cohort presents individuals who were not on any treatment for SCA. This 
untreated state may therefore present some biases. A detection/surveillance bias may be 
present where there was an inclination towards considering an outcome in one of the 
comparison groups. There may have been a length-time bias in which patients whose disease 
was discovered by screening for sickle cell anaemia, appeared to be asymptomatic, or they 
present with a milder phenotype when compared to individuals whose disease presents 
clinically with symptoms. Screening inclines towards identifying diseases that develop slowly 
and, therefore, present a ‘good’ prognosis. 
4.2.2 Ethnicity 
Individuals in the study cohort lived in the urban and peri-urban areas of the Yaoundé and 
Douala cities in Cameroon, with various ethnicities. These ethnicities refer to various regions 
within Cameroon. The ‘mixed ancestry’ group refers to individuals who have multiple 
ethnicities. For individuals in the HbAA group, one was of Bami descent and for individuals in 
the HbAS group there was one individual from each of the following groups: Bami, Beti, 




Table 7: Ethnicities of the patients in the study cohort 
ETHNICITY % ETHNICITY % ETHNICITY % 
Abbo 0.8 Banen 1.6 Eton 6.5 
Bafia 3.2 Bassa 8.8 Ewondo 12.9 
Bafut 0.8 Batoufam 0.8 Foulbe 0.8 
Bakaka 0.8 Bene 0.8 Haoussa 3.2 
Bamenda 0.8 Beti 2.4 Maka 0.8 
Bami 6.5 Bgnte 0.8 Mbamois 1.6 
Bamileke 5.6 Bulu 1.6 Nkambe 0.8 
Bamoun 3.2 Douala 1.6 Yambassa 3.2 
Bandjoun 0.8 Dschang 6.5 Mixed 
ancestry 
21.8 
4.3 CLINICAL PROFILE 
4.3.1 Haematological parameters 
The red blood cell count (RBC) in a million cells/µl, haemoglobin level (HbA) in g/dl, mean 
corpuscular volume (MCV) in fL, mean corpuscular haemoglobin concentration (MCHC) in 
g/dl, white blood cell count (WBC) in X𝟏𝟎𝟗/L, lymphocyte count in X𝟏𝟎𝟗/L, monocyte count 
in X𝟏𝟎𝟗/L, platelet level in X𝟏𝟎𝟗/L, foetal haemoglobin (HbF) as a percentage and 
haemoglobin alpha-2 (HbA2) as a percentage, was presented as the haematological 
parameters examined. These abbreviations and their respective units apply to all tables with 
these haematological parameters. 
Table 8: Reference values for the haematological parameters investigated 
 HEALTHY RANGE REFERENCE 
RBC 
4.2 - 6.1 million 
cells/µl 
Bunn (2011) 
HbA 12 - 17.5 g/dl 
Mayo Foundation for Medical Education and Research 
(2014) 
MCV 80 - 99 fL Schoenborn and Snyder (2012) 
MCHC 32 - 36 g/dl Bunn (2011) 
WBC 4.5 - 10 X109/L Bagby (2007); Dinauer and Coates (2008) 
LYMPHOCYTE 
COUNT 
1 - 3.5 X109/L Thomas (2007) 
MONOCYTE 
COUNT 
0.2 - 0.8 X109/L Thomas (2007) 
PLATELET LEVEL 150 - 450 X109/L Schmaier (2008) 
HbF Up to 2% 
Boyer et al. (1975); Wood et al. (1975); Rochette et al. 
(1994); Wojda et al. (2002) 




Table 9: Haematological profile for the study cohort: a comparison between HbAA, HbAS, 
and HbSS 































4.5 ± 1 4.3 2 9 
2
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4.6 ± 1.3 4.6 2 9 
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2.4 ± 1 2.2 0.4 5.6 
2
9 
2.8  ± 1.8 2.3 0.6 9 
13
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0.7 0 94 
2
8 
0.7  ± 0.5 0.5 0 2 
13
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7.8 ± 4.3 8.6 1 22 
1
5 
8.3  ± 5.6 7.3 1 20 
12
4 
13.9  ± 
9.6 




3.0 ± 1.3 3.3 0.1 5 
2
6 
3.3  ± 1.4 3.3 0.6 7.2 
15
5 
4.1  ± 2.1 3.8 0.9 
18.
2 
N = Number of cases; SD = Standard deviation; Min. = Minimum; Max. = Maximum 
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The number (N) of individuals differed across the genotypes because the haematological 
indices for each individual were not adequately recorded. Hence, there were a few 
incomplete profiles. However, this did not affect the study, as the numbers were sufficient 
for meaningful comparisons. HbAA and HbAS were asymptomatic and had haematological 
parameters that fell within the normal range. HbSS had haematological parameters that fell 
out of the normal range, with the exception of the platelet level. 
Table 10: Significance levels for the haematological profile for the study cohort: a 




RBC HbAA vs. HbAS 0.999 
HbAA vs. HbSS 0.433 
HbAS vs. HbSS 0.548 
HbA HbAA vs. HbAS 0.346 
HbAA vs. HbSS <0.0001 
HbAS vs. HbSS <0.0001 
MCV HbAA vs. HbAS 0.192 
HbAA vs. HbSS 0.785 
HbAS vs. HbSS 0.030 
MCHC HbAA vs. HbAS 0.269 
HbAA vs. HbSS 0.017 
HbAS vs. HbSS 0.909 
WBC HbAA vs. HbAS 0.772 
HbAA vs. HbSS <0.0001 
HbAS vs. HbSS <0.0001 
LYMPHOCYTE COUNT HbAA vs. HbAS 0.767 
HbAA vs. HbSS <0.0001 
HbAS vs. HbSS <0.0001 
MONOCYTE COUNT HbAA vs. HbAS 0.425 
HbAA vs. HbSS 0.471 
HbAS vs. HbSS 0.876 
HbA2 HbAA vs. HbAS 0.901 
HbAA vs. HbSS 0.007 
HbAS vs. HbSS 0.133 
Pot-hoc analysis revealed that there were significant differences for: (1) the HbA levels 
between unaffected individuals and patients (p<0.0001) and between carriers and patients 
(p<0.0001), (2) the MCV between carriers and patients (0.030; p<0.05), (3) the WBC between 
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unaffected individuals and carriers (p<0.0001), and between carriers and patients (p<0.0001), 
and, (4) the HbA2 level between unaffected individuals and patients (0.007; p<0.05). 
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Table 11: Literature derived haematological profile for HbSS 
CAMEROON 
TANZANIA 
(Cox et al. 2013) 
TURKEY 




(Lettre et al. 2008) 
BRAZIL 




(Gati et al. 2013) 




3.5 ± 6.1 
45
8 




8.3 ± 2.2 
45
8 













34.7 ± 4.3 
45
8 























13.9 ± 9.6 
45
8 




4.1 ± 2.1 - - - - - - - - - - 
N = Number of cases; SD = Standard deviation 
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Table 11 compares the haematological parameters of SCA patients from certain regions of 
the world. The Cameroonian patients in this study had a higher RBC, MCHC, WBC and HbF 
level, and a lower platelet level. The HbA and MCV values were variable across the regions. 
4.3.2 Gender-based haematological indices 
A non-parametric statistical test (Kruskal-Wallis Test for significance) was performed to 
investigate the presence of any differences between the haematological parameters based 
on gender. Analyses were performed separately for each genotype: HbAA- male vs. female, 
HbAS-male vs. female and HbSS-male vs. female. There were no significant differences 
(p>0.05) between the haematological parameters for HbAA based on gender. For HbAS, there 
was a significant difference (p=0.047; p<0.05) in the MCV between males and females. 
Females had a higher MCV (82fL) when compared to males (74fL). The MCV for males fell 
below the healthy range (80 – 99fL) (Table 9; Table 10), indicating smaller erythrocytes and 
therefore microcytic anaemia. For HbSS, there was a significant difference (p<0.0001) in the 
HbF level between males and females. Females had a higher HbF level (15.7%) when 
compared to males (10.8%). These values were higher than the normal range (Table 8; Table 
9). 
4.3.3 Clinical indices 
After the review and validation of the clinical data provided via interviewing the parent (in 
the case of a minor under 18 years of age) or patient (in the case of an adult), and by 
consulting their medical records, only 121 patients had data that was suitable for analysis. 
The analyses have been tabulated below. 
Table 12: Demographic data for the SCA patients in the study cohort 
  N Mean ± SD Median Minimum Maximum 
Age of Diagnosis (Years) 111 4.2 ± 4.5 3 0.5 21 





Table 13: Clinical characterisation for the SCA patients in the study cohort 
  N Mean ± SD Median Min. Max. 
BMI (kg/𝒎𝟐) 80.0 18.5 ± 3.5 18.2 12.0 27.0 
SBP (mmHg) 82.0 108.7 ± 
12.8 
108.0 86.0 156.0 
DBP (mmHg) 82.0 59.5 ± 9.1 58.0 43.0 93.0 
No. of VOCs/year 118.0 3.0 ± 4.2 2.0 0.0 40.0 
Overt stroke YES 8.0 - - - - 
NO 105.0 - - - - 
No. of consultations/year 108.0 2.2 ± 2.7 1.0 0.0 12.0 
No. of hospitalisations/year 110.0 1.9 ± 2.5 1.0 0.0 12.0 
N = Number of cases; SD = Standard deviation; Min. = Miminum; Max. = Maximum 
The BMI (kg/𝑚2), systolic blood pressure (SPB) (mmHg), diastolic blood pressure (DBP) 
(mmHg), number of vaso-occlusive pain crises (VOCs) per year, incidence of stroke, the 
number of hospital consultations per year and the number of hospitalisations per year was 
established for the SCA patients (HbSS) in the study cohort. 
Patients displayed a median BMI of 18.2 kg/𝑚2 (25th percentile = 15.7 kg/𝑚2; 75th percentile 
= 21.4 kg/𝑚2), SBP of 108 mmHg (25th percentile = 101mmHg; 75th percentile = 116mmHg), 
DBP of 58mmHg (25th percentile = 53mmHg; 75th percentile = 62.2mmHg), VOCs at 2/year 
(25th percentile = 1/year; 75th percentile = 4/year), and number of hospitalisations at 1/year 
(25th percentile = 0/year; 75th percentile = 2/year). A high number of VOCs (>3/year) was 
found among 48% of patients, with a few cases of overt stroke (7%), which is indicative of a 
more severe phenotype. Linear regression analysis, which incorporated the patient’s age and 
gender, did not reveal any significant difference in the number of VOCs, and hospitalisations, 
per year. However, males tended to have a higher number of VOCs per year (Likelihood Ratio: 
p=0.09). 
4.4 HAPLOTYPES OF THE HBB GENE CLUSTER 
The molecular characterisation of the 5’Gy, Gy, Ay, 3’ψβ and 5’β regions of the HBB gene was 
performed to determine which of the five (Arab-/Saudi-Indian, Bantu/Central African, Benin, 
Cameroon and Senegal) haplotypes occurred in the study population. 
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Figure 12: Gel electrophoresis images of the restriction enzyme profiles for HBB gene haplotyping 
Each restriction endonuclease created different banding patterns, which led to the formulation of a pattern, 
consisting of pluses (+) and minuses (-) for the determination of a haplotype. L= GeneRuler 100bp plus DNA 
Ladder (Thermo Scientific, California, USA); NTC= No-template control: clear, thereby indicating that no 
contamination had occurred. (a) 5’Gy: 657bp fragment, cut with XmnI (Promega, Madison, USA) produced -/- 
banding pattern. (b) Gy/Ay: 780bp fragment; cut with HindIII (Thermo Scientific, California, USA) produced 
the following banding patterns: -/+, -/-, and +/+. (c) 3’ψβ: 614bp fragment, cut with HincII (Thermo Scientific, 
California, USA) produced the following banding patterns: +/+ and -/+. (d) 5’β: 386bp fragment, cut with HinfI 










































































Table 14: Frequencies of the HBB gene haplotypes in SCA patients 
  Frequency 
  N 
chromosome  
% 
BENIN 173 66.3 
CAMEROON 55 21.0 
ATYPICAL 29 11.1 





TOTAL 262 100 
The Benin, Cameroon, Bantu and Arab-/Saudi-Indian haplotypes are the four known 
haplotypes. Atypical haplotypes refers to haplotypes that are not distinctive as a type, group, 
or class, and are classified as unusual haplotypes. In chromosomal frequencies, the Benin and 
Cameroon haplotypes were most prevalent in the patient cohort. 
 
Figure 13: HBB gene haplotype distribution in SCA patients 
The following haplotype combinations (N total = 157) occurred in the patient cohort: Benin/Benin (N = 71) 
42.2%, Benin/Cameroon (N = 42) 26.8%, Benin/atypical (N = 22) 14%, Cameroon/Cameroon (N = 8) 5.1%, 
Cameroon/atypical (N = 6) 3.8%, atypical (N = 3) 1.3%, Bantu/Cameroon (N = 2) 1.3%, Bantu/atypical (N = 1) 
0.6%, Benin/Arab-/Saudi-Indian (N = 1) 0.6% and Benin/Bantu (N = 1) 0.6%. 
In combination, the Benin/Benin, Benin/Cameroon, Benin/atypical and Cameroon/Cameroon 
haplotypes were most prevalent in the patient cohort. Further analysis was performed on 
these four haplotype combinations. 
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Depicted below, is the classification of patients according to their HBB haplotype status, in 
relation to their ethnicities. N represents the number of patients with a specific haplotype. 
The ‘mixed ancestry’ group refers to patients who have multiple ethnicities. 
Table 15: HBB gene haplotype distribution in SCA patients according to ethnicity 
Ethnicity N Haplotype Ethnicity N Haplotype Ethnicity N Haplotype 
Abbo 1 Benin/Cameroon Banen 1 Benin/Benin Ewondo 1 Bantu/Cameroon 
Bafia 1 Atypical/Cameroon 1 Cameroon/Cameroon 1 Atypical/Cameroon 
1 Benin/Benin Bassa 1 Cameroon/Cameroon 3 Benin/Atypical 
2 Benin/Atypical 3 Benin/Atypical 4 Benin/Benin 
Bafut 1 Benin/Atypical 7 Benin/Benin 5 Benin/Cameroon 
Bakaka 1 Benin/Atypical Batoufam 1 Benin/Atypical Haoussa 1 Atypical/Atypical 
Bamenda 1 Benin/Benin Bene 1 Benin/Cameroon 3 Benin/Benin 
Bami 1 Benin/Cameroon Beti 1 Benin/Atypical Mbamois 1 Benin/Atypical 
1 Atypical/Atypical 1 Atypical/Atypical Yambassa 1 Benin/Atypical 
2 Benin/Atypical Bgnte 1 Benin/Benin 1 Bantu/Cameroon 
3 Benin/Benin Bulu 2 Benin/Benin 1 Atypical/Atypical 
Bamileke 1 Benin/Cameroon Douala 1 Benin/Benin Mixed ancestry 2 Atypical/Atypical 
1 Benin/Atypical 1 Benin/Atypical 3 Benin/Cameroon 
6 Benin/Benin Dschang 1 Benin/Cameroon 10 Benin/Benin 
Bamoun 1 Benin/Cameroon 1 Atypical/Atypical 11 Benin/Atypical 
1 Benin/Atypical 6 Benin/Benin       
2 Benin/Benin Eton 1 Benin/Benin       
Bandjoun 1 Benin/Benin 1 Atypical/Atypical       
      2 Benin/Atypical       
      2 Benin/Cameroon       




Table 16: Haematological profile for the frequently occurring haplotype combinations in the patient cohort 
  BENIN/BENIN BENIN/CAMEROON BENIN/ATYPICAL CAMEROON/CAMEROON 




























RBC 67 2.8 ±  
0.8 
2.7 2 5 38 2.8 ± 
0.8 
2.6 1 6 15 7.6 ± 
19.7 
2.5 1 79 8 2.9 ± 
0.7    
2.7 2 4 
HEMOGLOBIN 
LEVEL 
67 8 ± 1.6 7.8 5.4 14.3 38 7.9 ± 
1.7 
7.7 4.9 13.7 15 6.9 ± 
1.5 
6.7 3.4 9.4 8 8.5 ± 
1.4     
8.5 6.4 10.
8 
MCV 67 83.8 ± 
10.8 
84 59 112 38 83.5 ± 
8.2 










MCHC 67 34.9 ± 
4.7 
33.9 28.6 52.9 38 34.8 ± 
4.1 
34.1 28.8 47.2 14 34 ± 
2.6 






WBC 67 14.1 ± 
6.2 
12.8 4.1 35.5 38 14.2 ± 
6.2 
13.4 4.9 33.9 15 18.8 ± 
10.2 






61 5.8 ± 3.2 4.8 1.6 17.5 32 5.9 ± 
3.5 




Monocyte count 61 1.5 ± 0.8 1.3 0 4 32 1.4 ± 
0.8 
1.1 0 4 8 1.2 ± 
0.5 
1.2 0 2 8 1.3 ± 
0.3 
1.3 1 2 
Platelet level 67 402.9 ± 
144.8 
402 110 725 38 343.7 ± 
90.5 
342 147 482 14 339.6 ± 
159 






HbF 56 16 ± 
11.8 
14.6 0 86 28 13.1 ± 
7.2 
14.8 0 27 14 15.1 ± 
7 
15.7 0 27 8 9.3 ± 
4.1 
9.9 2 16 
HbA2 65 4.7 ± 2.9 4 1.6 18.2 38 4.1 ± 1 4 2.1 6.6 15 3.5 ± 
0.8 
3.4 2.4 5.1 8 3.7 ± 
0.6 
3.6 2.6 4.5 




After performing Post-hoc analysis, for the haematological parameters vs. each haplotype 
(Benin/Benin vs. Benin/Cameroon; Benin/Benin vs. Benin/Atypical; Benin/Benin vs. 
Cameroon/Cameroon; Benin/Cameroon vs. Benin/Atypical; Benin/Cameroon vs. 
Cameroon/Cameroon; and Benin/Atypical vs. Cameroon/Cameroon), it was revealed that 
there were no significant differences between and within haplotype groups for all of the 
haematological parameters investigated. 
The age of diagnosis, in years, was classified according to the four most prevalent haplotypes 
found in this study. For Benin/Benin patients, the age of diagnosis (Mean ± SD) was 4.3 ± 4.3 
years, Benin/Cameroon 3.7 ± 3.2 years, Benin/Atypical 5.4 ± 7.5 years and 
Cameroon/Cameroon 6.8 ± 7.9 years. A one-way ANOVA Tukey’s Post-hoc Test was 
performed to determine if there were any significant differences between Benin/Benin vs. 
Benin/Cameroon, Benin/Benin vs. Benin/Atypical, Benin/Benin vs. Cameroon/Cameroon, 
Benin/Cameroon vs. Benin/Atypical, Benin/Cameroon vs. Cameroon/Cameroon, and 
Benin/Atypical vs. Cameroon/Cameroon. There was no significant difference between the 




Table 17: Clinical characterisation for the frequently occurring haplotypes in the patient cohort 
 BENIN/BENIN BENIN/CAMEROON BENIN/ATYPICAL CAMEROON/CAMEROON 
































BMI (kg/𝒎𝟐) 34 19.5 ± 
3.6 
20.4 12 27 22 17.8 ± 
3.5 
17.5 13 27 7 17.7 ± 
3.5 





SPB (mmHg) 35 110.2 ± 
13.6 
110 86 156 24 109.0 
± 12.1 
109.5 88 135 7 103.7 ± 
12.7 
102 87 127 8 114 ± 
12.8 
116.5 89 133 
DPB (mmHg) 35 61.6 ± 
10.2 
62 43 93 24 59.5 ± 
7.7 
58.5 47 79 7 58.1 ± 
11.3 
55 43 76 8 56.6 ± 
7.9 
54.5 47 71 
No. of VOC/year 61 2.7 ± 
2.6 
2 0 15 31 3.3 ± 
2.6 
3 0 10 8 1.9 ± 
1.2 
2 0 4 8 1.4 ± 
1.2 
2 0 3 
Stroke YES 4 - - - - 1 - - - - 0 - - - - 0 - - - - 
NO 53 - - - - 29 - - - - 7 - - - - 7 - - - - 
No. of 
consultations/year 
55 2.2 ± 
2.6 
1 0 10 28 2.7 ± 
3.2 
1.5 0 12 7 0.6 ± 
1.1 
0 0 3 7 1.0 ± 
1.4 
0 0 3 
No. of 
Hospitalisations/year 
55 1.8 ± 
2.2 
1 0 12 30 1.8 ± 
2.4 
1 0 12 8 1.5 ± 
2.1 
0.5 0 6 7 1.9 ± 
4.5 
0 0 12 
N = Number of cases; SD = Standard deviation; Min. = Minimum; Max. = Maximum 
Post-hoc analysis revealed that there were no significant differences between Benin/Benin vs. Benin/Cameroon, Benin/Benin vs. 
Benin/Atypical, Benin/Benin vs. Cameroon/Cameroon, Benin/Cameroon vs. Benin/Atypical, Benin/Cameroon vs. Cameroon/Cameroon, and 
Benin/Atypical vs. Cameroon/Cameroon in any of the clinical parameters investigated. 
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4.5 CO-INHERITANCE: SCA-α-THALASSEMIA 
The co-inheritance of α-thalassemia in SCA patients has been associated with a less severe 
phenotype. The molecular characterisation of the α-globin chain deletions associated with α-
thalassemia was determined by multiplex gap PCR. 
Figure 14: Gel image depicting the molecular analysis of the α-thalassemia deletion screening process, post 
electrophoresis 
M = GeneRuler 100bp plus DNA Ladder (Thermo Scientific, USA); NTC = No-template control; C = 3.7kb 
heterozygote (αα/α3.7) control; 1, 2, 3 = Patient DNA. The NTC lane was clear, thereby indicating that there 
was no contamination. The 3.7kb heterozygote control represented two bands, one for the normal (αα/αα) 
allele, and one for the 3.7kb deletion (α3.7/α3.7) allele, with 1800bp and 2020bp bands, respectively. In lane 
1, a 1800bp band was seen, indicating that this patient was “normal” (had all four α-globin chains). In lane 2, 
a 3.7kb heterozygote was seen. In lane 3, a 2020bp band was seen, indicating the 3.7kb homozygous deletion. 
Individuals with one or two α-globin deletions are carriers. 
There were 55 unaffected individuals (HbAA), 38 carriers (HbAS), and 161 patients (HbSS) who 
were screened to determine their α-globin deletion status. For unaffected individuals, 89.1% 
were (αα/αα), 9.1% (αα/α3.7) and 1.8% (α3.7/α3.7). For carriers, 65.8% were (αα/αα), 28.9% 






Figure 15: Prevalence and allele frequency of the 3.7kb deletion among patients and controls 
A. The prevalence of the 3.7kb α-globin gene deletions, expressed as a percentage (%; y-axis) is depicted for 
unaffected individuals (HbAA), carriers (HbAS) and patients (HbSS) (x-axis) in the following proportions, 
respectively, where (αα/αα), (α3.7/αα), and (αα/αα) represents no, one and two, α-globin gene deletions: 
(1) HbAA-(αα/αα) 89.1% (n=49), HbAA-(α3.7/αα) 9.1% (n=5), HbAA-(α3.7/α3.7) 1.8% (n=1); (2) HbA-(αα/αα) 
65.8% (n=25), HbAS-(α3.7/αα) 28.9% (n=11), HbAS-(α3.7/α3.7) 5.3%(n=2); (3) HbSS-(αα/αα) 62.8% (n=101), 
HbSS-(α3.7/αα) 30.4% (n=49), HbSS-(α3.7/α3.7) 6.8% (n=11). B. The allele frequency of the 3.7kb α-globin 
gene deletions in the HbAA, HbAS and HbSS cohorts was 6.5% (n=7), 19.7% (n=15) and 22% (n=71) respectively. 
Allele frequencies of the 3.7kb α-globin gene deletions were 11.8% and 22% in controls (HbAA 
and HbAS) and patients, respectively (p=0.006). Individually, the allele frequencies for HbAA 
and HbAS were 6.5% and 19.7%, respectively. Multinomial logistic regression analysis was 
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performed, which incorporated SCA, α-thalassemia, age and gender, which indicated that 
differential frequency in the 3.7kb α-globin gene deletions among patients and controls was 
driven by unaffected individuals (HbAA). HbAA individuals were four times less likely to have 
a single 3.7kb α-globin gene deletion [exponentiation of the β coefficient =4.02 (95% CI) (1.45-
11.13)] and five times less likely to have a double 3.7kb α-globin gene deletion than HbSS 
individuals [exponentiation of the β coefficient =5.42 (95% CI) (0.65-44.79)]. 
Considering HbSS, the 3.7kb α-globin gene deletions and gender, multinomial analysis 
indicated that, being male increased the likelihood of having the 3.7kb α-globin gene deletion 
(Likelihood Ratio p=0.013). HbAA individuals were four to five times more likely to have the 
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The frequency of α-globin deletions in SCA patients (HbSS) from the Cameroonian study 
cohort was determined and then compared to other reports in the literature. The results were 
tabulated from America (African-American; Guasch et al.1999), Uruguay (Afro-Uruguayan; Da 
Luz et al. 2006), India (Pandey et al. 2011), Brazil (Belisário et al. 2010), Oman (Nebor et al. 
2010), France (Bernaudin et al. 2008), and Tanzania (Cox et al. 2013). N refers to the number 
of cases. The frequency of individuals with all four α-globin chains (αα/αα), individuals with 
one deletion (αα/α3.7) and individuals with two deletions (α3.7/α3.7) were compared. The 
incidence of the α-globin deletions differs based on the region of the world, with the deletion 
of one α-globin chain being most common. 
4.5.3: Socio-demographic characterisation for the Control and Patient cohorts with 
(αα/αα), (αα/α3.7) and (α3.7/α3.7) 
The mean ages (mean ± SD) for the unaffected (HbAA) subjects who were (αα/αα) was 25.7± 
3.0 years, (αα/α3.7) was 27.0± 3.7 years and (α3.7/α3.7) was 35.0 ± 0.0 years. The mean ages 
(mean ± SD) for the carriers (HbAS) who were (αα/αα) was 21.4± 6.8 years, (αα/α3.7) was 
19.3± 11.1 years and (α3.7/α3.7) was 30.5 ± 16.5 years. The mean ages (mean ± SD) for the 
patient (HbSS) subjects who were (αα/αα) was 19.7 ± 10.1 years, (αα/α3.7) was 20 ± 12 years 
and (α3.7/α3.7) was 20.1 ± 16 years. 
The majority of the study cohort was female. A one-way ANOVA Tukey’s Post-hoc Test, 
revealed that there were no significant differences between age and gender across the α-
thalassemia genotypes, (αα/αα)/ (αα/α3.7)/ (α3.7/α3.7), where HbAA and HbAS was 
compared separately. The following combinations were compared for HbAA and HbAS 
cohorts, separately: (αα/αα) vs. (αα/α3.7), (αα/αα) vs. (α3.7/α3.7), (αα/α3.7) vs. (α3.7/α3.7), 




Figure 16: Age of diagnosis for the co-inheritance of SCA and α-thalassemia 
The age of diagnosis, in years, (y-axis) was compared to SCA patients who were HbSS-(αα/αα) (patients with 
no α-globin gene deletions), HbSS-(αα/α3.7) (patients with one α-globin gene deletion), and HbSS-(α3.7/α3.7) 
(patients with two α-globin gene deletions) (x-axis). HbSS-(αα/αα) had a median age of diagnosis of 2 years, 
HbSS-(αα/α3.7) 4 years and HbSS-(α3.7/α3.7) 5 years. There was a significant difference between the age of 
diagnosis and the α-thalassemia genotypes in SCD patients (p=0.026; p<0.05). 
The increasing number of 3.7kb α-globin gene deletions, with the age of diagnosis (p=0.026), 
is depicted by the box and whisker plot. Boxes have lines at the lower quartile, median and 
upper quartile. In the absence of neonatal screening, the age of diagnosis often corresponds 
to that of clinical manifestations that brings SCA to the clinician's attention. 
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Figure 17: Age of diagnosis of HbSS patients with no, one and two α-globin gene deletions at an age less 
than and greater than five years. 
The proportion of patients with 3.7kb α-globin gene deletions diagnosed before and after five years of age. 
The number of patients within each category that have no, one and two, α -globin gene deletions, (αα/αα), 
(αα/α3.7) and (α3.7/α3.7), respectively, is expressed as a percentage (y-axis), based on diagnosis before and 
after five years (x-axis). For diagnosis before five years, patients with no, one and two α-globin deletions were 
70.5%, 25% and 4.5%, respectively. For diagnosis after five years of age, patients with no, one and two α-
globin deletions were 45.5%, 39.4%, and 15.1%, respectively. 
The proportion of patients with the 3.7kb α-globin gene deletion, diagnosed after five years 
of age was significantly different to those diagnosed before five (Likelihood ratio, p=0.026; 
Linear-by-Linear Association, p=0.006). 
4.5.4: Haematological characterisation for the Control and Patient cohorts with (αα/αα), 
(αα/α3.7) and (α3.7/α3.7) 
The haematological indices were tested for significance across the α-thalassemia genotypes, 
(αα/αα)/ (αα/α3.7)/ (α3.7/α3.7), for HbAA and HbAS. The following combinations were 
compared separately for HbAA and HbAS cohorts: (αα/αα) vs. (αα/α3.7), (αα/αα) vs. 
(α3.7/α3.7), (αα/α3.7) vs. (α3.7/α3.7), and then the combinations for HbAA vs. HbAS. A  ONE-
WAY ANOVA Tukey’s Post-hoc Test, revealed that there were no significant differences 
between the haematological indices across the α-thalassemia genotypes and HbAA or HbAS. 
The lack of significance is due to the small sample size of 46 for HbAA-(αα/αα), 5 for HbAA-
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Table 19: Haematological characterisation for the Patient cohort (HbSS): HbSS-(αα/αα), HbSS-(αα/α3.7) and HbSS-(α3.7/α3.7) 
  HbSS - (αα/αα) HbSS- (αα/α3.7) HbSS-(α3.7/α3.7) 
  N Mean ± SD Median Min. Max. N Mean ± SD Median Min. Max. N Mean ± SD Median Min. Max. SD 
RBC 100 3.6  ± 7.7 2.6 1 79 49 3.3  ± 1 3.1 2 6 9 3.5  ± 1.1 3.7 1.9 5.5 1.1 
HAEMOGLOBIN 
LEVEL 
100 8.1  ± 2.2 7.7 3.2 17.9 49 8.8  ± 2.4 8.1 4.9 14.5 9 8.4  ± 2.5 8.5 5.4 14.3 2.5 
MCV 100 85.4  ± 11.1 86 17.8 112 49 79.6  ± 7.8 79.6 66 100 9 70.8  ± 12.6 69 59 101 12.6 
MCHC 99 35.2  ± 3.9 34.4 28.8 52.9 49 34  ± 4.9 32.7 28.6 54.3 9 33.2  ± 4.8 31.4 28.8 44.1 4.8 
WBC 100 15.7  ± 7.6 13.7 3 42.4 49 11.1  ± 4.4 10.5 2.9 24 9 9.3  ± 3.9 9.1 4.1 17.4 3.9 
Lymphocyte count 84 6.3  ± 3.6 5.5 1.4 21.6 42 4.3  ± 1.9 4.2 0.6 8.3 9 3.9  ± 2.2 2.9 1.6 8.2 2.2 
Monocyte count 84 1.6  ± 1.1 1.4 0.2 7.8 42 1.1  ± 0.6 1.1 0.2 3 9 1  ± 0.6 0.8 0.4 2.3 0.6 
Platelet level 99 386.7  ± 
131.5 
372 110 725 49 371.5  ± 
127.9 
375 147 615 9 281.6  ± 117.8 247 163 559 117.8 
HbF 81 14  ± 10.8 12.6 0 86.2 33 12.9  ± 6.4 13.5 0 26 8 13.8  ± 7.7 14.9 3 27.3 7.7 
HbA2 96 4  ± 2.4 3.7 0.9 18.2 48 4.1  ± 1.8 3.9 1.1 13.2 9 4.2  ± 0.9 4.4 2.5 5.3 0.9 




Table 20: Significance values for the haematological characterisation for the patient 
cohort (HbSS): HbSS-(αα/αα), HbSS-(αα/α3.7), and HbSS-(α3.7/α3.7) 
Haematological parameter α-thalassemia genotype p-value 
RBC 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.971 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 1.000 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.989 
Hb 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.221 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.949 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.833 
MCV 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.004 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) <0.0001 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.015 
MCHC 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.259 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.211 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.711 
WBC 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) <0.0001 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.153 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.965 
LYMPHOCYTE COUNT 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.002 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.083 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.956 
MONOCYTE COUNT 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.024 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.129 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 0.873 
HbA2 
HbSS-(aa/aa) vs. HbSS-(aa/a3.7) 0.946 
HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) 0.980 
HbSS-(aa/a3.7) vs. HbSS-(a3.7/a3.7) 1.000 
Significance is set at the 0.05 level (p<0.05). 
To correct for multiple testing, a one-way ANOVA Tukey’s Post-hoc Test was performed.  
There were significant differences between patient groups for the following haematological 
parameters: (1) MCV – (αα/αα) and (αα/α3.7) (0.004; p<0.05), (αα/αα) and (α3.7/α3.7) 
(p<0.0001), and (αα/α3.7) and (α3.7/α3.7) (0.015; p<0.05); (2) WBC - (αα/αα) and (αα/α3.7) 
(p<0.0001); (3) lymphocyte count - (αα/αα) and (αα/α3.7) (0.002; p<0.05); and (4) monocyte 
count - (αα/αα) and (αα/α3.7) (0.024; p<0.05). The co-inheritance of the α-globin gene 
deletions suggested an improved haematological phenotype for SCA patients in the study 
cohort as there was a significant decrease in the MCV, WBC, lymphocyte, and monocyte 






Table 21: Literature-derived haematological parameters for SCA patients with α-thalassemia 
 CAMEROON 
AFRICAN AMERICAN (Embury et al. 
1982a) 
BRAZILIAN (Belisário et al. 2010) 
AFRICAN AMERICAN (Guasch et al. 
1999) 








































































































79.6 ± 7.8 
70.8 ± 
12.6 











34 ± 4.9 33.2 ± 4.8 - - - - - - 
34.9 ± 
0.2 





















































4.1 ± 1.8 4.2 ± 0.9 - - - - - - - - - 2.8 ±0.4 3.3 ± 0.6 3.8 ± 0.4 
N = Number of cases; SD = Standard deviation 
 
85 
Other studies in the literature reported on a decrease in the HbA level, MCV, MCHC, WBC, 
platelet level and HbF, and a decrease in the HbA2 level, with an increase in the number of α-
globin gene deletions. The Cameroonian study cohort revealed a decrease in the HbA level, 
MCV, MCHC, WBC, platelet, and HbF levels. 
The mean ± SD for the age of diagnosis for HbSS-(αα/αα), HbSS-(αα/α3.7), and HbSS-
(α3.7/α3.7) is 3.5 ± 3.9, 5.1 ± 5.1 and 5.7 ± 5.3 years respectively. The following groups were 
compared: HbSS-(aa/aa) vs. HbSS-(aa/a3.7), HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7), and HbSS-
(aa/a3.7) vs. HbSS-(a3.7/a3.7). A ONE WAY ANOVA Tukey’s Post-hoc test, revealed that there 
were no significant differences between and within groups when comparing the age of 
diagnosis across the groups. 
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Table 22: Clinical characterisation for the patient cohort with (αα/αα), (αα/α3.7) and (α3.7/α3.7) 
 HbSS - (αα/αα) HbSS- (αα/α3.7) HbSS-(α3.7/α3.7) 
























BMI (kg/𝒎𝟐) 48 18.5  ± 3.5 18 12 27 25 18.3  ± 4 17.7 13 27 7 19.6  ± 2.4 18.3 17 23 2.4 
SBP (mmHg) 49 
108.6  ± 
13.6 
108 86 156 27 
109.5  ± 
12.7 
108 89 135 6 
106.2  ± 
6.2 
105.5 99 116 6.2 
DBP (mmHg) 49 58.5  ± 9.3 56 43 93 27 
61.7  ± 
8.6 
60 47 79 6 58.2  ± 9.2 60.5 45 70 9.2 
No. of VOC/year 75 2.9  ± 2.4 2 0 15 34 3.7  ± 6.9 2 0 40 9 1.7  ± 1.1 1 1 4 1.1 
Stroke 
YES 6 - - - - 1 - - - - 1 - - - - - 
NO 65 - - -  33 - - -  7 - - -  - 
No. of consultations/year 70 2.3  ± 2.7 1 0 12 31 2.1  ± 2.9 1 0 12 7 1.3  ± 1.6 1 0 4 1.6 
No. of 
hospitalisations/year 
70 1.9  ± 2.4 1 0 12 33 1.9  ± 3 1 0 12 7 1.9  ± 1.6 2 0 4 1.6 
N = Number of cases; SD = Standard deviation; Min. = Minimum; Max. = Maximum 
The following groups were compared: HbSS-(aa/aa) vs. HbSS-(aa/a3.7), HbSS-(aa/aa) vs. HbSS-(a3.7/a3.7) and HbSS-(aa/a3.7) vs. HbSS-
(a3.7/a3.7). Post-hoc analysis, one-way ANOVA Tukey’s Post-hoc Test, revealed that there were no significant differences between and within 
groups of patients with the various genotypes relating to α-thalassemia for the clinical characteristics investigated. 
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4.6 SNP GENOTYPING IN THE HMIP, BCL11A, HGB XmnI-158&OR51B5/6 LOCI 
The effects of α-thalassemia on key clinical and haematological indices in the generalised 
linear regression model, adjusted for age, sex and the five SNPs that influence HbF levels, 
have been tabulated. 
Table 23:Effects of α-thalassemia on key clinical and haematological indices, in 
generalised linear regression models, adjusted for age, gender and five SNPs* that 




Single deletion vs. No deletion 
 




Estimates (SE) p-values Estimates (SE) 
p-
values 
Consultations Day/year -1.32 (0.63) 0.038  -1.31 (1.06) 0.221 110 
Hospitalisation Day/year -0.17 (0.34) 0.608  -0.37 (0.57) 0.514 104 
Vaso-occlusive crisis Number/year -0.57 (0.50) 0.253  -1.49 (0.84) 0.079 121 
RBC count million cells/µl 0.37 (0.16) 0.021  1.03 (0.27) 0.0002 149 
Hemoglobin g/dl 0.58 (0.37) 0.120  0.72 (0.63) 0.25 150 
HbA2 (%) 0.23 (0.52) 0.656  0.04 (0.87) 0.956 143 
HbF (%) -1.55 (1.57) 0.327  0.97 (2.64) 0.715 147 




WBC count X109/L -3.43 (1.04) 0.001  -4.31 (1.75) 0.015 150 
Lymphocytes count X109/L -2.15 (0.655) 0.001  -2.41 (1.102) 0.030 130 
Monocytes count X109/L -0.51 (0.20) 0.01  -0.67 (0.34) 0.05 130 
Platelets count X 109/L -4.80 (27.49) 0.86  -45.42 (46.23) 0.32 149 
SE = Standard Error 
*HbF related SNPs are: BCL11A rs4671393, HBS1L-MYB rs28384513, HBS1L-MYB rs9399137, HBS1L-MYB 
rs9402686, HBS1L-MYB rs9494142 and OR51B5/6 rs5006884. 
 
The co-inheritance of α-thalassemia was associated with a lower consultation rate (p=0.038). 
The effects of the co-inheritance of α-thalassemia on the RBC count, MCV and lymphocyte 
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count were observed. Two SNPs were significantly associated with specific haematological 
indices: BCL11A rs4671393 with the HbF level (p=0.005) and HMIP rs9399137 with a lower 
lymphocyte count (estimate=-2.09816; SD =1.02912; p=0.044). In addition, females had a 
significantly higher MCV (estimate=3.88, SD =1.73; p=0.02), HbA2 (estimate=1.02; SD =0.48; 
p=0.035) and HbF level (estimate=3.82; SD =1.44; p=0.009). 
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CHAPTER 5: DISCUSSION 
5.1 PRIMARY FINDINGS  
Currently, there is little data available on the prevalence of α-thalassemia occurring with SCA 
(HbSS) within the Cameroonian context. This study showed that Cameroonian SCA patients 
were more likely to co-inherited α-thalassemia than the controls and exhibited predominantly 
3.7kb α-globin single gene deletion. Haplotype analysis illustrated a high prevalence of the 
Benin haplotype and a lower prevalence of the Cameroon haplotype. The co-inheritance of 
α-thalassemia was associated with an improved clinical phenotype in SCA patients. The 
improved clinical phenotype explains the age of diagnosis, which increased with the number 
of α-globin gene deletions. The results from this study have implications for clinical follow-
ups, anticipatory guidance, or counselling of SCA patients and their families, and future 
research in Cameroon, and on the African continent. 
 
A high prevalence of the 3.7kb α-globin gene deletion has been reported among SCA patients 
in Brazil (29 %) (Belisário et al. 2010), India (32%) (Pandey et al. 2011), the UK among African 
Britons (34%) (Day et al. 2012), Guadeloupe (36%) (Tarer et al. 2006), Saudi Arabia (40%) 
(Alsultan et al. 2012), the USA among African Americans (41%) (Guasch et al. 1999), Oman 
(43%) (Wali et al. 2002), France among Africans (48%) (Bernaudin et al. 2008), and Tanzania 
(58%) (Cox et al. 2013). However, none of these studies compared the prevalence of the 3.7kb 
α-globin gene deletion to HbAA and HbAS individuals from the same setting. The present 
study has provided a unique contribution toward consolidating the hypothesis of a possible 
positive effect of the 3.7kb α-globin gene deletion on the survival of SCA patients. A decade 
ago, in Congo, researchers reported a significant difference in coinheritance, with 67.2% of 
SCA patients who had co-inherited the 3.7kb α-globin gene deletion, as compared to 54.8% 
of HbAA adults (Mouélé et al. 2000). In Yemen, a similar trend was reported with 34.6% of 
SCA patients carrying the 3.7kb α-globin gene deletion, compared to 26.3 % in the HbAA group 
(El-Hazmi and Warsy 1999). The present study shows that the prevalence of the 3.7kb α-
globin gene deletions in the control cohort (HbAS and HbAA) was comparable to that reported 
previously in many other settings across Africa, such as, (1) 15.8% in Kenya (Foote et al. 2013), 
(2) 15.1 % in Rwanda (Gahutu et al. 2012), (3) 20.8% in Guinea (Millimono et al. 2012), and, 
(4) 10%-25% in high-altitude villages in Northern Tanzania (Enevold et al. 2007). The 
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differential frequency among various populations was attributed deleterious environmental 
forces, like the prevalence of malaria or bacteraemia in patients (Steinberg 2005), although 
this needs to be confirmed by future research. 
This study is the first of its kind to study SCA in a Cameroonian population (according to a 
PubMed search, using the key words ‘Cameroon sickle cell disease/anaemia’). The clinical 
components examined in this study such as the haematological parameters, BMI, SBP, DBP, 
VOCs, incidence of stroke, number of hospital consultations and the number of 
hospitalisations has not been previously examined in a single study, to the best of the 
investigator's knowledge. These findings have contributed to the pool of knowledge regarding 
the molecular characterisation of SCA in Cameroon. Furthermore, these findings could have 
implications on the selection of the site and population for future studies in the field of SCA 
and α-thalassemia. This study also had a capacity-building dimension in genomics research 
relating to SCA. This study, from design and sample collection to the performing of the 
molecular experiments, data analysis and reporting, was performed, in full, on the African 
continent. These findings add to the global pool of data that will become available to 
researchers, clinicians, and genetic counsellors across the world, with the added aim of 
improving disease prevention and management within Cameroon and eventually extending 
to the rest of Africa. 
5.2 HAEMATOLOGICAL INDICES: PATIENTS vs. CONTROLS 
The haematological indices in Cameroonian SCA patients were similar to what was reported 
in patients in the literature, with moderate to severe anaemia and elevated levels of WBCs 
(Table 11). In this study, the haematological profile for the unaffected individuals was 
compared to the haematological profile of the SCA patients (Table 9). The haematological 
parameters from this study were compared to a reference list compiled and represented by 
Table 8. The unaffected and carrier cohorts had a haematological profile that fell within the 
healthy range (Tables 8 and 9). 
There was a significant difference in the HbA level between HbAA and HbSS individuals, and 
HbAS and HbSS individuals (Tables 9 and 10). Patients had a lower HbA level, which is an 
indicator of anaemia (Rochester and Minn 2011). The literature supports this finding (Herrick 
1910; Nicoll et al. 2008; Hussein and Hadad 2010). 
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A significantly high WBC count was found in the Cameroonian SCA cohort under study, 
between unaffected individuals (HbAA) and HbSS patients, and between carriers (HbAS)  and 
HbSS patients, where patients displayed marginally higher levels (Tables 8, 9 and 10). Similar 
results were found in other studies (Kasschau et al. 1996; Hebbel and Vercellotti 1997; Lard 
et al. 1999; Bagby 2007; Dinauer and Coates 2008). Olatunji and Davies (2000) reported that 
an increased WBC leads to a rise in the number of hospitalisations, and, a decrease in the HbA 
and HbF levels, in SCA patients. 
Lymphocytes and monocytes are classified as white blood cells (Thomas 2007; Kaushansky et 
al. 2010) and had an elevated count similar to WBC (Tables 9 and 10). Since high WBCs are 
associated with an increase in VOCs, the patients in the study cohort should have had high 
VOC incidences; however, this was not the case (Kasschau et al. 1996; Hebbel and Vercellotti 
1997). Patients in the study cohort had low incidences of VOCs (Median = 2/year) (Table 13), 
which indicated a milder form of SCA. 
HbA2 is found in adults in minute amounts (2-3%) (Liebhaber et al. 1980). High levels of HbA2 
were reported in HbSS patients (Craver et al. 1997; Huisman, 1997). There was a significant 
difference between the HbA2 level of HbAA and HbSS individuals in the study cohort, which 
resulted in patients having a higher level than the normal range (Tables 8, 9 and 10). This 
finding is similar to other studies (Craver et al. 1997; Huisman, 1997). Deviations from normal 
HbA levels, WBC, lymphocyte count and HbA2 levels for patients in the study cohort was also 
similar to other studies (Tables 8, 9, 10 and 11; Kasschau et al. 1996; Hebbel and Vercellotti 
1997; Lard et al. 1999). 
The haematological indices were classified in the literature based on gender, specifically RBC, 
HbA level, MCV and MCHC (Bunn 2011; Rochester and Minn 2011; Schoenborn and Snyder 
2012). Since the individuals in the study cohort were not gender-matched and there were no 
major differences between the haematological parameters across gender, the values specific 
to male or female were negligible. Furthermore, the other studies in the literature did not 
consider the haematological parameters based on gender, which allowed this study to be 
comparable to the other studies in the literature (Table 11). 
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5.3 CLINICAL SEVERITY IN SCA PATIENTS 
The BMI, SBP, DBP were in the normal ranges for patients in the study cohort (Table 13). 
However, comparative data for the unaffected and carrier individuals was not gathered, 
hence a phenotypic profile of the BMI, SBP, and DBP was only compiled for the patient cohort. 
Body mass index (BMI) was of importance because SCA has been associated with hindering 
the growth of pre-adolescents, irrespective of gender (Stevens et al. 1986; Akodu et al. 2014). 
The BMI scale classified a number less than 18.5kg/𝑚2 as underweight, 18.5kg/𝑚2-
24.9kg/𝑚2 as normal/healthy, 25kg/𝑚2-29.9kg/𝑚2 as overweight and 30kg/𝑚2 or more as 
obese (WHO 1995). Patients in the study had a normal BMI (Table 13). 
Blood pressure (BP) is an important factor as it is linked to the occurrence of stroke (Akingbola 
et al. 2014; Gosmanova et al. 2014). For adults, a healthy SBP reading is between 110mmHg 
- 140mmHg, with the optimal reading at 120mmHg, and a healthy DBP reading is between
60mmHg - 90mmHg, with the optimal reading at 80mmHg. HbSS patients generally have a 
lower than normal SBP and DBP (De Jong et al. 1982; Pegelow et al. 1997; Ernst et al. 2000; 
Ekure et al. 2012). SCA patients in this study (all were adults) had a slightly lower SBP and DBP 
(Table 13). This is due to (1) vasodilatation and (2) an elevation in the renal tubular water and 
sodium secretion thereby decreasing the arterial pressures and in turn lowering the SBP (Grell 
et al. 1981; Homi et al. 1993; Rodgers et al. 1993; Pegelow et al. 1997; Aderibigbe et al. 1999). 
Pain crises are a measure of disease severity and are used by clinicians to classify SCA as mild 
(less than three pain crises/year) or severe (more than three pain crises/year) (Nebor et al. 
2011). The median number of VOCs per year was two, which indicated a less severe level of 
pain experienced by patients in this study cohort (Table 13). However, this was not an 
accurate measure of severity, as each individual's pain threshold differed and pain episodes 
were not often reported. 
Stroke is a severe, frequent complication associated with SCA (Verduzco and Nathan 2009; 
Gueguen et al. 2014) with debilitating effects on the patient’s life (Tengs et al. 2001). Stroke 
is used as a proxy of severity to identify patients with SCA (Platt et al. 1994). Seven percent of 
the patients in the study cohort were affected by stroke (Table 13). This was a relatively high 
proportion, which is confirmed by previously published data on Cameroonian SCA patients 
(Njamnshi et al. 2006). 
MARYAM BIBI RUMANEY UNIVERSITY OF CAPE TOWN MSc in Human Genetics 2013 
RMNMAR005         Dissertation 
93 
The number of consultations per year was assessed to determine how often patients 
frequented the clinic. This allowed for the establishment of the degree of patient care 
required for each patient. The median number of consultations per annum was one (Table 
13). This indicated that there was a lower level of care required, which can be attributed to 
the majority of the patients in the study cohort having had a milder form of SCA (median of 
two per year – less than three; Table 13; Clarke and Higgins 2000). However, this low number 
could also be attributed to the inability of patients to afford regular consultations, in terms of 
the associated medical and transportation costs (Wonkam et al. 2014a). The majority of care 
is provided by family members, which may indicate a greater level of care required by patients 
(Wonkam et al. 2014a). 
SCA is characterised by severe pain crises due to the obstruction of the blood vessels by the 
sickled erythrocytes thereby making hospitalisation for pain or other complications a 
common occurrence (Wilson et al. 1979; Brousseau et al. 2010). A study by Allen-Liles et al. 
(2014) reported that the hospital-led management of VOCs in SCA patients decreased their 
length of stay, thus emphasising the need to examine the number of hospitalisations to assess 
the degree of disease severity and to establish the type of patient care required. The median 
number of hospitalisations for the patient cohort was one (Table 13), which suggested a 
relatively mild phenotype. In a first world context, VOCs will result in a hospitalisation. 
However, within the Cameroonian context, this is not the case (Wonkam et al. 2014a). 
Cameroonians, on average, are unable to afford medical aid and transportation costs to the 
hospital, therefore relying on care from their family members (Wonkam et al. 2014a). Thus, 
the low number of hospitalisations could be due to a lack in affordability and not entirely due 
to a milder phenotype. 
5.4 HAPLOTYPES OF THE HBB GENE 
The allele frequencies of the haplotypes that occurred in this patient cohort, illustrated that 
the Benin haplotype was the most common (Table 14). In addition, the combination of 
haplotypes in patient cohort illustrated that the Benin/Benin (42.2%), Benin/Cameroon 
(26.8%), Benin/atypical (14%) and Cameroon (5.1%) types were most prevalent (Figure 14). 
The Benin haplotype was initially found in people from Central West Africa (Curtin 1969). High 
(95%) frequencies of the Benin haplotype have been reported in Tunisian populations 
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(Fattoum 2006), with lower frequencies in the Venezuelan (29.2%) and Brazilian populations 
(20 - 28.8%; Moreno et al. 2002; Da Luz et al. 2006; Adorno et al. 2008). The Benin/Cameroon 
haplotype occurs in 1.6% of the Brazilian population (Adorno et al. 2008). 
This study found a relatively low proportion of the Cameroon haplotype (Table 14; Figure 14). 
The Cameroon haplotype occurs more frequently in SCA patients in Sudan (Mohammed et al. 
2006; Elderdery et al. 2012). This raises the question of the geographical origin of this 
haplotype. It is possible that the origin of the HbSS mutation was associated with the 
Cameroon haplotype in Sudan and not Cameroon and that the first description in Cameroon 
was due to population migration, which introduced this haplotype into Cameroon 
(Mohammed et al. 2006; Elderdery et al. 2012). A comparative study of the Cameroon 
haplotype in both Cameroonian and Sudanese patients could unravel this mystery. 
The Bantu and Arab-/Saudi-Indian haplotypes occurred in low percentages (less than 1%) in 
the patient cohort under study. Atypical haplotypes were previously shown to be common in 
the Cameroonian population (Sarnaik and Ballas 2001) and deserves further investigation by 
way of deep sequencing. This method allows for the establishment of the pattern of particular 
nucleotides in a sequence of DNA, where the depth of the method is several times greater 
than the length of the sequence being analysed (Meyerson et al. 2010; Ajay et al. 2011; 
Hampton et al. 2011). This makes the estimation of other quantities possible including the 
detection of SNPs (Meyerson et al. 2010; Ajay et al. 2011; Hampton et al. 2011). Deep 
sequencing offers high coverage, which overcomes inaccuracies in base calling and assembly, 
as well as high-level accuracy (Meyerson et al. 2010; Ajay et al. 2011; Hampton et al. 2011). 
The accuracy of sequencing is increased by sequencing individual genomes several times 
(Meyerson et al. 2010; Ajay et al. 2011; Hampton et al. 2011). This aids the determination of 
additional SNPs in the HBB gene region, as well as gives further insight into the classification 
of the atypical haplotypes discovered in the Cameroonian cohort under study. 
The patients in the study cohort were of various Cameroonian ethnicities (Table 15). The 
majority of patients with the Benin/Benin haplotype were of mixed ancestry origin, for 
Benin/Cameroon patients were Ewondo, for Benin/Atypical patients were mixed ancestry, 
and for Cameroon/Cameroon patients were Banen and Bassa (Table 15). 
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There were no significant associations between the haematological parameters and the 
haplotypes that occurred in the Cameroonian study cohort (Table 16). This was in agreement 
with the study by Mohammed et al. (2006). The comparison of the clinical parameters across 
the four most frequently occurring haplotype combinations did not reveal any major 
differences (Table 17). These findings were in agreement with the study by Steinberg et al. 
(1998). 
5.5 CO-INHERITANCE: SCA and α-THALASSEMIA 
The current study examined the effect of two α-globin gene deletions, the 3.7kb, and 4.2kb, 
deletion. The 4.2kb deletion was not detected in this study cohort (Figure 15). This implies 
that the 3.7kb deletion may only apply to a Cameroonian setting (sample size of 262 
individuals). 
This study revealed a high frequency of the co-inheritance of α-globin gene deletions (36%) 
in SCA patients, which was higher than the prevalence of these deletions in the Cameroonian 
unaffected (HbAA) and carrier individuals (HbAS) (Table 18). The high frequency in HbSS 
individuals was comparable to previous reports in the literature (Table 18; Guash et al. 1999; 
Bernaudin et al. 2008; Belisário et al. 2010; Nebor et al. 2010; Cox et al. 2013). 
HbAA-(αα/αα) individuals had a healthy haematological profile. These were 
healthy/normal/unaffected individuals. HbAA-(αα/α3.7) were unaffected individuals with 
one α-globin deletion and HbAA-(α3.7/α3.7) were unaffected individuals with two α-globin 
deletions. HbAS-(αα/αα) individuals had a healthy haematological profile. These were carriers 
with no α-globin gene deletions. HbAS-(αα/α3.7) were carriers with one α-globin deletion and 
HbAS-(α3.7/α3.7) were carriers with two α-globin deletions. The only abnormality displayed, 
for HbAA-(αα/α3.7), HbAA-(α3.7/α3.7), HbAS-(αα/α3.7), and HbAS-(α3.7/α3.7) was a MCV 
that was below the normal range, thereby indicating smaller erythrocytes (Murphy 1999; 
Culligan and Watson 2009). 
The co-inheritance of α-thalassemia and SCA was significantly associated with a lower MCV 
between and within groups, WBC between (αα/αα) and (αα/α3.7) patients, lymphocyte count 
between (αα/αα) and (αα/α3.7) patients, and monocyte count between (αα/αα) and 
(αα/α3.7) patients, all of which were reported to be associated with an improved clinical 
phenotype (Table 19; Table 20; Table 21). Other studies reported an increase in HbA (Table 
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21) and HbA2 (Steinberg and Embury 1986), and a decrease in MCV (Table 21; Steinberg et al. 
1995), and WBC (Belisário et al. 2010). These results are similar to results from this study 
(Table 19). A reduction in the MCV is due to the loss of the α-globin genes (Belisário et al. 
2010), which in turn affords a protective effect against the SCA phenotype by decreasing the 
amount of intravascular sickling, thereby alleviating pain (Condon et al. 1983). The decrease 
in the WBC is due to a decrease in the haemolytic rate, the amount of sickled erythrocytes 
and the inflammatory process (Belisário et al. 2010). 
The literature has reported an improved haematological phenotype for SCA patients with an 
increase in α-globin gene deletions when compared to patients with no deletions (Belisário 
et al. 2010; Pandey et al. 2011). Even so, α-thalassemia's protective effect against the severity 
of SCA is contested (Joly et al. 2011), although the majority of the literature suggests that α-
thalassemia is associated with an improved phenotype in SCA patients (Condon et al. 1983; 
Belisário et al. 2010; Dabari et al. 2012; Pandey et al. 2011). 
The relative delay of diagnosis was explained by the non-existence of any SCA screening 
policies in Cameroon (Wonkam et al. 2014a). The median age of diagnosis for the patients in 
the study cohort was three years (Table 12). Other studies reported the age of diagnosis to 
be approximately ten years in Senegal (Diop et al. 1999), two years in Nigeria (Brown et al. 
2010) and three years in Uganda (Mpalampa et al. 2012). The data represented indicates that 
the co-inheritance of α-thalassemia could delay the clinical manifestations of SCA, thereby 
positively affecting the survival of Cameroonian patients. This explains the elevated allele 
frequency of the 3.7kb α-globin gene deletions among patients vs. controls (Figure 17; Figure 
18).  
Fabry et al. (1984) reported that in the first ten years of life among African American HbSS 
individuals, the prevalence of the 3.7kb α-globin gene deletion was comparable to that in the 
general African American population (17%), while after 20 years of age, the prevalence 
increased to 49%. Similarly, in Cuban patients, the prevalence of the 3.7kb α-globin gene 
deletions increased with age (Martinez et al. 1996). Alpha-thalassemia may be linked to 
improved survival in patients (Martinez et al. 1996). The age of diagnosis associated with the 
co-inheritance of the α-thalassemia trait is useful in describing a context where neonatal 
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screening for SCA is non-existent. This is especially true for Cameroon, where SCA diagnosis 
is only made once patients have manifested symptoms. 
Multivariate analysis revealed that the co-inheritance of α-thalassemia trait was associated
with a lower consultation rate in this cohort (Table 23). There were no significant differences 
between the co-inheritance of the 3.7kb α-globin gene deletions and the clinical parameters
(Table 22; Table 23). This finding may be due to the small sample size and the challenge to 
define a SCA severity scoring system that could be applied universally (Coelho et al. 2012). 
Furthermore, the potential deleterious effect of α-thalassemia on the number of painful 
episodes reported previously (Tarer et al. 2006; Dabari et al. 2012) could be difficult to 
validate within the Cameroonian context, where free medical services to patients are 
unavailable. Pain tolerance and socio-economic factors could have influenced the number of 
hospital visits and thereby biased our evaluation of clinical events. 
It has been shown that individuals who have SCA and the 3.7kb α-thalassemia deletion, 
displayed a low RBC and serum iron level, indicative of an afforded protection against severe 
anaemia (Stuart and Nagel 2004; Morris 2008; Mariani et al. 2009; Pandey et al. 2012). The 
relationship between α-thalassemia and environmental factors like bacteraemia and malaria 
should be studied further in terms of the survival of patients. 
The association with α-thalassemia, number of VOCs, hospital consultations, and 
hospitalisations should be interpreted with caution due to the self-reported nature of these 
clinical measures and the variable degree of pain tolerance. There were no significant 
differences between the α-thalassemia genotypes, BMI and blood pressure in SCA patients. 
A study by Joly et al. (2011) highlighted the difficulties of using clinical outcomes to assess the 
effect of α-thalassemia. However, the most established effect of α-thalassemia was its 
influence on the haematological parameters. 
The improved haematological indices could be the major factor that contributes to the 
general well-being and life expectancy of SCA patients. Ultimately it may explain the higher 
prevalence of the 3.7kb α-globin gene deletion among patients than unaffected individuals. 
In the present study, the results of the generalised linear regression models seem to indicate 
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that other genomic and demographic factors could also affect the haematological indices 
(Table 23). 
5.6. LIMITATIONS AND RESEARCH RECOMMENDATIONS 
One shortcoming of this project is that the study cohort was not age and gender matched. In 
terms of gender, there were no major differences between the haematological parameters 
when comparing them across genders. The majority of the literature has not taken gender 
into account, although when clinically reporting on the haematological indices, gender is 
taken into account. This study had a gender bias as the majority of the study cohort was 
composed of females. 
The majority of subjects in the study cohort were adults. We recommend that the subjects be 
carefully age and gender matched for any future studies, as well as addressing the comparison 
of the BMI and blood pressure of controls. Medical records were not adequately completed 
and although the statistical programme utilised was able to deal with missing data, a 
complete record is always advisable. In addition, the age distribution of patients may have 
biased the HBB haplotypes and the distribution of α-thalassemia. Further investigation is 
required to investigate HBB gene haplotypes and the α-thalassemia genotypes in different 
age groups. 
The quality of DNA for certain individuals was poor as DNA was extracted from frozen blood 
by the salting out method, which is most effective on fresh blood samples. This resulted in 
additional repetition of experiments several times (up to five times) and having to further 
purify the DNA samples. The latter did not always render positive results. With every 
purification, the amount of DNA is drastically reduced, even though the quality of the sample 
is enhanced. A commercial purification kit should be utilised as the DNA yield and the quality 
of the sample is better. Of the 300 samples analysed, 38 samples was discarded due to poor 
quality. 
HbF quantification was limited by age and methodology. The median ages of individuals in 
the study cohort were 26, 23 and 18 years for HbAA, HbAS and HbSS respectively (Table 6). 
This is essentially an adult cohort. An HbF level of 2% is the maximum found in a healthy 
individual (Table 8), with up to 20% as the maximum in SCA individuals (Kar et al. 1986; 
Akinsheye et al. 2011; Jain et al. 2012). The median HbF levels were 8.6%, 7.3% and 13.5% 
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respectively, for HbAA, HbAS and HbSS in the study cohort (Table 9). Other studies in the 
literature reported lower mean HbF levels for patients (6.4% for African American and 9.2% 
for Brazilian SCA patients) (Table 10), compared to those found in this study (13.9%; Table 9). 
The HbF level for HbSS-males and HbSS-females is 10.8% and 15.7% respectively. For the 
haplotype groups the HbF levels were 14.6%, 14.8%, 15.7% and 9.9% respectively, for 
Benin/Benin, Benin/Cameroon, Benin/Atypical and Cameroon/Cameroon (Table 16). For the 
co-inheritance section of the study, high levels of HbF was seen with an increase in the 
amount of α-globin gene deletions (Table 19), whereas Belisário et al. (2010), reported a 
decrease in HbF with an increase in the number of α-globin gene deletions. Although the HbF 
mean-values for patients fell within the acceptable range (<20%), these values were widely 
discrepant with maximums of 86% (Table 9; Table16; Table 19). These discrepancies indicate 
that there was a limitation in the precision of HbF quantification. The majority of the 
quantification was performed by ADT. This method is cost-efficient, easily reproducible and 
allows for the detection of HbA, HbS, HbF, and HbC (Ondei et al. 2007). It does not allow for 
the detection of HbD, HbG, HbO, and HbE (Ondei et al. 2007). In addition, it does not provide 
precise identification of the variant due to the co-migration of resembling forms (Ondei et al. 
2007). In contrast, the HPLC method is a fast, precise, and more accurate method of HbF 
quantification (Ondei et al. 2007). We recommend using HPLC whenever possible in future 
studies, which will allow for more accurate measurements. 
Multiple SNPs within the HindIII restriction site, located in the gamma-globin intervening 
sequence II, were observed which produced the same RFLP pattern. This suggests the 
incapacity of RFLP analysis to decode the complexity of sequence variations that effects 
genomic structure in this gene region. The data generated by this study suggests that high-
density SNP mapping may be necessary to accurately explain the association between the 
HBB gene haplotypes and the varying clinical phenotypes relating to SCA. 
There were no positive control samples available for the HbSS diagnostic testing section and 
for the HBB gene haplotyping section of the project. Guidance was obtained from the 
available literature and the positive control samples will be established in future research. 
For future research iniatives, the role of malaria in relation to the data obtained in this study 
could be analysed. Clinical data on whether or not patients had malaria was not recorded. 
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Specifically for Cameroon, which is a high malaria endemic area affecting 90% of the 
population (WHO, 2014), as a future study, the role of co-inheritance of malaria in SCA and α-
thalassemia can be explored, specifically for the Cameroonian population. This will add data 
to the pool of information that becomes available for epidemiological purposes. Furthermore, 
future studies can look at identifying certain domain proteins or amino acid motifs which are 
selectively expressed in the malaria parasite, that infect HbAS individuals (Beaudry et al. 
2014). These research approaches could provide deeper insight into the mechanism of 
protection by HbAS in malaria co-infection cases. In general, there is lack of well-designed 
epidemiological and molecular studies to confirm the malaria hypothesis for the high 
prevalence of these genetic disorders. Moreover, accurate estimation of these hemoglobin 
disorders would be desirable for proper utilization of health resources in developing 
countries. 
5.7. POLICY AND PRACTICAL IMPLICATIONS  
SCA patients had an elevated possibility of many complications that compromised their state 
of health and wellbeing. The extent of the phenotypic diversity seen in these patients re-
iterated the significance of alternative genetic loci that may contribute to the ever-changing 
disease severity. The confirmation of the knowledge that α-thalassemia has a positive effect 
on, and possibly a strong selection for the survival of SCA patients, along with the capacity to 
test for this disease within an African setting, could offer the possibility of profiling patients 
from birth. 
The molecular exploration of SCA and α-thalassemia made it possible to gain insight into the 
development of valuable local molecular diagnostic laboratories, diagnostic tools, and 
additional tools for use in a clinical setting to improve the quality of medical care provided to 
patients. This study identified the genotype to phenotype connection of SCA in Cameroon and 
it further helped towards the anticipatory guidance in the care of patients, by identifying 
those who are susceptible to SCA.  
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CHAPTER 6: CONCLUSION AND PERSPECTIVES 
The co-inheritance of α-thalassemia with SCA was associated with an improved 
haematological profile, with an increase in the number of α-globin gene deletions. The 
possible positive effect of the co-inheritance of α-thalassemia on SCA patients’ survival could 
explain the high proportion of α-thalassemia among SCA patients when compared to the 
unaffected controls. These results have implications for disease management in Cameroon in 
terms of genetic counselling and the detection of SCA. 
Despite the fact that more than 70% of SCA sufferers live in Africa (about 13 million people), 
expenditure on care and research on the African continent, remains negligible. Most advances 
in the understanding and management of this condition have been based on research 
conducted in the in other parts of the world. The present study illustrated the capacity of an 
African team to conduct molecular research on SCA in Africa and thereby provide a clearer 
perspective for major collaborations and research opportunities with researchers in the rest 
of the world. Regional collaborations should be built to fast track SCA molecular research on 
the continent. The possibility of novel haplotypes could shed insight on other aspects of the 
disease.  
If designed appropriately, future studies in Africa could explore the potential beneficial effect 
of the co-inheritance of the α-thalassemia trait and SCA, on specific phenotypes such as (1) 
haemolysis (Nouraie et al. 2013), (2) the frequency of gallstones (Vasavda et al. 2007), (3) 
albuminuria (Guasch et al. 1999; Nebor et al. 2010; Day et al. 2012) or (4) the risk of stroke 
(Hsu et al. 2003; Belisário et al. 2010; Flanagan et al. 2011). The comparison of the frequency 
of the 3.7kb α-globin gene deletion in SCA patients, across populations from different 
ethnicities and geographical locations, should be made with caution, as the advantageous 
effect of α-thalassemia has been associated with age and the occurrence of malaria (Enevold 
et al. 2007). 
Our confirmation of the knowledge that α-thalassemia has a positive effect on and possibly a 
strong selection for the survival of SCA patients, along with the capacity to test for this disease 
within an African setting, could offer the possibility of profiling patients from birth. The data 
presented by this dissertation is encouraging.  In spite of gaps in medical records and 
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incomplete phenotyping data in the control, the statistical programmes used were able to 
adequately account and work with missing data to produce accurate statistical outcomes. If 
patients are profiled, a closer follow-up protocol could be implemented. Adult and neonatal 
screening of SCA in Cameroon could improve the ability of practitioners to provide 
appropriate genetic counselling and care.  
 
As much as there is a gap in research there is also a gap in care. Even with the information 
provided by additional research, there is still a lot of work that must be done on the ground. 
Cameroonians are often unable to afford medical aid and transportation costs to the hospital, 
therefore relying on care from their family members (Wonkam et al. 2014a). To lift this 
burden and aleviate this disease will require work from all sectors. 
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APPENDIX 
A1: INTRODUCTORY EXPLAINATION 
Dear patients, parents, and tutors 
A research study titled “Sickle Cell Anaemia in Cameroon: Co-Inheritance of α-Thalassemia, HBB 
Gene Haplotypes, Clinical & Haematological Characterisation” is to be carried out by the Faculty of 
Biomedical Science, Faculty of Medicine at the University of Yaoundé and the University of Cape 
Town’s Division of Human Genetics. The project is under the supervision and the direction of 
biologists, clinicians, geneticists, and haematologists at these institutions. This study relates to a 
Cameroonian sickle cell anaemia (SCA) context, without distinction of age, gender, or ethnicity. 
Unaffected individuals, carriers, and sickle anaemia patients will be required for this study. 
SCA is a chronic disease, which is characterised by anemia. It is marked by sickle-shaped red blood 
cells, and manifests in the form of episodic pain in the joints, fever, leg ulcers and jaundice. The 
disease occurs in individuals who are homozygous (HbSS) for the mutant haemoglobin (HbS) gene. 
There is no cure for SCA. It is frequent in Cameroon, affecting approximately 20% of the general 
population. It was declared a Public Health Priority in Cameroon. 
Alpha-thalassemia (α-thalassemia) is a blood disorder, which leads to the decreased production and 
increased destruction of red blood cells. Hemoglobin in the red blood cells carries oxygen for all 
organs in the body. The loss of red blood cells results in low haemoglobin. This is as the result of loss 
of α-globin genes (1, 2, 3, or 4). 
The aim of this study is to investigate the prevalence of α-thalassemia in a sample of Cameroonian 
SCA patients, and to study the correlation between the α-thalassemia genotypes and phenotypes in 
SCA patients. 
The study will consist of interviewing individuals, patients, and/or parents of the patients, to collect 
the following information: 
1. Socio-demographic information such as: age, gender, ethnicity, and level of education for all
participants.
2. Clinical information such as: BMI, blood pressure, incidence of stroke, number of vaso-occlusive
pain crises per year, the number of consultations per year, and the number of hospitalisations for
the patients.
3. The haematological indices such as: the red blood cell count (RBC), haemoglobin level (HbA),
mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), white
blood cell count (WBC), lymphocyte count, monocyte count, platelet level, foetal haemoglobin level
(HbF), and haemoglobin alpha-2 (HbA2) will be determined from blood using the haematological
testing service at Haematology Laboratory of the Centre Pasteur, Yaoundé for all participants.
Interviews will be conducted at the recruitment sites (Yaoundé Central Hospital, Laquitine Douala 
Hospital and the surrounding sites). All information is and will remain confidential. The data 
generated will only be used for research purposes. 
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If you decide to partake in this study, you will be required to provide the above mentioned 
information (1, 2 and 3) and 10ml of blood (taken from the arm). The drawing of blood will be 
performed by professional nurses and the haematological report generated by haematologists. The 
process will take 45 minutes. 
The risks relating to participation in this study are minimal. The drawing of blood is painful in terms 
of the prick and the few seconds of extraction, which may result in blue mark forming. However, the 
process is not fatal, and therefore no other problems will be encountered due to the drawing of 
blood . The utmost care will be taken to ensure a sterile environment. 
This study will not give the participant any direct benefit, monetary or otherwise. Participation is 
purely voluntary, free, and confidential. 
The participant’s results will be individually communicated to them. If the participant does not wish 
to be informed of their results, their decision will be respected and the results will not be disclosed.  
The information from the questionnaire and the haematological analyses will be preserved in form 
of a computerized database at the Faculty Biomedical Science and the Faculty of Medicine at the 
University of Yaoundé, and the Division of Human Genetics at the University of Cape Town. This 
information will be accessible only to the persons involved in this study. The participant will be able 
to withdraw their consent at any time. No disadvantage for the subsequent medical monitoring will 
follow from this decision. The team guarantees the protection of the confidentiality of the 
participants in study by respecting the following principles: 
- To interpret and transmit the results of all analyses to the participants who shall request for it. 
- To assure respect for good clinical and biological practices. 
- To respect the self-government and respectability of every subject. 
- To guarantee the confidentiality of participant data. 
- To share research conclusions with thestudy  participants. 
- To assure the appropriate broadcasting of the research results. 
- To inform participants of the research-related evolution of knowledge. 
For more information, contact: 
1. Prof. J. Ngogang supervisor of the study (Laboratory of Biochemistry of CHUY, such: 99922353) 
2. Prof. A. Wonkam, responsible for the study (Faculty of medicine of Yaoundé, Such: 96401593; 
University of Cape Town) 
3. Dr Mr Monny Lobe, joint manager of the study, (doctor responsible for the Centre of reference to 
the Central Hospital of Yaoundé Tel: 77517004) 
4. Ngo Bitoungui Valentina Josiane (PhD student, Tel: 99722383, email: vngobitoungui@yahoo.fr). 
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A2: TEMPLATE OF THE INFORMED CONSENT DOCUMENT 
ASSENT _____________ OR CONSENT ___________ 
Relative : Mother   Father   Tutor 
Name: .......................................................................................................... 
First name: ...................................................................................................... 
Date of birth : ................................................ 
Patient Name ............................ ............................................................................ 
First name ..................................................................................................... 
Date of birth .................................................. 
I hereby confirm that I have understood, with my satisfaction, and that I have had enough time to 
reflect on my decision and ask the necessary questions, the study. 
I accept that the research of the biological, and genetic characteristics, mentioned below, are carried 
out on my sample of blood /sample of blood of my above-mentioned child. 
• Hémogramme (Numeration Formulates Blood).
• Haemoglobin electrophoresis for the confirmation of the diagnosis, and evaluation of the rate of
foetal haemoglobin.
• Genetic analysis: (1) genetic confirmation of the diagnosis of SCA, (2) investigation of the genetic
factors that influence the severity of SCA (identification of the HBB gene haplotypes and the α-globin
deletions).
I accept that the data collected will be preserved in a computerized form, with the aim of research 
for the improvement of SCA. The data will be treated in a strictly confidential manner. 
I voluntarily partake in this study. I may withdraw my agreement of participation at any time without 
having to give reasons. 
I approve the conservation of my/child’s sample of blood or DNA sample: 
• For further and future research, while maintaining the strictest confidentiality.
Signature  Date and place ............................... 
Investigator 
I hereby confirm that I have informed the patient above, of every aspect of the study and I have 
answered all his/her questions. 
Name ............................................     First name ............................................. 
Place and date ...................................Signature ........................................... 
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A3: TEMPLATE OF THE QUESTIONAIRE 
NRO……………………… 
Name of the patient : ....................................................................................... Address: 
......................................  Such:......................./........................ 
Date of birth: .................................. 
Level of education:   No formal education1   Primary education2    Secondary education3 Tertiary 
education4  
SOCIO-DEMOGRAPHICS DATA OF THE PARENTS 
1. Father1      Mother2  Tutor3   (Male4 Female5) 
2. Year of birth: Father : .......................... Mother : ............................ 
3. Name of the father : ........................................Ethnic group: ........................... 
4. Name of the mother : ....................................Ethnic group : ........................... 
5. Marital statute:   Single1    Married2      widow/widower3  Divorced4 
6. Type of marriage:      Monogamic1   Polygamic2 
7. Religion:  Christian1  Muslim2    other: ............................ 
8. Level of education:   No formal education1   Primary education2    Secondary education3  
Tertiary education4
9. Profession: Father : .............................. Mother : .................................. 
10. Direct income: Father : .............................. Mother : .................................. 
11. Indirect income: Father : .............................. Mother : .................................. 
Pedigree: 
CLINICAL PHENOTYPE OF SCA PATIENTS  
Frequency of VOCs/annum during last 5 years 
Age of the diagnosis …………….. 
Painful crises .............. 
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Episode of cerebral vascular accident: yes1   no 2   unknown 3 
Acute thoracic syndrome ................. 
Painful crisis - swelling of the back of the hands and feet often associated with a swelling with the 
fingers (Dactylitise)……… 
Acute splenic sequestration ..................... 
Number of consultations/year ............................ 
Number hospitalisations/year .......................... 
Date from the last transfusion: less than 6 months1     more than 6 months2 
  Use of hydroxyurea: Yes1         No2 







Distribution: Lymphocytes ..............Monocytes .................. 
Platelets ............................................. 
2 - Electrophoresis of haemoglobin: (HbSS) 
Hb F ........ 
Hb A ............ 
Hb A2 ............. 
Hb C ............... 
GENOTYPAGE AND SEQUENCING 
1-Molecular confirmation of SCA by ADT (S)
YES1 
NO2 
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 2-Haplotype of the HBB gene:         
- Cameroon1                           - Senegal2                                           - Benin3            
- Bantu4           - Atypical5                                        - Arab-Indian6  
3-Specific Variations of the genome, which affects the rate of HbF – α GLOBIN GENE ANALYSIS: 
() No deletion1              
()  Type 2-heterozygote2                       
() Type 2-homozygote3  
(/-) Alpha triplication4 
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A4: CLINICAL AND EXPERIMENTAL DATA OF INDIVIDUALS IN THE STUDY COHORT 
Table 24: Characterisation of patient information, clinical and experimental data 
The characterisation of subject information used in the study is presented in this table. Colours characterise the study cohort according to unaffected controls 
(HbAA; green), carriers (HbAS; blue) and patients (HbSS; red). The following abbreviations and their units are as follows: male (M), female (F), age in years, red 
blood cell count (RBC) in a million cells/μl, haemoglobin level (HbA) in g/dl, mean corpuscular volume (MCV) in fL, mean corpuscular haemoglobin concentration 
(MCHC) in g/dl, white blood cell count (WBC) in109X/L, lymphocyte count (L) in 109X/L, monocyte count (M) in 109X/L, platelet level (P) in 109X/L, foetal 
haemoglobin (HbF) as a percentage and haemoglobin alpha-2 (HbA2) as a percentage, the age of diagnosis (AOD) in years and the number of vaso-occlusive 
crises (VOCs) per year. Phase I, II and III refers to the data collected from the three experimental parts performed. 
SUBJECTS SEX AGE ETHNICITY EDUCATION RBC HbA MCV MCHC WBC L M P HbA2 HbF AOD VOCs STROKE CONSULTATIONS HOSPITALISATIONS PHASE I PHASE II PHASE III 
RC42                                       HbAA  (aa/aa) 
RC43                                       HbSS BENIN/CAMEROON (aa/aa) 
RC44                                       HbSS BENIN/CAMEROON (aa/aa) 
RC45 F 17     2.6 7.1 86.8 31.5 17.5     433.0 3.2 0.0           HbSS BENIN/CAMEROON (aa/aa) 
RC46                                       HbSS BENIN/BENIN (aa/aa) 
RC47 F 43     2.9 9.2 92.6 34.5 13.7     315.0 3.0 20.0           HbSS BENIN/BENIN (aa/aa) 
RC49 M 9     2.5 6.6 81.3 32.9 24.0     373.0 3.2 18.1           HbSS BENIN/CAMEROON (aa/a3.7) 
RC50 M 14     3.1 7.6 74.2 32.7 15.8     396.0 3.5 0.0           HbSS BENIN/BENIN (aa/a3.7) 
RC51 M 8     3.5 8.5 79.3 30.6 24.4     414.0 2.3 21.6           HbAA  (aa/aa) 
RC52                                       HbAS  (aa/aa) 
RC53 F 11     2.5 6.4 82.0 31.9 23.2     246.0 4.4 26.5           HbSS   (aa/aa) 
RC54 M 7     2.2 6.2 80.0 34.5 21.9     148.0 3.4 26.2           HbSS BENIN/ATYPICAL (aa/a3.7) 
RC55                                       HbSS ATYPICAL/CAMEROON (aa/aa) 
RC59 F 9     2.8 7.5 86.3 31.0 22.5     233.0 3.4 17.8           HbSS BENIN/ATYPICAL (aa/aa) 
RC60                                       HbSS BENIN/BENIN (aa/a3.7) 
RC61 F 28     78.8 3.4 17.8   19.4       5.1 13.3           HbSS BENIN/ATYPICAL (aa/aa) 
RC62 M 17     2.5 7.1 86.2 33.3 24.5     404.0 3.3 22.4           HbSS BENIN/BENIN (aa/aa) 
RC63 M 10     3.0 6.9 68.3 34.2 16.9     515.0 4.2 0.0           HbSS BENIN/BENIN (aa/aa) 
RC69 M 16     3.9 8.4 66.6 32.2 14.3     378.0 6.9 0.0           HbSS BENIN/ATYPICAL (aa/aa) 
RC70 F 18     4.7 9.6 68.0 30.5 29.9     354.0 3.3 19.0           HbSS   (a3.7/a3.7) 
RC71 F 11     2.5 6.4 82.0 31.9 23.2     246.0 4.4 26.5           HbSS BENIN/ATYPICAL (aa/aa) 
RC72                                       HbSS BENIN/ATYPICAL (aa/a3.7) 
RC73 F 10     2.6 7.4 79.0 36.2 26.4     345.0 3.0 0.0           HbSS BENIN/BANTU (aa/aa) 
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RC74 F 40 3.2 8.4 77.1 34.5 33.9 399.0 3.1 14.6 HbSS BENIN/CAMEROON (aa/aa) 
RC76 F 27 3.9 8.1 68.8 30.2 12.7 339.0 4.3 20.1 HbSS BENIN/CAMEROON (aa/a3.7) 
RC77 HbSS BENIN/CAMEROON (aa/aa) 
RC78 HbSS ATYPICAL/CAMEROON (aa/aa) 
RC79 F 9 3.4 8.4 79.6 30.7 20.7 408.0 3.1 14.6 HbSS ATYPICAL/CAMEROON (aa/a3.7) 
RC81 M 13 1.8 6.0 103.3 32.3 39.3 266.0 2.5 13.6 HbSS BENIN/ATYPICAL (aa/aa) 
RC83 M 15 3.2 6.8 64.8 32.7 14.7 177.0 4.5 27.3 HbSS BENIN/CAMEROON (a3.7/a3.7) 
RC84 F 37 3.2 8.9 79.9 34.8 9.2 225.0 2.7 17.9 HbSS BENIN/ATYPICAL (aa/aa) 
RC85 F 13 2.4 6.8 86.2 33.5 35.5 442.0 6.8 86.2 HbSS BENIN/CAMEROON (aa/aa) 
RC87 F 33 3.6 12.2 HbSS BENIN/ATYPICAL (aa/aa) 
RC88 M 18 2.8 7.6 79.9 33.4 23.6 294.0 3.5 0.0 HbSS BENIN/BENIN (aa/aa) 
RC89 F 16 4.2 8.6 71.9 28.6 15.0 474.0 3.7 0.0 HbSS BENIN/ATYPICAL (aa/a3.7) 
RC90 M 11 HbSS BENIN/CAMEROON (aa/a3.7) 
RC91 HbSS BENIN/BENIN (aa/aa) 
RC92 F 24 3.7 8.6 71.2 32.3 16.9 457.0 3.3 15.4 HbSS (aa/a3.7) 
RC93 F 9 2.9 8.0 81.7 33.5 42.4 524.0 2.8 18.3 HbSS BENIN/ATYPICAL (aa/aa) 
RC95 HbSS BENIN/ATYPICAL (aa/a3.7) 
RC98 HbSS BENIN/BENIN (aa/aa) 
RC103 HbSS BENIN/ATYPICAL (a3.7/a3.7) 
RC105 HbSS (aa/aa) 
RC106 HbSS (aa/aa) 
RC107 HbAA (aa/aa) 
RC108 HbAA (aa/aa) 
C1 F 26 4.8 16.0 76.0 44.3 5.7 2.6 0.6 296.0 2.4 9.4 HbAA (aa/aa) 
C2 F 24 9.3 13.3 81.0 35.3 4.1 0.4 94.0 73.0 3.6 10.6 HbAA (aa/aa) 
C3 F 42 4.0 8.1 66.0 30.5 4.8 0.6 1.4 300.0 1.9 12.1 HbSS BENIN/ATYPICAL (aa/a3.7) 
C4 F 16 4.7 13.2 79.0 35.2 7.8 0.5 1.2 354.0 4.0 HbAA (aa/aa) 
C5 F 20 4.7 12.0 78.0 33.0 4.1 1.5 0.4 203.0 1.1 HbSS ATYPICAL/SENEGAL (aa/a3.7) 
C6 M 48 5.2 13.6 82.0 31.0 2.9 1.1 0.2 157.0 HbSS (aa/a3.7) 
C7 HbAA (aa/aa) 
C8 HbSS BENIN/ATYPICAL (aa/aa) 
C9 F 19 4.5 11.6 75.0 34.7 4.6 2.6 0.4 189.0 2.8 HbAA (aa/aa) 
C10 M 21 5.1 13.3 74.0 35.5 8.9 4.4 1.3 249.0 3.6 HbSS (aa/a3.7) 
C11 F 32 8.2 14.3 83.0 34.2 3.0 1.4 0.2 196.0 1.7 HbSS (aa/aa) 
C12 F 24 4.2 12.8 81.0 37.4 5.9 2.5 0.7 242.0 5.0 HbAA (aa/aa) 
C13 F 24 3.9 11.5 84.0 35.8 8.3 2.7 2.3 284.0 3.9 HbAS (aa/aa) 
C14 M 23 4.9 14.2 85.0 34.0 4.8 1.6 0.8 174.0 2.2 HbAS (aa/a3.7) 
C15 F 17 4.6 12.9 88.0 31.4 4.5 2.1 0.5 377.0 2.2 HbSS (aa/aa) 
C16 F 22 4.0 11.8 81.0 36.6 11.2 4.0 1.3 224.0 3.3 9.7 HbAA (aa/aa) 
C17 F 29 5.4 16.1 85.0 35.0 5.8 2.8 0.8 228.0 3.7 9.9 HbAA (aa/aa) 
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C18 M 24     4.7 14.7 90.0 34.7 6.8 3.1 0.3 193.0 1.8             HbAA   (aa/aa) 
C19 M 12     6.2 15.9 74.0 34.6 5.8 1.4 0.6 252.0 2.8             HbAS   (aa/a3.7) 
C20 M 21     4.3 13.0 78.0 38.7 4.4 1.8 0.4 2.1 0.9             HbAA  (aa/aa) 
C23 M 42     4.3 13.2 94.0 33.1 6.9 3.3 0.4 183.0 4.3             HbAA  (aa/aa) 
C26 F 27     4.8 13.0 87.0 31.3 5.5 2.2 0.4 221.0 2.6             HbSS BENIN/BENIN (aa/a3.7) 
C27 F 47     4.3 10.0 72.0 31.9 4.9 2.5 0.3 137.0 2.9 17.1           HbAS  (a3.7/a3.7) 
C29 F 35     3.9 11.8 82.0 30.6 5.2 0.6 1.1 181.0 0.6 7.3           HbAS  (aa/aa) 
C30 M 4     5.1 11.7 73.0 31.3 2.0 1.2 0.3 278.0 4.8             HbAS  (aa/a3.7) 
C31 F       4.5 13.2 87.0 33.9 4.9 2.0 1.1 256.0               HbSS   (aa/aa) 
C32 F 24     4.3 10.4 64.0 37.6 4.8 1.6 0.7 334.0 1.2 5.4           HbAA  (aa/a3.7) 
C34                                       HbAS  (aa/aa) 
C36 F 30     4.4 14.0 83.0 38.6 8.4 4.4 1.3 99.0 4.9 9.9           HbAA  (aa/aa) 
C39 F 4     2.7 8.5 95.0 31.4 9.2 5.6 0.8 379.0 2.8             HbAA  (aa/aa) 
C40 F 23     4.2 14.2 85.0 40.5 6.1 3.4 0.5 201.0 1.3 3.8           HbAA  (aa/aa) 
C41 F 23     5.4 18.7 79.0 43.5 5.7 2.2 1.1 152.0 3.4             HbAS   (aa/aa) 
C42 F 28     4.8 13.5 85.0 33.2 5.1 2.1 0.5 262.0 4.1             HbAA  (aa/aa) 
C43 M 21     5.2 16.2 81.0 38.3 4.7 2.1 0.8 163.0 0.4 7.8           HbAA  (aa/aa) 
C44 M 16     5.1 12.9 81.0 31.2 4.3 2.9 0.9 340.0 3.3             HbAA  (aa/aa) 
C46 F 36     4.7 12.9 88.0 30.8 3.6 1.8 1.1 250.0 3.2 0.8           HbAA  (aa/aa) 
C47 F 24     3.8 15.0 91.0 43.8 4.8 2.1 1.3 228.0 4.2 10.4           HbAA  (aa/aa) 
C48 F 23     4.1 13.0 82.0 38.4 5.3 1.9 0.4 210.0 3.3 10.7           HbAA  (aa/aa) 
C49 M 31     5.6 13.1 77.0 30.5 5.6 2.5 0.4 138.0 2.3             HbAS  (aa/a3.7) 
C50 F 28     4.9 13.5 84.0 32.6 4.7 2.0 0.4 160.0 4.4             HbAS  (aa/aa) 
C51 F 22     4.7 12.5 74.0 36.5 7.0 1.7 0.8 290.0 1.2 7.0           HbAA  (aa/aa) 
C52 M 34     5.3 18.7 80.0 44.3 5.1 2.5 0.9 181.0 3.0 10.0           HbAA  (aa/a3.7) 
C53 M 42     5.4 16.5 82.0 37.2 4.0 1.7 0.7 258.0 4.2 11.0           HbAA  (aa/aa) 
C54 F 21     4.1 11.5 77.0 36.1 4.6 2.3 0.4 278.0 4.6 10.8           HbAA  (aa/aa) 
C55 F 22     4.6 9.8 63.0 33.8 6.5 2.3 0.9 254.0 0.9 7.3           HbSS ATYPICAL/ATYPICAL (aa/aa) 
C58 F 18     4.5 13.2 87.0 33.9 4.9 2.0 1.1 256.0 2.3             HbSS   (aa/aa) 
C63 F 27     4.0 10.9 69.0 38.9 5.0 0.8 1.1 111.0   11.0           HbAA  (aa/a3.7) 
C64 F 27     4.1 13.1 88.0 36.3 5.7 3.0 0.7 212.0 4.0             HbAA  (aa/aa) 
C70 F 29     4.3 10.7 56.0 44.1 5.7 1.4 0.4 260.0 2.3             HbAS  (aa/aa) 
C73 M 35     4.1 12.3 82.0 35.9 4.6 2.1 0.6 247.0 0.5             HbAA  (a3.7/a3.7) 
C75 F 28     5.5 11.3 68.0 29.9 5.8 1.8 1.3 454.0 4.2 <0,8           HbAA  (aa/aa) 
C78 F 29     4.0 10.3 83.0 31.3 6.9 3.3 0.4 235.0 3.3             HbAS  (aa/aa) 
C79 M 38     5.0 14.5 91.0 32.3 4.9 1.4 0.7 230.0 2.2 AS           HbSS  (aa/a3.7) 
C82 F 8     5.1 11.6 74.0 30.6 6.9 4.3 0.6 340.0 4.3 1.3           HbAS  (aa/aa) 
C83 M 8     5.2 12.8 80.0 30.6 9.3 3.7 0.9 153.0 4.0             HbAS  (aa/aa) 
C85 F 26     5.2 16.4 76.0 41.7 5.2 2.5 0.8 178.0 3.6             HbAA  (aa/aa) 
C86 F 19     9.3 16.0 78.0 33.8 3.2 1.1 0;3 147.0 2.5 4.3           HbAS  (aa/aa) 
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C96 F 26 4.3 12.0 87.0 32.4 5.0 2.2 0.8 272.0 3.1 0.9 HbAA (aa/a3.7) 
C97 F 43 3.7 10.5 77.0 36.5 3.1 1.5 0.2 99.0 3.9 4.9 HbAA (aa/aa) 
C99 F 24 4.6 13.4 84.0 33.5 7.7 4.5 0.8 214.0 3.7 10.0 HbAS (aa/aa) 
C103 M 36 4.9 17.9 83.0 44.6 6.7 1.9 0.6 153.0 4.2 9.5 HbSS (aa/aa) 
C106 F 22 3.8 13.5 79.0 45.1 5.6 2.1 0.8 341.0 11.1 HbAA (aa/aa) 
C108 F 26 4.2 12.4 78.0 37.6 2.8 2.0 0.3 193.0 4.5 4.6 HbAA (aa/aa) 
C113 F 27 4.2 13.0 86.0 36.5 4.7 2.3 0.8 246.0 3.9 10.8 HbAA (aa/aa) 
C114 M 28 5.2 15.8 83.0 36.7 4.4 2.1 0.6 306.0 1.6 3.5 HbSS (aa/aa) 
C121 F 24 4.4 11.2 72.0 35.2 8.4 2.1 1.6 226.0 1.6 4.5 HbAA (aa/a3.7) 
C124 F 20 4.2 13.0 81.0 38.1 5.5 3.3 0.6 123.0 3.4 4.5 HbAA (aa/aa) 
C125 F 30 4.5 13.6 81.0 37.7 4.0 1.7 0.6 235.0 0.1 HbAA (aa/aa) 
C127 F 14 2.1 12.8 82.0 32.0 4.8 2.4 0.5 291.0 4.0 HbAS (a3.7/a3.7) 
C133 F 23 4.3 16.1 82.0 45.2 3.3 1.8 0.4 249.0 5.4 HbAA (aa/aa) 
C134 M 28 4.8 13.3 79.0 34.7 5.7 3.2 0.7 190.0 1.6 HbAA (aa/aa) 
C137 M 27 5.5 15.7 80.0 35.6 5.0 2.7 0.9 133.0 3.8 3.9 HbAA (aa/aa) 
C139 F 38 4.1 12.6 92.0 32.9 5.9 2.1 0.5 249.0 3.3 <0,8 HbAA (aa/aa) 
C140 M 33 4.2 12.8 81.0 37.4 5.9 2.5 0.7 242.0 3.0 HbAA (aa/aa) 
C141 HbAA (aa/aa) 
C145 F 24 5.0 15.6 90.0 34.8 8.7 2.8 0.5 651.0 4.8 HbAA (aa/aa) 
57 M 27 EWONDO SECONDARY 3.80 8.3 68.0 32.0 20.4 4.7 0.8 586.0 3.2 3.7 0.5 2 NO 9 3 HbAS (aa/aa) 
75 M 28 5.7 16.7 78.0 37.3 3.6 1.4 0.3 364.0 1.2 0.7 HbAS (aa/aa) 
78 HbAS (aa/aa) 
80 M 27 4.8 14.8 81.0 38.3 4.1 0.8 0.4 145.0 3.2 12.6 HbAS (aa/aa) 
83 M 27 4.8 15.8 90.0 36.7 3.3 1.1 0.3 164.0 3.3 3.6 HbAA (aa/aa) 
84 F 19 MIXED ANCESTRY SECONDARY 2.4 6.9 83.0 34.2 12.2 6.3 1.6 190.0 2.9 12.6 0.5 0 NO 0 1 HbAS (aa/aa) 
87 F 16 4.6 12.7 78.0 35.6 4.5 2.7 0.6 220.0 9.1 HbAS (aa/aa) 
99 F 10 BAMI SECONDARY 3.9 8.5 70.0 31.0 5.4 2.2 0.3 318.0 2.7 19.9 6 0 NO 5 5 HbAS (aa/aa) 
108 M 27 BAMI SECONDARY 2.0 7.9 88.0 28.6 13.5 5.6 1.3 433.0 HbAA (aa/aa) 
120 F 15 MIXED ANCESTRY SECONDARY 3.0 6.3 71.0 29.7 12.1 6.0 1.1 432.0 5.5 15.3 9 2 NO 0 0 HbSS BENIN/CAMEROON (aa/a3.7) 
123 M 11 ETON SECONDARY 3.6 9.7 83.0 32.6 15.9 8.3 0.8 340.0 3.8 9.4 2 2 NO 2 3 HbSS BENIN/ATYPICAL (aa/aa) 
126 M 12 DSCHANG PRIMARY 2.6 7.7 87.0 34.6 10.6 4.3 1.2 316.0 2.3 15.2 5 1 NO 2 4 HbSS BENIN/CAMEROON (aa/aa) 
127 M 10 BAMI PRIMARY 2.8 7.0 79.0 31.9 16.8 4.7 2.4 164.0 3.8 7.2 4 2 NO 0 0 HbSS BENIN/ATYPICAL (aa/a3.7) 
128 M 37 MIXED ANCESTRY TERTIARY 2.1 6.0 80.0 36.3 8.0 3.4 2.1 583.0 3.8 10.9 2 1 NO 1 4 HbSS BENIN/BENIN (aa/aa) 
129 M 13 BAMI SECONDARY 2.40 7.7 88.0 36.3 16.4 9.2 1.8 408.0 4.5 10.7 HbSS BENIN/ATYPICAL (aa/aa) 
130 M 19 MIXED ANCESTRY SECONDARY 1.4 5.5 95.0 40.0 19.5 11.3 1.6 350.0 4.8 0.0 0.8 2 NO 1 0 HbSS BENIN/ATYPICAL (aa/aa) 
131 M 10 EWONDO PRIMARY 3.1 6.4 66.0 31.9 12.0 6.6 1.2 472.0 3.8 7.8 3 2 NO 0 0 HbSS ATYPICAL/CAMEROON (aa/a3.7) 
134 F 49 YAMBASSA SECONDARY 3.8 8.5 72.0 30.8 7.2 2.9 0.7 283.0 4.5 5.2 6 2 NO 3 4 HbSS ATYPICAL/ATYPICAL (a3.7/a3.7) 
135 F 32 BASSA PRIMARY 2.4 6.9 82.0 35.7 10.6 6.2 0.9 540.0 3.8 10.7 2 1 NO 0 0 HbSS BENIN/ATYPICAL (aa/aa) 
136 F 11 MIXED ANCESTRY SECONDARY 2.1 7.2 91.0 37.6 13.0 5.0 0.8 484.0 2.4 9.3 0.5 0 NO 0 0 HbSS BENIN/ATYPICAL (aa/aa) 
137 F 11 HAOUSSA PRIMARY 3.7 9.4 81.0 31.2 6.7 2.7 0.6 355.0 2.7 9.5 0.6 2 NO 10 12 HbSS ATYPICAL/ATYPICAL (aa/a3.7) 
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138 M 18 ETON SECONDARY 2.7 7.8 80.0 35.7 6.2 2.8 1.0 350.0 2.6 15.6 1 0 NO 0 12 HbSS ATYPICAL/ATYPICAL (aa/aa) 
140 M 7 MIXED ANCESTRY PRIMARY 2.6 7.6 86.0 34.3 21.2 10.2 1.3 514.0 3.4 9.1 2 2 NO 3 0 HbSS BENIN/ATYPICAL (aa/aa) 
141 M 23 BATOUFAM SECONDARY 3.8 9.3 78.0 31.6 12.3 5.0 0.9 356.0 4.4 6.7 16 1 NO 0 0 HbSS BENIN/ATYPICAL (aa/aa) 
142 M 17 BAKAKA SECONDARY 2.6 9.5 81.0 36.3 18.0 9.8 1.4 424.0 3.4 12.1 0.5 1 NO 1 0 HbSS BENIN/ATYPICAL (aa/aa) 
143 F 29     4.6 11.7 83.0 31.0 4.4 2.3 0.2 204.0 6.0             HbAS  (aa/a3.7) 
144 M 20 EWONDO SECONDARY 2.8 8.9 88.0 36.7 10.8 3.9 2.1 465.0     5 1 NO 0 2 HbSS BENIN/ATYPICAL (aa/aa) 
145 M 6 MIXED ANCESTRY PRIMARY 3.1 6.6 62.0 34.3 19.3 11.1 2.1 483.0 3.5 0.8 0.5 0 NO 0 0 HbSS ATYPICAL/ATYPICAL (aa/aa) 
146 M 21 EWONDO SECONDARY 2.4 7.0 84.0 35.8 9.0 2.3 1.6 334.0     2 2 NO 4 0 HbSS BENIN/BENIN (aa/aa) 
177 M 7 BETI PRIMARY 2.8 6.9 73.0 33.9 19.0 9.0 1.9 287.0 4.2 6.8 3 1 NO 0 0 HbAS  (aa/aa) 
181 F 24 MIXED ANCESTRY SECONDARY 3.3 8.9 87.0 31.2 7.2 3.3 0.6 529.0 3.2 22.3 4 0 NO 4 3 HbSS BENIN/BENIN (aa/aa) 
183 F 18 BETI TERTIARY 2.10 7.8 94.0 39.3 18.9 4.5 1.6 501.0 4.4 8.0 0.6 2 NO 0 0 HbSS   (aa/aa) 
184 F 37 EWONDO SECONDARY 1.4 5.8 98.0 41.8 31.9 21.6 3.8 477.0 3.5   0.5 0 NO 0 3 HbSS BENIN/CAMEROON (aa/aa) 
185 F 6   PRIMARY 2.7 8.4 85.0 36.6 11.2 4.7 1.2 602.0 5.7 11.2           HbSS BENIN/BENIN (aa/aa) 
189 M 7 EWONDO PRIMARY 3.0 7.2 76.0 31.9 10.2 4.4 0.9 376.0 3.4 7.8 2 2 NO 1 4 HbSS   (aa/a3.7) 
190 M 4 BAMOUN PRIMARY 2.9 6.8 67.0 35.4 20.3 8.3 1.6 362.0 2.9 4.6 1 2 NO 0 12 HbSS BENIN/BENIN (aa/aa) 
193 F 27 BASSA TERTIARY 4.3 9.6 73.0 30.3 10.3 5.9 0.9 375.0 6.1 23.4 7 0 NO 3 0 HbSS BENIN/ATYPICAL (aa/a3.7) 
194 F 18 MIXED ANCESTRY SECONDARY 3.3 8.0 73.0 33.5 25.4 4.4 3.0 406.0 4.1 6.8 0.5 2 NO 2 1 HbSS BENIN/BENIN (aa/aa) 
195 M 16 BASSA SECONDARY 2.3 6.2 80.0 33.9 16.2 10.1 1.8 273.0 3.2 12.3 2 2 NO 4 4 HbSS BENIN/BENIN (aa/aa) 
197         1.6 3.2 90.0 34.0 4.0 2.3 0.4 290.0               HbSS   (aa/aa) 
198 F 9 YAMBASSA PRIMARY 3.00 7.6 77.0 33.1 11.9 3.8 0.6 526.0 2.6 6.8 6 1 NO 0 4 HbSS BANTU/CAMEROON (aa/a3.7) 
200 M 6 BAMI PRIMARY 1.9 5.5 89.0 32.9 8.5 3.1 0.9 471.0 3.3     2 NO 3 4 HbSS BENIN/CAMEROON (aa/a3.7) 
201 M 8 BAFUT PRIMARY 3.0 7.7 84.0 30.5 23.2 9.6 2.8 650.0 3.5 11.0 2 2 NO 0 1 HbSS BENIN/ATYPICAL (aa/aa) 
202 F 10 BETI PRIMARY 3.2 8.2 75.0 34.0 23.7 8.4 2.2 535.0 4.0   2 1 NO 2 0 HbSS ATYPICAL/ATYPICAL (aa/aa) 
210 F 14 EWONDO SECONDARY 2.5 7.8 89.0 37.7 13.5 5.6 1.3 579.0 4.8   3 1 NO 1 1 HbSS BANTU/CAMEROON (aa/aa) 
211 M 8 MIXED ANCESTRY PRIMARY 2.9 8.2 81.0 34.4 17.4 6.4 1.3 208.0 4.3 8.2 3 0 NO 0 4 HbSS BENIN/ATYPICAL (aa/aa) 
214 M 19 BAMI SECONDARY 2.2 6.6 99.0 32.1 13.1 6.1 1.7 262.0 3.1 18.1 3 1 NO 3 6 HbSS   (aa/aa) 
216 M 13 HAOUSSA PRIMARY 2.9 7.7 85.0 31.6 18.0 4.9 1.4 233.0 2.6 15.6 5 2 NO 3 0 HbSS BENIN/BENIN (aa/aa) 
217 M 10 BAMI PRIMARY 3.8 8.3 71.0 30.4 14.9 6.6 1.0 341.0 4.1 15.9 3 2 NO 0 0 HbSS BENIN/BENIN (aa/a3.7) 
218 M 5 EWONDO PRIMARY 2.9 8.0 83.0 33.0 11.2 5.5 1.1 460.0 4.3             HbSS BENIN/CAMEROON (aa/a3.7) 
219 F 35 EWONDO SECONDARY 2.8 8.0 93.0 31.4 9.5 4.0 0.9 486.0 4.0   3 1 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
223 F 15 YAMBASSA SECONDARY 1.8 4.9 92.0 29.7 10.6 4.8 3.0 228.0 3.1 9.2 3 1 NO 1 0 HbSS BENIN/ATYPICAL (aa/a3.7) 
224 M 51 BASSA SECONDARY 2.1 6.7 90.0 35.3 9.7 1.9 0.4 155.0 3.6 8.8 13 1 NO 0 0 HbSS BENIN/ATYPICAL (aa/a3.7) 
225 F 21 BAMILEKE TERTIARY 2.60 8.2 86.0 36.6 10.4 4.4 0.8 449.0 3.9 16.4 0.5 2 NO 5 5 HbSS BENIN/BENIN (aa/aa) 
227 F 31 EWONDO TERTIARY 2.3 7.7 92.0 36.0 10.0 5.5 0.7 351.0 3.6 3.0 0.6 1 NO 0 0 HbSS BENIN/CAMEROON (aa/aa) 
229 F 10 EWONDO PRIMARY 2.6 7.7 89.0 33.6 10.5 4.9 0.6 463.0 4.7 16.4 7 2 NO 1 1 HbSS BENIN/CAMEROON (aa/a3.7) 
230 F 39 BENE SECONDARY 2.5 9.1 94.0 38.2 13.9 8.2 1.8 374.0 3.2 18.4 0.8 1 NO 4 4 HbSS BENIN/CAMEROON (aa/aa) 
231 F 27 BAFIA NONE 1.5 6.0 100.0 40.1 14.4 5.7 2.0 444.0 3.9   4 1 NO 1 3 HbSS BENIN/ATYPICAL (aa/aa) 
233 F 23     4.4 15.9 80.0 45.2 5.2 2.2 0.8 275.0 3.3 10.0           HbAS  (aa/aa) 
234 M 18 MAKA SECONDARY 4.9 9.2 64.0 29.1 4.4 2.2 0.2 169.0 7.2 4.2 5 0 NO 0 0 HbAS  (aa/aa) 
236 F 26     4.1 14.9 83.0 44.1 3.5 2.2 0.3 138.0               HbAS  (aa/aa) 
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321 F 10 MIXED ANCESTRY PRIMARY 3.2 6.1 60.0 31.4 11.9 6.7 1.2 209.0 4.0 18.4 0.7 1 NO 0 3 HbSS BENIN/ATYPICAL (a3.7/a3.7) 
322 M 34 MIXED ANCESTRY SECONDARY 2.8 8.2 93.0 31.8 9.9 3.1 1.2 517.0 7.2   0.5 1 NO 0 5 HbSS BENIN/ATYPICAL (aa/a3.7) 
323 F 28     4.3 16.4 84.0 45.1 5.7 2.9 0.5 108.0 1.0 4.8           HbAS  (aa/a3.7) 
324 F 32     4.3 16.4 84.0 45.1 5.7 2.9 0.5 108.0 1.0 4.8           HbAA  (aa/aa) 
325 F 28 DOUALA TERTIARY 2.7 8.4 100.0 31.4 10.5 5.7 1.2 615.0 3.4   21 1 NO 0 2 HbSS BENIN/ATYPICAL (aa/a3.7) 
326 F 4 FOULBE NONE 4.3 9.9 77.0 28.8 9.6 4.5 0.8 323.0               HbSS   (aa/aa) 
328 F 25 MIXED ANCESTRY SECONDARY 3.9 14.0 78.0 46.3 4.9 2.6 0.8 265.0 3.1 19.8 7 1 NO 0 0 HbSS   (aa/a3.7) 
329 M 27 ETON TERTIARY 3.3 10.0 90.0 33.3 7.7 3.4 0.4 281.0 3.9 25.9 6 1 NO 3 0 HbSS   (aa/aa) 
330 F 20 BAMI NONE 1.7 5.7 112.0 30.5 28.7 17.5 2.9 270.0 2.3 17.6 1 2 NO 3 3 HbSS BENIN/BENIN (aa/aa) 
331 M 22 MBAMOIS SECONDARY 2.6 8.1 90.0 34.9 10.0 5.1 1.5 262.0 2.1 1.1 6 1 NO 1 2 HbSS   (aa/aa) 
333 M 18 EWONDO SECONDARY 2.3 5.4 67.0 35.2 17.4 8.2 2.3 163.0 3.1 3.0 1 1 YES 0 2 HbSS BENIN/ATYPICAL (a3.7/a3.7) 
334 M 16 EWONDO SECONDARY 3.6 9.8 90.0 30.6 11.2 5.2 1.0 589.0 4.0 11.1   2 NO 3 3 HbSS BENIN/BENIN (aa/aa) 
335 M 48 BASSA SECONDARY 4.1 10.8 81.0 32.5 11.6 4.3 1.5 584.0 3.3 1.6 20 0 NO 0 0 HbSS CAMEROON/CAMEROON (aa/a3.7) 
336 F 19 MIXED ANCESTRY SECONDARY 2.2 7.7 104.0 33.6 12.5 6.1 0.5 598.0 4.2   5 1 NO 10 6 HbSS BENIN/ATYPICAL (aa/aa) 
337 F 31 BAMILEKE SECONDARY 1.7 5.8 97.0 35.4 12.2 3.2 0.8 572.0 5.5 13.6 7 1 NO 2 2 HbSS BENIN/BENIN (aa/aa) 
339 M 8 HAOUSSA PRIMARY 4.1 9.4 67.0 34.5 15.1 5.0 1.8 498.0     2 1 NO   1 HbAS  (aa/a3.7) 
340 F 8 DSCHANG PRIMARY 3.3 8.4 81.0 32.0 10.4 4.3 1.3 394.0 3.3 27.3 0.5 2 NO 6 1 HbSS BENIN/BENIN (aa/aa) 
341 F 34 HAOUSSA PRIMARY 2.4 7.6 91.0 34.4 14.0 4.1 1.6 325.0 4.2 15.9 15 1 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
342 F 31 YAMBASSA TERTIARY 3.3 7.9 72.0 33.0 9.6 2.3 0.9 442.0 4.0 17.0 0.5 1 NO 0 0 HbSS   (aa/a3.7) 
343 F 24 BANEN SECONDARY 2.1 9.2 80.0 54.3 8.1 5.2 1.3 491.0 3.9 10.8 5 1 NO 3 1 HbSS CAMEROON/CAMEROON (aa/a3.7) 
344 F 20 MIXED ANCESTRY TERTIARY 2.1 6.9 93.0 36.0 13.1 5.1 1.3 358.0 3.4 23.2 1 2 NO 6 1 HbSS BENIN/BENIN (aa/aa) 
346 F 6 BAMILEKE PRIMARY 3.4 8.5 75.0 32.6 8.8 4.8 1.7 438.0 4.9 21.9 5 1 NO 1 1 HbSS BENIN/BENIN (aa/a3.7) 
347 M 23 DSCHANG SECONDARY 2.8 7.7 80.0 34.8 10.5 5.4 0.9 556.0 4.0   2 2 NO 8 6 HbSS ATYPICAL/ATYPICAL (aa/aa) 
348 M 29 ETON SECONDARY 5.5 12.1 76.0 28.8 9.4 3.7 0.7 392.0 4.9 4.8 0.6 1 NO 1 1 HbSS BENIN/ATYPICAL (aa/a3.7) 
349 M 24 MIXED ANCESTRY SECONDARY 4.2 7.7 64.0 28.8 10.9 2.8 0.6 559.0 5.3 15.4 7 1 NO 4 1 HbSS BENIN/BENIN (a3.7/a3.7) 
350 M 32 MIXED ANCESTRY TERTIARY 1.8 6.2 88.0 38.9 12.3 6.2 1.8 412.0 3.6 10.4 0.5 1 NO 3 1 HbSS BENIN/BENIN (aa/aa) 
351 F 47 DSCHANG PRIMARY 2.6 6.8 86.0 30.1 9.4 3.9 2.0 200.0 8.0 14.8 17 1 NO 4 4 HbSS BENIN/BENIN (aa/aa) 
352 F 14 BASSA SECONDARY 5.5 14.3 59.0 44.1 7.3 2.0 1.2 200.0 4.0 14.3 0.5 1 NO 0 0 HbSS BENIN/BENIN (a3.7/a3.7) 
353 M 21   SECONDARY 1.9 8.9 101.0 32.1 10.4 3.9 0.8 354.0 4.4 10.5 3         HbSS BENIN/ATYPICAL (a3.7/a3.7) 
354 M 5     5.0 11.3 70.0 32.7 7.9 3.7 1.7 440.0 1.9             HbSS BENIN/BENIN (aa/a3.7) 
355 M 24 MIXED ANCESTRY SECONDARY 2.9 8.8 89.0 34.4 16.9 6.7 7.8 192.0 4.8 11.0 6 1 YES 2 3 HbSS ATYPICAL/ATYPICAL (aa/aa) 
356 F 12 BAMILEKE PRIMARY 2.6 9.4 93.0 38.4 14.2 6.8 2.3 243.0 2.2 26.3 0.5 2 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
357 M 8 MIXED ANCESTRY PRIMARY 2.5 7.5 82.0 36.3 13.5 5.4 1.1 320.0 5.5 8.9 2 2 NO 12 1 HbSS BENIN/CAMEROON (aa/a3.7) 
358 M 15 DSCHANG NONE 2.7 6.8 83.0 29.9 12.8 5.5 1.5 661.0 3.5 13.5 12 1 NO 1 1 HbSS BENIN/BENIN (aa/aa) 
359 F 14 ETON SECONDARY 4.3 8.7 69.0 29.6 5.8 2.8 0.4 278.0 4.7 16.3 14 1 NO 1 0 HbSS BENIN/CAMEROON (a3.7/a3.7) 
360 F 17 BAMOUN SECONDARY 2.3 7.7 83.0 39.7 8.6 3.1 1.2 410.0 4.4   2 1 NO   1 HbSS BENIN/ATYPICAL (aa/a3.7) 
361 F 28 MIXED ANCESTRY TERTIARY 2.2 7.4 92.0 36.3 12.5 4.4 0.9 259.0 4.2 14.1 6 1 NO 2 1 HbSS BENIN/CAMEROON (aa/aa) 
362 F 11 BAFIA PRIMARY 2.0 5.8 88.0 33.7 18.2 8.8 1.0 333.0 3.9             HbSS BENIN/CAMEROON (aa/aa) 
363 F 19 BAMILEKE SECONDARY 2.2 8.5 98.0 39.8 12.9 6.0 1.6 402.0 3.7 18.5 11 2 NO 4 1 HbSS BENIN/BENIN (aa/aa) 
364 M 4 BANDJOUN PRIMARY 2.0 9.8 93.0 52.9 14.7 7.8 2.9 296.0 2.7 14.1 2 1 NO 1 1 HbSS BENIN/BENIN (aa/aa) 
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365 F 34 BANEN NONE 3.6 9.6 77.0 34.4 15.2 7.2 1.1 351.0 5.9 14.0 12 1 NO 1 2 HbSS BENIN/BENIN (aa/a3.7) 
366 M 24 ETON TERTIARY 3.5 13.7 82.0 47.2 4.9 1.6 0.7 147.0 3.8 13.3 7 1 NO 3 12 HbSS   (aa/a3.7) 
367 F 16 DSCHANG SECONDARY 3.7 8.5 76.0 30.6 4.1 1.6 0.5 241.0 2.5 27.3 14 1 NO 1 3 HbSS BENIN/BENIN (a3.7/a3.7) 
368 F 5 ETON PRIMARY 2.60 6.4 75.0 32.8 13.5 5.2 0.8 598.0 13.2 18.4 4 1 NO 3 3 HbSS BENIN/BENIN (aa/a3.7) 
369 F 21 BAMILEKE SECONDARY 2.0 7.8 94.0 42.4 22.5 1.9 2.5 482.0 3.6 14.9 0.5 2 NO 5 0 HbSS BENIN/CAMEROON (aa/aa) 
370 F 9   PRIMARY 2.0 6.0 95.0 31.9 16.0 7.3 1.3 453.0 3.1 29.3           HbSS BENIN/BENIN (aa/aa) 
371 M 16 BAMENDA SECONDARY 2.1 6.9 81.0 40.7 17.3 3.3 3.5 328.0 4.9   2 1 NO 5 1 HbSS BENIN/BENIN (aa/aa) 
372 M 19 BAMOUN SECONDARY 2.70 11.1 80.0 51.1 18.5 9.7 3.3 110.0 4.0 8.9 0.5 1 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
373 M 15 BASSA SECONDARY 2.6 6.6 76.0 33.6 16.8 7.2 1.8 625.0 3.9 9.4   1 NO 0 2 HbSS BENIN/BENIN (aa/aa) 
374 M 11 DSCHANG PRIMARY 2.1 7.8 94.0 40.3 14.9 8.3 2.1 243.0 3.9 13.5 7 1 NO 2 2 HbSS BENIN/BENIN (aa/a3.7) 
375 M 11 ABBO PRIMARY 2.6 7.4 91.0 31.4 13.4 7.1 2.2 283.0 3.3 15.3 5 2 NO 12 1 HbSS BENIN/CAMEROON (aa/aa) 
376 M 40 MIXED ANCESTRY TERTIARY 3.3 8.3 75.0 33.5 12.6 7.0 1.0 489.0 3.7   1 1 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
377 F 20 MIXED ANCESTRY PRIMARY 2.5 7.1 90.0 30.9 8.9 3.8 1.2 596.0 4.5 17.2 8 2 NO     HbSS BENIN/BENIN (aa/a3.7) 
378 M 24 BASSA SECONDARY 2.2 7.3 97.0 33.6 12.3 4.7 1.3 615.0 3.2 12.6 1 1 NO 0 2 HbSS BENIN/BENIN (aa/aa) 
379 F 5 MIXED ANCESTRY PRIMARY 2.6 8.3 86.0 37.3 25.4 10.4 3.0 267.0 4.0   2 1 NO 1 2 HbSS BENIN/ATYPICAL (aa/aa) 
381 M 21 BAFIA SECONDARY 2.4 7.9 94.0 35.5 12.4 6.5 1.5 393.0 2.2 10.3 0.5 1 YES 5 1 HbSS ATYPICAL/CAMEROON (aa/aa) 
382                                       HbSS BENIN/ATYPICAL (aa/a3.7) 
383 M 26 DOUALA PRIMARY 2.4 7.1 77.0 37.8 8.7 4.0 1.1 378.0 4.1 12.2 3 1 NO 1 1 HbSS BENIN/CAMEROON (aa/a3.7) 
384 M 14 ETON SECONDARY 2.9 7.3 81.0 31.6 13.8 7.6 1.4 304.0 4.5 16.7 7 2 NO 6 0 HbSS BENIN/CAMEROON (aa/a3.7) 
385 M 38 EWONDO TERTIARY 3.2 9.0 78.0 35.6 13.7 6.6 0.9 472.0 3.8   3 1 NO 6 1 HbSS BENIN/CAMEROON (aa/aa) 
386 F 18 MIXED ANCESTRY SECONDARY 3.1 8.6 82.0 33.9 9.8 4.2 1.4 329.0 4.8   0.5 2 NO 4 1 HbSS BENIN/BENIN (aa/a3.7) 
387 F 17 EWONDO SECONDARY 1.6 7.1 111.0 41.2 29.3 15.2 3.9 248.0 18.2 22.9 1 2 YES 6 4 HbSS BENIN/BENIN (aa/aa) 
388 M 21 BAFIA SECONDARY 2.1 6.9 82.0 40.2 13.4 7.8 1.3 344.0 6.6   1 2 NO 6 4 HbSS BENIN/ATYPICAL (aa/a3.7) 
389 F 22 DSCHANG TERTIARY 2.2 6.5 83.0 36.1 12.8 6.8 1.5 290.0 3.2 16.0 10 0 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
390 F 28 EWONDO TERTIARY 2.6 7.3 78.0 35.5 10.6 5.7 0.9 339.0 4.3   0.8 2 YES   1 HbSS   (aa/a3.7) 
391 F 15 DULU SECONDARY 2.1 7.7 95.0 39.4 17.4 4.4 2.6 190.0 4.9 23.6 2 1 NO 0 0 HbSS BENIN/BENIN (aa/aa) 
393 F 31 MIXED ANCESTRY TERTIARY 1.9 6.8 96.0 36.5 12.3 2.9 1.2 493.0 4.6 12.0 2 0 NO     HbSS BENIN/ATYPICAL (aa/aa) 
394 M 19 BAMOUN SECONDARY 3.2 10.1 85.0 37.5 14.0 4.1 2.5 296.0 4.8   1 1 NO 2 1 HbSS BENIN/CAMEROON (aa/a3.7) 
395 M 27 BGNTE SECONDARY 4.3 9.8 66.0 34.6 10.9 4.0 1.6 593.0 4.7   0.5 1 NO 0 0 HbSS BENIN/ATYPICAL (aa/a3.7) 
397 F 15 BASSA SECONDARY 3.0 7.4 69.0 36.1 9.1 4.6 1.1 247.0 5.3   5 1 NO     HbSS BENIN/BENIN (a3.7/a3.7) 
398 M 12 BAMILEKE SECONDARY 2.5 7.7 85.0 36.6 21.3 11.3 1.7 593.0 3.8 5.4 4 2 YES 1 1 HbSS BENIN/ARAB-INDIAN (aa/aa) 
399 M 2 MIXED ANCESTRY NONE 3.9 10.6 82.0 32.7 15.4 9.7 2.4 272.0 6.2 20.6 1 1 NO 0 0 HbSS BENIN/ATYPICAL (aa/aa) 
400 F 14 BAMILEKE SECONDARY 3.4 9.7 82.0 35.1 28.5 16.0 2.5 725.0 6.8 12.5 3 1 NO 2 0 HbSS BENIN/BENIN (aa/aa) 
401 F 29 BASSA SECONDARY 2.6 7.2 80.0 35.3 13.0 6.4 1.1 292.0 2.7 10.3 14 1 YES 0 0 HbSS BENIN/BENIN (aa/aa) 
402 F 28 MIXED ANCESTRY TERTIARY 3.5 8.7 78.0 32.3 10.2 3.3 0.8 456.0 18.1 11.2 7 1 YES 3 1 HbSS BENIN/BENIN (aa/aa) 
403 M 22 MBAMOIS PRIMARY 2.6 9.5 93.0 38.5 10.6 6.2 0.8 372.0 4.5 23.8 0.6 1 NO 1 1 HbSS BENIN/ATYPICAL (aa/aa) 
404 F 15 BASSA SECONDARY 2.9 9.2 84.0 37.2 10.9 5.2 2.6 403.0 3.7 16.1 8 2 NO 1 4 HbSS BENIN/BENIN (aa/aa) 
405 F 8 DULU PRIMARY 3.2 8.8 82.0 33.8 20.9 9.9 0.8 560.0 1.6 15.1 3 1 NO 10 2 HbSS BENIN/BENIN (aa/aa) 
406 M 20 NKAMBE SECONDARY 4.3 9.9 77.0 28.8 9.6 4.5 0.8 323.0 4.6 10.9 0.5 1 NO 1 1 HbSS   (aa/aa) 
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A5: PREPARATION OF 1XTE BUFFER 
The following components were required: (1) 10mM Tris (Sigma-Aldrich, Munich, 
Germany), (2) HCl acid (Sigma-Aldrich, Munich, Germany) and (3) 1mM EDTA (Sigma-
Aldrich, Munich, Germany). A 100ml solution was prepared by adding 1ml of 1M Tris-HCl 
(pH 8.0) and 0.2ml EDTA (0.5 M). These components were mixed and the remaining volume 
was topped up with distilled water until the 100ml mark. This buffer was stored at room 
temperature. 
A6: PREPARATION OF AN AGAROSE GEL 
The agarose gels used in this study were prepared according to the weight/volume (w/v) 
ratio. Various percentages were required: 
1. A 1.5% agarose gel, was prepared using 1.5g of agarose (Seakem Lonza, Basel, 
Switzerland) mixed in 100ml of 1XTBE buffer (Appendix A8). The mixture was 
swirled by hand, and then heated, using a microwave, at medium power for 1min 
or until the agarose has completely dissolved. Upon cooling, EtBr (0.5ug/ml) (Sigma-
Aldrich, Munich, Germany; Appendix A7) was added and mixed gently by swirling. 
The mixture was poured into a casting tray and allowed to solidify. After 30 minutes, 
the gel was ready for use. 
2. A 2% agarose gel, was prepared using 2g of agarose (Seakem Lonza, Basel, 
Switzerland) mixed in 100ml of 1XTBE buffer (Appendix A8). The mixture was 
swirled by hand, and then heated, using a microwave, at medium power for 1 
minute or until the agarose has completely dissolved. Upon cooling, EtBr (0.5ug/ml; 
Sigma-Aldrich, Munich, Germany; Appendix A7) was added and mixed gently by 
swirling. The mixture was poured into a casting tray and allowed to solidify. After 
30 minutes, the gel was ready for use. 
A7: PREPARATION OF EtBr (0.5µg/ml) 
EtBr (0.5µl; Sigma-Aldrich, Munich, Germany) was added to 10ml of distilled de-ionised 
water and mixed gently by swirling in a container with a lid. 
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A8: PREPARATION OF 1XTBE BUFFER 
A 5X stock solution of TBE was prepared dissolving 0.45M Tris (Sigma-Aldrich, Munich, 
Germany) and 0.44M Boric acid (Sigma-Aldrich, Munich, Germany) in 900ml deionized 
water. EDTA (0.5M; pH 8.0) was added and the solution was adjusted to a final volume of 
1L. This buffer was stored at room temperature (~22°C). Thereafter, a working solution 
was prepared for agarose gel electrophoresis. The stock solution was diluted with 
deionized water in the 1:10 ratio. The final solute concentrations were 45mM Tris-borate 
and 1mM EDTA. 
A9: PREPARATION OF LOADING DYE 
The following components were required to prepare the loading dye: (1) 0.25% 
Bromophenol Blue (Merck; Darmstadt, Germany), (2) 40% Sucrose (Merck, Darmstadt, 
Germany) and (3) 59.75% sterile water. Components (1), (2) and (3) were mixed together, 
and half of a NaOH (Sigma-Aldrich, Munich, Germany) pellet was added to create a slightly 
basic mixture. The mixture was stored at -20°C. 
A10: PREPARATION OF RBC LYSIS BUFFER 
The following components were used to prepare the RBC lysis buffer: (1) 155mM NH4Cl 
(Sigma-Aldrich, Munich, Germany), (2) 12mM NaHCO3 (Sigma-Aldrich, Munich, Germany), 
(3) 0.1mM EDTA (Sigma-Aldrich, Munich, Germany), and (4) distilled water. A 1L solution
was prepared by dissolving the NH4Cl, NaHCO3, and EDTA in distilled water. The mixture 
was then filter sterilised using a 0.2µm filter and stored at 4°C. 
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